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Selective delivery of drugs to localized regions of tissue within the body is a complex problem, 
representing one path through which the efficacy of many pharmaceutical compounds can be 
enhanced. Many pharmaceutical compounds show excellent activity in vitro, but their uses are 
severely limited in vivo. Unstable active conformations, limited membrane diffusion, rapid 
metabolism and/or clearance, decreased solubility, and dose-limiting systemic toxicity are just a 
few areas in which potential problems exist, halting drug development. Compounds exist 
possessing ideal pharmacologic activity for treating specific disease states, but they are simply 
unable to be delivered in adequate quantities or in the proper active conformation to the target 
site in the body. The following dissertation details the synthesis, characterization, and 
performance of a series of polyurethane drug delivery systems based on amino acids and the 
simple carbohydrates. The materials were synthesized from lysine diisocyanate (LDI) and 
glycerol with the aid of various tertiary amine and organometallic urethane catalysts. Candidate 
drugs were incorporated into the materials by way of labile urethane and urea linkages; 
subsequent drug release relied on the passive hydrolysis of the tethering bonds. Drug release 
from the materials correlated to material morphology, urethane catalyst, and chemical 
functionality of the incorporated drug. A single-phase polyurethane material was designed, 
synthesized, and shown capable of simultaneously releasing multiple pharmacologic agents at 
different rates. Finally, naturally occurring ionic ligands were incorporated into the LDI-glycerol 
polyurethanes to alter their swelling characteristics and release kinetics. This endeavor has 
resulted in the formulation of a series of polyurethane materials, capable of long-term controlled 
release of pharmacologic agents within the body. The structure-function relationships elucidated 
provide key design criteria, which can ultimately be used to develop such advanced degradable 
polyurethane materials. 
SYNTHESIS AND CHARACTERIZATION OF NOVEL POLYURETHANE DRUG 
DELIVERY SYSTEMS 
Wesley N. Sivak, PhD 
University of Pittsburgh, 2007
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1.0  INTRODUCTION 
Many pharmaceutical compounds show excellent activity in vitro, but their uses are severely 
limited in vivo. Unstable active conformations, limited membrane diffusion, rapid metabolism 
and/or clearance, decreased solubility, and dose-limiting systemic toxicity are just a few areas in 
which potential problems exist that can halt drug development [1]. Indeed compounds exist that 
possess ideal pharmacologic activity for treating specific disease states, but they are simply 
unable to be delivered in adequate quantities or in the proper active conformation to the target 
site in the body. The camptothecins are one such family of compounds and one member in 
particular, 7-tert-butyldimethylsilyl-10-hydroxycamptothecin (DB-67), displays potent anti-
tumor activity but is plagued with delivery obstacles such as poor solubility and poor active-state 
stability[2]. 
Chemotherapy has played a central role in the management and sometimes the 
elimination of hematological malignancies and solid tumors. Despite reduced clinical morbidity 
and mortality, virtually all chemotherapeutics cause unacceptable damage to normal tissues when 
used in doses required to eradicate cancer cells [3]. Improved selectivity in the delivery of anti-
cancer drugs to tumor tissues offers one possible solution. Therapeutic efficacy could be 
markedly enhanced and dose-limiting toxicity could be greatly diminished if high concentrations 
of anti-cancer agents could be selectively administered to only malignant cells.  
The majority of current cancer chemotherapeutic agents are low molecular weight (MW) 
chemicals, possessing a high pharmacokinetic volume of distribution, which leads to the 
presence of cytotoxic compounds throughout the entire patient. The exposure of normal tissues 
to the drug is manifested in the many well-known side effects to rapidly dividing cells, e.g., bone 
marrow suppression, alopecia, sterility, and the sloughing of gut epithelial cells [4]. Low MW 
anticancer compounds are also rapidly removed by renal excretion and can be subject to 
deactivation by chemical processes or enzymatic degradation. Chemotherapeutic drugs 
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invariably have a very narrow therapeutic index that separates the toxic dose from the clinically 
effective dose. Furthermore, the development of multi-drug resistance (MDR) pumps in tumor 
cells exacerbates the problem of achieving selective toxicity [5].  
Camptothecins are a special class of anticancer agents that act as topoisomerase I (topo I) 
inhibitors and appear to be quite active in human cancers previously reported resistant to 
chemotherapy [6]. These agents are analogs of the plant alkaloid 20(S)-camptothecin and interact 
with topo I and DNA to form cleavage complexes – preventing the resealing of the topo I-
mediated DNA single strand breaks [7]. This interaction eventually leads to double-strand DNA 
breaks and apoptosis. 
The pharmaceutical development and clinical utility of the camptothecins are limited by 
the distinctive dynamics of these agents in the blood stream. All of the camptothecins now in 
clinical development contain a ?-hydroxy-?-lactone moiety, and they exist in two distinct forms 
at the physiological pH of 7.0 and above. The biologically active “lactone-closed” form reacts 
with water to form a biologically inactive “lactone-opened” (carboxylate) form [8, 9] as shown 
in Figure 1. 
 
N
N O
O
O
OH
Si
OH
N
N O
O
O
OH
Si
OH
OH
  
 
 
Figure 1 - Structure of DB-67 - lactone and hydroxy acid 
 
This simple chemical hydrolysis dynamically inactivates the parent drug. Furthering the 
problem, the predominant human blood serum protein, albumin (HSA), preferentially binds the 
carboxylate form – shifting the equilibrium towards the inactive moiety [10-12]. Because 
camptothecins are S-phase specific drugs, optimal topo I inhibitory activity is only obtained 
when the tumors of a patient are continuously exposed to the drug. Accordingly, establishing 
conditions where a therapeutically relevant concentration of the lactone-closed form of a 
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camptothecin is present over a suitable period of time for tumor cells to cycle through the S-
phase is a major challenge. 
Surgically implantable polymer matrices loaded with chemotherapeutic agents provide a 
successful approach to localized drug delivery. The matrix is loaded with the desired agent and 
then implanted within the tumor site, following as complete a surgical resection as clinically 
possible. The matrix releases its drug load over a period determined by the characteristics of the 
encapsulating polymer, delivering drug to the neoplastic cells existing in the peritumoral region 
that otherwise would give rise to recurring tumor. The advantage of polymer-based delivery over 
current catheter technology is that the polymers are not subject to clogging and blockage of 
tissue debris; in addition, drugs can be more accurately delivered to a specific site within the 
body and there are no concerns with respect to patient compliance [13]. Our goal is to develop a 
biodegradable polyurethane matrix capable of delivering DB-67 intratumorally or to remaining 
tumor cells within the resection margins following surgical removal.  
Numerous modalities for selective delivery of anti-tumor compounds to cancer cells have 
been described, with the most successful of these systems largely based on degradable synthetic 
polymers. These systems have shown limited efficacy in combating the growth and spread of 
metastatic tumors, yet a systematic approach to their design and synthesis has not yet been 
undertaken. Beginning with a degradable polyurethane drug delivery system based on lysine 
diisocyanate (LDI) and glycerol, we propose to begin a thorough analysis of the system’s drug 
delivery capabilities. This study should result in the design, synthesis and implementation of 
highly effective drug delivery systems for the DB-67 compound that can later be applied to other 
suitable therapeutics. The specific aims of the series of studies detailed in this manuscript are 
summarized below. 
 
Specific Aim 1: Develop and characterize an LDI-glycerol polyurethane film for delivery of 
a pharmacological agent. Polyurethane films incorporating DB-67 through labile urethane 
linkages were synthesized with use of an organometallic catalyst. Drug content and release from 
the films was assessed. The cytotoxicity profile of these films against a panel of malignant 
glioma cell lines was compared to polyurethane alone. 
Hypothesis 1.1 LDI-glycerol polyurethanes can be fashioned into degradable films suitable for 
drug delivery applications. 
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Hypothesis 1.2 The pharmacologic agent DB-67 can be incorporated into polyurethane films. 
Hypothesis 1.3 Polyurethane films containing a pharmacologic agent will exhibit cytotoxicity in 
vitro.  
 
Specific Aim 2: Develop and characterize an LDI-glycerol polyurethane foam for delivery 
of a pharmacological agent. Polyurethane foams incorporating DB-67 through labile urethane 
linkages were synthesized with use of two tertiary amine catalysts. Drug content and release 
from the foams was assessed. The cytotoxicity profile of these foams against a panel of 
malignant glioma cell lines was compared to polyurethane alone. 
Hypothesis 2.1 LDI-glycerol polyurethanes can be fashioned into degradable foams suitable for 
drug delivery. 
Hypothesis 2.2 A pharmacologic agent DB-67 can be incorporated into LDI-glycerol 
polyurethane foams. 
Hypothesis 2.3 LDI-glycerol polyurethane foams containing a pharmacologic agent will exhibit 
cytotoxicity in vitro. 
 
Specific Aim 3: Analyze how the functional groups present on a drug affect its release from 
LDI-glycerol polyurethane foams. A series of LDI- glycerol polyurethane foams incorporating 
naphthalene and some of its functionalized derivatives was prepared. The naphthalene analogs 
were incorporated into the polyurethane network via labile urethane linkages with use of a 
tertiary amine catalyst. Content and release from the foams was assessed. 
Hypothesis 3.1 Naphthalene and its various analogs can be incorporated into LDI-glycerol 
polyurethane foams. 
Hypothesis 3.2 Release of the analogs from the foams will occur at differing rates. 
Hypothesis 3.3 The release rates will correlate to the functional groups present on the various 
naphthalene analogs. 
 
Specific Aim 4: Develop LDI-glycerol polyurethane foams capable of the controlled release 
of multiple anti-cancer compounds at different rates. Polyurethane foams incorporating DB-
67, doxorubicin and paclitaxol – alone and in combination – were prepared. The drugs were 
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incorporated into the polyurethane foam via labile urethane linkages via a tertiary amine catalyst. 
Content and release of the drugs from the foams was assessed.  
Hypothesis 4.1 DB-67, doxorubicin, and paclitaxol can be incorporated alone and in 
combination into LDI-glycerol polyurethane foams. 
Hypothesis 4.2 Release of the drugs from the foams will occur at different rates. 
Hypothesis 4.3The release rates can be correlated to the pendant functional groups present on 
each drug. 
 
Specific Aim 5: Incorporate cationic and anionic ligands into LDI-glycerol polyurethane 
films and foams to alter their rates of drug release. A series of polyurethane foams and films 
incorporating choline chloride (CC) and isethionic acid (DMB), was prepared. The non-ionic 
species 3,3-dimethylbutanol was used as a control. DB-67 was incorporated into the 
polyurethane films and foams via labile urethane linkages via a tertiary amine catalyst. Content 
and release of DB-67 from the films and foams was assessed.  
Hypothesis 4.1 Ionic ligands can be incorporated into LDI-glycerol polyurethane foams. 
Hypothesis 4.2 Release of the drugs from the films and foams will occur at different rates. 
Hypothesis 4.3 The release rates can be correlated to the ionic ligands present in each 
polyurethane material. 
 
1.1 POLYURETHANES 
Polyurethanes are used often in medical device applications, and their use continues to grow. 
Compared with other polymers, polyurethanes often require sophisticated manufacturing 
processes and are more expensive on a price-per-pound basis. For example, the average flexible 
PVC compound sells for 85 cents per pound, while the typical polyurethane sells for 10–20 times 
that amount [14]. So, what is it that motivates medical device developers to use them? The 
answer is quite simple: polyurethanes can be used in applications where other materials fail. 
Polyurethanes are among the most versatile construction materials that can be formulated for 
medical devices. By controlling the components in the formulation, one can produce 
 6 
polyurethanes in the form of flexible foams, rigid foams, and elastomers. They are tough, 
biocompatible, and hemocompatible, and they can be processed using extrusion, injection 
molding, film blowing, solution dipping, and two-part liquid molding. 
Polyurethanes’ unique chemistry gives them this versatility. The vast majority of 
polyurethanes are segmented polymers, meaning they have a soft segment that provides 
flexibility and a hard segment that provides strength. These polyurethanes are made from three 
basic building blocks: the backbone, the diisocyanate, and the chain extender. The backbone, 
usually a long chain molecule, provides flexibility to the polymer. The diisocyanate and the 
chain extender combine to form the hard segment, which acts as a cross-link. It provides the 
polymer with high tensile strength and high elongation threshold. Generally, the diisocyanate is 
to blame the majority of the toxicity associated with the production of polyurethane materials 
[15, 16]. 
Polyurethanes are made from either aromatic or aliphatic diisocyanates. Aromatic 
diisocyanates contain benzene rings, which create polyurethanes that are generally tougher, 
stronger, and less costly than the aliphatics. The aromatics generally have tougher hard segments, 
which are more chemically resistant and give rise to higher tensile strength and elongation than 
aliphatics. Aliphatic diisocyanates contain hydrocarbon backbones without any benzene rings. 
Aliphatic polyurethanes make strong polymers but lack the chemical resistance of aromatics. 
They are more expensive than aromatics and are used primarily in applications that require good 
light stability. There are thousands of possible combinations of the basic building blocks used to 
create aromatic and aliphatic polyurethanes, thereby providing device engineers with a myriad of 
options for their products. 
1.1.1 Polyurethane synthesis 
The term polyurethane is broadly used to describe materials that contain urethane, urea or 
isocyanurate linkages as part of the polymer backbone. Urethane, urea and isocyanurate bonds 
are formed via the reaction of isocyanate with hydroxyl, amine or other isocyanates, respectively. 
Isocyanates are essentially carbonyl compounds with multiple double bonds, and the reaction 
mechanisms closely corresponds to the reaction mechanisms observed for common carbonyl 
compounds [17]. The first reaction step of carbonyl compounds is the addition between the 
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electrophilic carbonyl carbon of the carbonyl compound and the nucleophilic center of the 
nucleophilic compound. Similarly, the urethane formation starts with the reaction between the 
carbonyl carbon of the isocyantate and the alcohol oxygen (Figure 2). 
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Figure 2 - Urethane formation 
 
The nucleophile, in this case the alcohol, attacks the electrophile ,the carbonyl carbon of the 
isocyanate, generating an intermediate species. Proton transfer from the alcohol carbon to the 
isocyanate nitrogen accompanies electron transfer from the isocyanate’s carbonyl carbon to its 
nitrogen, producing a urethane bond. The greater the electrophilicity or nucleophilicity of the 
reacting centers is, the higher is the rate of carbonyl reaction. Accordingly, the rate of urethane 
formation increases with these reactivity factors.  
 Similar to urethane formation, an isocyanate can also react with an amine to generate a 
urea bond (Figure 3). 
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Figure 3 - Urea formation 
 
In this case, the primary amine functions as the nucleophile and the carbonyl carbon of the 
isocyanate still functions as the electrophile. Proton and electron transfer occur in an analogous 
manner, generating a urea bond. Other important reactions occur during the formation of 
polyurethanes, and they are shown in Figure 4. For simplicity, the reactants are depicted as 
monofunctional, although polyurethanes will be generated from di- or multi-functional reactants. 
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Figure 4 - Some reactions that occur during the formation of polyurethanes 
 
All of the aforementioned isocyanate reactions can be broken into three categories: 
gelling, cross-linking and blowing. The gelling reactions refer to those that do not produce a 
volatile product, such as urethane or urea formation, and yield linear polymers (assuming di-
functional reactants). The cross-linking reactions function via the active hydrogen in the urethane 
and urea groups, and these species crosslink the polyurethane by reaction with another 
isocyanate to form allophonate and biuret, respectively. The isocyanurte linkage, also formed via 
a cross-linking reaction, provides rigidity and thermal stability. Isocyanates can also form 
dimers, called uretidiones, that also result in cross-linked polymer, but this is far less common 
that the trimerization reaction. 
 The blowing reaction, or the reaction between isocyanate and water, is of fundamental 
importance to urethane chemistry. The reaction produces carbamic acid as an intermediate. As 
the carbamic acid readily decomposes into an amine and carbon dioxode gas, the polyurethane 
expands into foam. The amine generated in this process is then free to react with another 
isocyanate to form a urea linkage, curing the foam as it expands. Physical blowing agents such as 
chlorofluorocarbons and methylene chloride can also be used to produce foams, but these foams 
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are generated by the vaporization of these liquids and not by a chemical reaction. The blowing 
reaction is used to manufacture foam cushioning for a variety of commercial applications in the 
auto and home industries.  
 It is the precise control and sequencing of the blowing, gelling, and cross-linking 
reactions that determine the final properties of the polyurethane [18]. For example, if the blowing 
reaction occurs too quickly in a water-blown foam, the foam will expand rapidly and will not 
have sufficient mechanical strength to prevent a collapse. Conversely, if the gelling reactions 
occur to rapidly, the gas resulting from the blowing reaction will not be able to expand the 
polyurethane matrix. Thus, the precise balance of these reactions determines the resulting 
physical properties; this balance is primarily controlled by the amount and type of catalyst 
present. 
1.1.2 Polyurethane catalysis 
For polyurethanes, the catalyst is most responsible for controlling the reaction time and for 
defining polymer architecture that influences the ultimate mechanical properties. Specifically, it 
is the catalyst’s activity and selectivity towards each of the many reactions occurring in the 
formation of polyurethanes that determine the structure of the resulting material. It is possible to 
accelerate the reactions of carbonyl compounds via Lewis acids and bases, and many urethane 
catalysts function in this manner [19]. The myriad of catalyst choices available to the 
polyurethane chemist presents a significant challenge, and often a blend of catalysts is used to 
obtain the desired results. 
 There are three major classes of polyurethane catalysts: tertiary amines, organometallics, 
aprotic salts; only tertiary amine and organometallic catalysts will be discussed. Amine catalysts, 
especially tertiary amines, form the largest class of catalysts used in the manufacture of 
polyurethanes. Tertiary amines catalyze both the gelling and blowing reactions to different 
extents, but they are generally not very active isocyanurate catalysts. Increased catalyst basicity 
generally increases activity, and steric hindrance plays a significant role too. Triethylene-diamine 
or 1,4-diazobicyclo[2.2.2]-octane (DABCO) is the most widely employed tertiary amine catalyst 
used in the production of polyurethanes. Its unusually high activity in spite of decreased basicity 
is due to a lack of steric hindrance. While DABCO is generally regarded as a powerful gelling 
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catalyst, it is also a powerful catalyst of the blowing reaction [20]. In contrast, the catalyst 4,4’-
(oxydi-2,1-ethane-diyl)bismorpholine or dimorpholino-diethylether (DMDEE) is another tertiary 
amine catalyst that is highly specific for the blowing reaction [21]. The structures of some of the 
more commonly used tertiary amine catalysts are shown in Figure 5. 
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Figure 5 - Structures of some commonly used urethane amine catalysts 
 
 Several mechanisms have been invoked to explain the observed rate data in amine-
catalyzed isocyanate and isocyanate trimerization reactions. Most of the mechanisms are 
variations of two mechanisms proposed by Baker and for the tertiary amine catalyzed formation 
of urethane [22-24]. The first mechanism consists of the formation of an isocyanate-amine 
complex followed by reaction with an alcohol. The second consists of the formation of an 
activated amine-alcohol complex followed by reaction with the isocyanate. The former 
mechanism suggests that the nucleophilicity of the amine is the dominant factor; the latter 
implies that the amine basicity is dominant. Experimental evidence, as well as shortcomings, for 
both methods exists, although a mechanism based on an isocyanate-amine complex is generally 
more accepted.  
Organometallic compounds are another large class of catalysts used in the synthesis of 
polyurethanes. The most common of these catalysts are organotin compounds, which are salts of 
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organic acids, especially the dialkyltin dicarboxylates. Among the more common organometallic 
catalysts are dibutyltin dilaurate ([CH3(CH2)3]2Sn[OCO(CH2)10CH3]2), stannous octoate 
(Sn(OCOC7H15)2), dibutyltin diacetate ([CH3(CH2)3]2Sn[OCOCH3]2), and dibutyltin 
dimercaptide ([CH3(CH2)3]2Sn(SC12H25)2). The organometallic catalysts tend to be more 
selective for the gelling reactions than the tertiary amines. A few of the limitations of organotin 
compounds are there high toxicity and their tendency to lose activity in the presence of water. 
Since polyurethanes are generally synthesized under anhydrous conditions, only the latter 
generally poses a problem. A synergy in catalytic activity has been observed when tertiary 
amines are used in combination with organotin compounds [25]. 
 Other varieties of metal-based catalysts are also available. These include mercury-, lead-, 
iron-, bismuth-, and cobalt-based compounds that are routinely used for coating and elastomers 
applications. These catalysts generally exhibit a higher degree of selectivity for the gelling 
reactions relative to the amine and organotin catalysts [18]. However, many of these heavy metal 
catalysts face uncertain futures due to toxicological and environmental concerns. However, 
bismuth salts are an exception and possess decreased toxicological concerns, as they are 
routinely employed in the medical field as diagnostic imaging dyes and as anti-diarrhea 
medications [26, 27].  
  Several mechanisms have been proposed for the organometallic catalysis of isocyanate-
hydroxyl reactions [28-30]. The most prevalent mechanism is that of a ternary complex of 
isocyanate, hydroxyl, and the organometallic catalyst. It has been proposed that the 
organometallic catalyst can first complex with either the isocyanate or alcohol followed by 
complexation with the other reactant. Others favor the formation of a Lewis acid-isocyanate 
complex followed by complexation with the alcohol.  Still others claim that the organometallic 
catalyst increases the electrophilic character of the isocyanate group and brings the alcohol and 
isocyanate in close proximity. Indeed there is still an ongoing debate regarding the exact 
mechanisms governing the organometallic catalysts, but lack of a true and definite mechanism of 
action has not impeded their use in the commercial production of polyurethanes.  
 Catalysts play a vital role in reducing reaction times and in controlling the polymer 
properties in the synthesis of polyurethane materials. Each catalyst has a unique activity and 
selectivity for the reactions that occur during the formation of polyurethane. Of the many types 
of polyurethane catalysts, the most important and most widely used are the tertiary amines and 
 12 
the organotin compounds. The combinations of catalysts are often required to provide the proper 
balance between ease of processing and physical property requirements. A variety of approaches 
have also been made to meet the changing environmental and manufacture concerns, such as 
toxicity, odor and delayed activity [20]. 
1.2 DRUG DELIVERY 
Over the past three decades, significant advances have been made in drug delivery technology. 
This realization has come about and been accelerated in recent years due to the substantial 
decline in the development of new pharmaceutical compounds [31]. Drug delivery has now truly 
become a multidisciplinary endeavor. Emerging technologies now rely on new discoveries in all 
fields of science. Drug delivery, which takes into consideration the carrier, the route, and the 
target, has evolved into a strategy of processes or device designs to enhance the efficacy of 
therapeutic agents through controlled release. This may involve enhanced bioavailability, 
improved therapeutic index, or improved patient compliance. Drug delivery, or controlled 
release, has been defined by Flynn as “the use of whatever means possible, be it chemical, 
physiochemical, or mechanical, to regulate a drug’s access rate to the body’s central 
compartment, or in some cases, directly to the involved tissues” [32]. 
Countless attempts have been made over the years in attempts to formulate a truly 
selective delivery strategy as envisioned by Flynn. In the beginning of the 20
th
 century, P. Erlich 
first described this idea in his concept of “magic bullets” [33], consisting of haptophore (binding 
component to target) and toxophore (cytotoxic part). As a haptophore, he proposed the use of an 
antibody. Nevertheless, it took another 70 years for drug delivery and drug targeting to become 
areas of active research, arousing the interest of many people.  
When looking back on the history of drug delivery and targeting, several keystone 
discoveries are noticeable in the period of the 1960s and 1970s. Erlich’s concept of using an 
antibody as a haptophore was experimentally proven in the treatment of several tumors 
inoculated into experimental animals. Toxophores used in these experiments were 
radiotherapeutic agents (radioactive iodine) [34, 35], cytotoxic drugs (e.g., chlorambucil) [36], 
and diptheria toxin [37]. The concept of biodegradable polymers for sustained drug release was 
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first introduced in the early 1970’s, following the introduction of bio-resorbable sutures [38]. 
The first drug to be delivered from a biodegradable drug-delivery system was cyclazocine, an 
opioid antagonist that has been used as an analgesic and in the treatment of narcotic dependence; 
it was reported in 1971 and delivered drug via a poly(DL-lactide) implant [39]. Since then, 
biodegradable polymers have become increasingly popular, and numerous new polymers have 
been synthesized and employed for drug delivery applications. 
On the other hand, it was also discovered that conjugating a drug to an appropriate 
polymeric carrier could modulate drug uptake by cells, and Ringsdorf presented the first clear 
concept of targetable polymeric drugs [40]. Because polymers follow different cellular uptake 
mechanisms than their low-molecular weight analogs, they are introduced into the cell neither by 
permeation through the plasma membrane nor by means of transport proteins. Polymers are 
internalized into the cellular compartment through a process called endocytosis [41]. Endocytosis 
begins with the enclosure of the polymer by a part of the plasma membrane to form an 
intracellular vesicle. The intracellular vesicles with ingested polymers are transferred to 
organelles called endosomes, which are eventually carried to lysosomes. Ringsdorf envisioned 
that drug delivery could further be improved by tailoring polymers that could not only 
incorporate drugs, but also molecules that could guide the drugs to cells.  
 These early discoveries paved the way for the development of many technologies aimed 
at limiting the systemic exposure of therapeutics, while increasing their availability to select 
tissues. Site-selective drug delivery has been proven successful in the laboratory with strategies 
such as liposomes, hydrogels, synthetic peptides, synthetic polymers, and nanoparticles just to 
name a few. Among the diverse applications of macromolecular drug formulations, the treatment 
of solid tumors is one in which intensive research has been devoted. However, there has been 
limited clinical impact because of these advances. With continued technological advances and 
re-tailoring of currently available systems, the drug delivery field will continue to move toward 
its goal of improving therapeutic efficacy through site-specific release strategies. 
Drug delivery strategies can be divided into two categories based upon their method of 
administration – systemic and local delivery strategies. Although there exists some crossover 
between the two divisions, most modern drug delivery systems can be categorized in this 
manner. Systemic drug delivery formulations are generally introduced into the body’s vascular 
space, relying on selective mechanisms to reach and affect the diseased tissues. Local 
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administration strategies place the drug in a particular body compartment and passive release 
mechanisms dictate the rate and time course of administration of the therapeutic compound to the 
diseased tissue. Many advances have been made over the years in both of these types of systems, 
and a review of their progress is certainly warranted here. 
1.2.1 Systemic delivery 
Although the technologies underlying systemic drug delivery formulations vary to a considerable 
degree, they all rely on three basic tenants. First, a protective carrier mechanism limits the drug’s 
exposure in extraneous tissues, protects it from inactivation, and inhibits premature release. 
Second, a targeting moiety is associated with the carrier mechanism and it is able to recognize 
and remain at the targeted tissues. Third, a site-specific or time-delayed release strategy is 
employed to deliver the drug only once it has reached and invaded the targeted tissue.  
 Water-soluble polymers were first applied in the biomedical field as plasma expanders. 
Compounds such as poly(glutamic acid), dextran, poly(vinyl alcohol), poly[N-(2-
hydroxypropyl)methacrylamide] (HPMA), and poly(ethylene glycol) (PEG) had been shown to 
exhibit increased circulation times relative to their low-molecular weight counterparts. This is 
because renal clearance is significant for molecules with relatively small molecular weights. 
Proteins with MW lower than 40,000 show a very short plasma half-life because of rapid renal 
clearance [42].  However, it was demonstrated that the urinary excretion of soybean trypsin 
inhibitor (MW ~20,000) could be significantly reduced through conjugation to water-soluble 
polymers including PEG and dextran [43]. In a rational manner water-soluble plasma expanders 
became used as starting components to design polymer-drug conjugates. 
 Another important aspect of drug targeting is the modulation of distribution and 
disposition of drugs by binding with appropriate carrier systems. After administration of 
macromolecular drug formulations via the intravenous route, their transport in the body 
compartment is principally governed by diffusion and convection. Even if effective homing 
moieties are installed in the conjugate, they are of no use unless the conjugates reach the vicinity 
of the target cell to ensure close contact. So how is it that macromolecular drug conjugates are 
able to reach specific targets when administered systemically to the vasculature compartment? 
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 Solid tumor masses exist outside of the vascular space and are one indication in which 
site-specific delivery of macromolecular therapeutics has found some success. This is due to the 
unique biology of tumor masses and that changes in vasculature architecture that this biological 
profile promotes. It is now well accepted that because of activation of kinin-generateing cascade 
and the secretion of vascular permeability factor, blood capillaries in tumor tissues develop 
considerably high density with enhanced permeability due to loose interendothelial junctions. 
This process leads to enhanced passive transport of macromolecular substances, such as proteins 
and polymeric drugs, across the blood vessel into the interstitial spaces of the tumor tissues. 
 On the other hand, the development of a lymphatic drainage system is insufficient in 
tumorous tissues, resulting in poor tissue drainage of macromolecular substances. Consequently, 
macromolecular substances may exhibit a considerable accumulation in the tumor due to the 
synergistic effect of the increased vascular permeability and the decreased tissue drainage. This 
effect has been systematically studied by the Maeda group at Kumamoto University, Japan, and 
is termed “enhanced permeability and retention” (EPR) effect [42, 44]. EPR has become one of 
the major guiding principles in drug targeting using macromolecular carriers. However, it should 
be noted that this effect also takes place in sites of increased inflammatory reaction as a result of 
several causes, including microbial infections. 
 Obviously, the EPR is a great advantage of using macromolecular drugs for targeting. 
Low-molecular weight analogs readily suffer from glomerular excretion from the bloodstream, 
whereas macomolecular drugs are expected to achieve a prolonged half-life in the bloodstream 
because of decreased glomerular filtration and renal excretion. Obviously, extended circulation is 
a requisite for sufficient EPR effect. However, prolonged circulation is not always achieved for 
macromolecular carrier systems. An increase in hydrophobic character or induction of cationic 
charges in the carrier significantly alters the distribution, resulting in significant accumulation in 
the liver, resulting in rapid clearance from the blood stream. In terms of prolonged circulation 
and a resulting increase in plasma half-life, conjugation of drugs to macromolecular carriers with 
neutral or slightly anionic character generally gives good results. 
 Tumor invasion, metastasis, and resistance to chemotherapeutic drugs remain as major 
obstacles to the successful treatment of cancer, even in light of these findings. To further 
overcome some of these limitations, therapeutics that further increase the specificity and 
efficacy, while at the same time reduce the toxicity of the therapeutics are being explored. 
 16 
Features unique to malignant human tumor cells can be exploited in the development of targeting 
therapeutic agents. For example, cancer cells often over-express specific tumor-associated 
antigens, carbohydrate structures, or growth factor receptors on their cell surface. Incorporation 
of a recognizable moiety into the macromolecular carrier structure allows for actively targeted 
drug delivery systems. Potential targeting moieties include monoclonal, polyclonal antibodies 
and their fragments, carbohydrates (galactose, mannose), peptides/proteins (melanocyte 
stimulating hormone, transferring, growth factors), glycolipids, vitamins, and other ligands. 
Active macromolecular conjugates can first utilize EPR effect to arrive within the sect tumorous 
tissues, and then use active targeting moieties to be selectively transported into tumor tissues at 
much higher rates. 
 Macromolecules without a specific affinity to plasma membrane components are taken 
up through a non-selective process called “fluid-phase endocytosis” in which polymers are 
engulfed into endosomes along with liquid components. This process is a result of normal 
immune surveillance and antigen presentation common to the immune system. On the other 
hand, when macromolecules show and affinity for a plasma membrane and adsorb onto it, they 
are internalized into the cell by “adsorptive endocytosis”, which can have uptake rates 10-fold 
higher compared to fluid-phase endocytosis. 
 Studies on endocytic uptake of HPMA copolymers bearing tyrosineamide (Tyr-NH2) 
residues have shown there is an intense increase in uptake rate into rat visceral yolk sacs when 
10 mol% of the copolymer side groups were terminated with Tyr-NH2 [45]. This result was 
considered to be due to an increase in the contribution of nonspecific adsorptive endocytosis with 
an increase in the hydrophobic character of the copolymer chain owing to the increased number 
of the hydrophobic aromatic residue, tyrosine. Nonspecific adsorptive endocytosis is also 
significant for the cellular uptake of cationic polymers because of the negatively charged features 
of cellular plasma membranes. Results showing the increased hepatic uptake of charged dextran 
in a rat in vivo model have been obtained and also demonstrate the feasibility of the strategy [46]. 
 In the case of endocytosis through receptors expressed on the surface of the target cell 
plasma membrane (receptor mediated endocytosis), the uptake rate reach even 1,000 fold higher 
values than those observed with fluid-phase endocytosis. Receptor mediated endocytosis is quite 
common for many kinds of cell species. For example, low-density lipoprotein (LDL), a natural 
vehicle for cholesterol, known to be taken up by liver parenchymal cells through LDL receptors 
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expressed on these cellular surfaces. Receptor mediated endocytosis is not only extremely 
efficient, but also highly specific. Cellular-specific targeting has been made possible through 
these discoveries and can be used as a route to deliver a drug into a particular cell population in a 
particular site in the body. Incorporation of site-specific ligands onto the surface of 
macromolecular carrier systems should enable highly specific carrier systems for therapeutics 
capable of treating selected tissues in the body.  
1.2.2 Localized delivery 
Many technologies exist for localized delivery of drugs to select regions of the body. The driving 
force for the deliver can function via a variety of mechanisms such as diffusion, dissolution, 
osmotic pressure, biodegradation, and even micro-magnetic, mechanical, and electrical systems. 
With these types of systems, a body compartment can be selected and considered an isolated 
system. Various release strategies can then be employed to deliver drug to only the local tissues 
within a desired region. Subsections of the body compartment can even be selected for treatment 
via this strategy. Since the target organ system remains isolated from the remainder of the body, 
many dose-limiting systemic toxicities can be avoided entirely. Localized delivery systems also 
give the physician much tighter control on the extent and duration of therapeutic exposure.  
Catheter technology has found many uses in both systemic and local drug delivery 
systems. Implantable drug delivery devices can be designed to transmit drugs and fluid directly 
into the bloodstream without the repeated insertion of needles. These systems are particularly 
well suited to the delivery of insulin, steroids, chemotherapeutics, antibiotics, analgesics, total 
parental nutrition and heparin. These types of devices are placed completely under the skin – 
usually in a convenient but inconspicuous location. The patient is aware of only a small bump 
under the skin. Because the device is subcutaneous, with no opening in the skin, there is little 
chance of infection or interference with daily activities. These devices can even be refilled by 
simple injection through the skin and a septum into the pump reservoir. 
A catheter can also be attached to the exit port of an implantable pump to perfuse a 
discrete location distant from the site of implantation. In this manner, drug solutions may be 
delivered into solid tissues. The miniature pump is capable of changing local drug concentrations 
around the catheter tip without influencing the rest of the body. Flows of 0.5 – 1.0 μl/hr appear to 
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be low enough that hydraulic damage or edema is minimal in the micro-perfused region [31]. 
This strategy has proven successful in the treatment of many neurological malignancies, where 
the size of the pump prohibits spinal and cranial implantation [47-49]. However, catheters are 
often subject to blockage and clogging by tissue debris, which can seriously hinder the 
performance of the device. 
Implanted polymer matrices loaded with a therapeutic provide another approach to 
localized drug delivery. The typical polymers that are used in medicine can be divided into two 
groups: those that are introduced for a chronic period of time and polymers whose presence is 
transient. The former includes the use of polymeric materials in cardiovascular surgery, 
orthopedics, plastic surgery, and otolaryngology. Such applications impose high demands on the 
stability of the materials used. The latter includes the use of polymers for drug delivery 
applications, where the material is no longer needed after the drug supply has been exhausted. 
The matrix is loaded with the desired agent and then implanted at the treatment site. If 
degradable polymers are not used, one is often required to harvest the implant. The major 
disadvantage to implantable polymer systems is that they are not refillable, as is the pump 
system. If a further dose is required, another implant must be placed at the treatment site, often 
requiring repeated surgical intervention. 
Currently available polymers for site-specific controlled release can be classified into 
four major categories: diffusion controlled systems, solvent-activated systems, magnetically 
controlled systems, and chemically controlled systems. Diffusion controlled systems involve 
either a reservoir or a matrix. In reservoir type systems, a layer of non-biodegradable polymeric 
material, through which a drug slowly diffuses, surrounds a core reservoir. The properties of the 
drug and the encapsulating polymer govern the diffusion rate of the drug out of the system. One 
of the problems with such reservoir systems is that it must be removed from the body when the 
drug load has been depleted. Another potentially life-threatening problem may be encountered 
when the reservoir accidentally ruptures and a large amount of drug is suddenly released into the 
surrounding tissues (known as “drug dumping”) [50, 51]. In a matrix type diffusion-control 
system, the drug is uniformly distributed throughout the polymer matrix and is released at a 
predetermined rate as drug particles are displaced from the polymer network. In such a system, 
there is no inherent danger of drug dumping in the case of accidental rupture of and 
encapsulating membrane. 
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Solvent-activated systems can be classified as either osmotically controlled or swelling 
controlled. In osmotically controlled polymer systems, an external fluid containing low 
concentrations of drug moves across a semi-permeable membrane to a region inside the device, 
where is the drug is in high concentration. Osmotic pressure tends to decrease the concentration 
gradient between one side of the membrane and the other. The inward movement of fluid forces 
the dissolved drug out of the device through a small orifice. In swelling controlled systems, the 
polymer holds a large quantity of water without dissolving. Typically, hydrogels, consisting of 
cross-linked hydrophilic macromolecules, are used for these types of applications [52-55]. As the 
system swells, the gel’s permeability for low molecular weight solutes (i.e., drugs) changes and 
these agents are released at a controlled rate as the gel continues to swell. 
Magnetically controlled drug delivery systems have been developed from proteins such 
as albumin and magnetic microspheres and are used in site-specific chemotherapy applications. 
Because of the magnetic nature of the resulting particles, they are theoretically capable of 
enhanced area-specific accumulation when the body is subject to an external magnetic field. 
Although still experimental, this carrier system has been shown capable of accommodating a 
wide variety of drug loads. Two advantages of this type of approach are the high efficiency for in 
vivo targeting and controllable release of drug at the microvascular level. A few electrically 
controlled polymers are also currently being developed for the controlled release of drugs [56]. 
Chemically controlled systems also have two classes: the “pendenant chain” system and 
the biodegradable system. The pendent chain system is one in which the drug molecule is 
chemically linked to the backbone of a polymer. In the presence of enzymes or fluids, chemical 
or enzymatic hydrolysis occurs with concomitant release of the drug as a controlled rate. The 
drug may be linked directly to the polymer or can be linked via a “spacer” group. In the 
biodegradable system, polymers gradually decompose and bring about a controlled release of 
drug. The drug is dispersed uniformly throughout the polymer and is slowly released as the 
polymer disintegrates. The two major advantages to this type of system are that polymers do not 
have to be removed from the body after the drug supply is exhausted, and the drug does not need 
to be water-soluble. In fact, because of these factors future use of biodegradable polymers is 
likely to increase more that any other type of polymer in the future. The LDI-glycerol 
polyurethanes discussed within this dissertation are essentially a blend of the pendant chain and 
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biodegradable system technologies, incorporating compounds via labile chemical bonds into a 
degradable polyurethane matrix. 
1.2.3 Biodegradable systems 
Biodegradable polymers may be synthetic or natural in origin. Some of the widely used synthetic 
biodegradable polymers in drug delivery technology are summarized in Table 1.  
 
Table 1 - Structure of some common biodegradable polymers 
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Natural degradable polymers include human serum albumin, low-density lipoproteins (LDLs), 
bovine serum albumin, gelatin, collagen, hemoglobin, polysaccharides, etc. [57]. Use of the 
natural polymers is often limited by difficulties in purification and large-scale manufacture, in 
addition to the potential to cause immunogenic and adverse reactions. With advances in polymer 
science over the past 30 years in the synthesis, handling and degradation mechanisms, many 
synthetic and natural polymers are being successfully employed in drug delivery applications. 
Irrespective of their source, all biodegradable polymers share some common characteristics: (1) 
stability and compatibility with the drug molecule, (2) biocompatible and biodegradable, (3) ease 
of manufacture on a large scale, (4) amenability to sterilization, and (5) flexibility to yield 
multiple release profiles [38]. Among the polymers listed in Table 1, polyesters, polylactones, 
poly(amino acids), and polyphosphazenes, predominantly undergo bulk erosion; polyorthoesters 
and polyanhydrides predominantly undergo surface erosion. 
Temporal drug release, delivering drug over an extended period of time and/or at a 
specific time, is advantageous for types of drugs such as chemotherapeutics, anti-inflammatory 
agents, antibiotics, opoid antagonists just to name a few [3, 4, 53, 58-60]. In general, drug release 
from biodegradable polymeric devices is controlled by diffusion of drug and/or polymer erosion. 
In practice, both of these mechanisms play a role in controlling the release rate; one dominates 
the other depending on the drug, morphology of the carrier, and other physiochemical 
characteristics. Release of small drug molecules from polymeric systems is largely governed by 
diffusion; diffusion closely follows Fick’s diffusion equation. In contrast, release of 
macromolecules such as proteins and peptides from polymer systems is more complex because it 
depends largely on polymer degradation. 
 Biodegradable polymers generally undergo three types of degradation [61]. Type I 
degradation refers to the polymer where the degradation occurs along the main chain of the 
polymer. The cleavage of linkages between monomers results in a continuous decrease in 
molecular weight. Most of the linear biodegradable polymers follow this degradation pattern. 
Type II degradation occurs when water-soluble polymer is made insoluble by ubiquitous cross-
linking with a hydrolysable covalent bond. As the cross-links erode, polymer fragments become 
soluble and diffuse away from the bulk material mass. Type III degradation involves a 
degradation of a polymer side chain. This type of degradation has been observed with partially 
esterified maleic anhydride copolymers [62, 63]. The polymer becomes water-soluble as the side 
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chain carboxylate groups are ionized. Often times, polymer drug delivery systems will function 
via various combinations of the aforementioned degradation types. 
The desire to build into polymers precise zero-order surface erosion substrates, without 
alteration of the integrity of the inner structures, has been difficult to achieve. Although surface 
erosion can account for a significant portion of the release process, diffusion of the drug out of 
the device or solvent into the polymer ultimately contributes to the drug-release process and 
causes unpredictable changes in release rate that may not be desirable. However, a variety of 
factors has been identified that allow for the design of controlled release delivery systems. 
Changes in molecular weight and co-polymerization are two parameters that can be used 
to alter the degradation rates of controlled release systems. To date, the largest body of literature 
exists on polyesters such as poly(DL-lactide) or poly(DL-lactide-co-glycolide). These polyesters 
are commercially available with varied molecular weights and monomer ratios of lactide and 
glycolide. They are also available with acid end groups to impart higher hydrophilicity. Addition 
of low-molecular-weight poly(DL-lactide) (MW 2000 Da) increases drug release from a 
biodegradable poly(DL-lactide) (MW 120,000 Da) drug delivery system [64]. It was found that 
the duration of action could be varied over a range of several hours to months by changing the 
amount of low-molecular-weight poly(DL-lactide). 
The molecular weight of the drug species can also be varied to control the release profile. 
In the case of macromolecular drugs, major portions are released by polymer degradation and 
erosion, and a small portion is released by the diffusion mechanism. For instance, polypeptides 
usually have limited solubility in a polymer matrix of the aqueous channels present in the 
delivery system could be tortuous and narrow to facilitate diffusion. Reports from the literature 
indicate that the release of macromolecular drugs is tri-phasic, characterized by a high intial or 
“burst” release, a lag phase, and finally the release of drug at a higher rate until depletion. 
Physiologically, this may mean a brief period of therapeutic activity or even acute toxicity, a 
period of no activity corresponding to the lag phase, and finally sustained activity.  
 Many classes of polymers are hydrophobic and crystalline in nature and need certain 
modifications in order to have acceptable biodegradation and drug release. As an example, 
polycaprolactone is crystalline and hydrophobic, and it can take years for complete dissolution in 
the body. Similar to polylactides, the biodegradation rates of polycaprolactones can be hastened 
by blending with polymers such as PLA and PGA or alkylamines [65, 66]. Plasticizers can also 
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be added to polymeric systems to alter their degradation properties in addition to their 
mechanical properties. Addition of the plasticizer has been reported to reduce the glassy nature 
of the polymers, reduces the porosity, and may deform the surface owing to dehydration, all 
resulting in altered drug release [67, 68]. 
 The method of prepartion and processing used to manufacture the release system can 
have significant effects on the ultimate release rates observed. Degradtion of the polymer matrix 
and as well as the stability of the drug should be considered be for selecting a manufacturing 
process. Vapreotide, a somatostatin analogue, incorporated PLGA implants formulated by two 
different manufacturing techniques, extrusion and injection molding, and the influence of 
processing methods on the in vitro degradation of the polymer was studied [69]. Both methods 
decreased the molecular weight and polydispersity index of the polymer, but there was no 
change in the crystalline network. The extruded implants degraded more rapidly in vitro than the 
injection molded ones and showed higher early releases rates. The physiochemical properties of 
solvents used in the fashioning of biodegradable drug implants can affect the release profiles as 
well. The boiling point, volatility, and miscibility with other solvents need to be considered 
especially in the case of formulated micro- and nano-spheres. Solvent effects tend to alter the 
micro-sphere morphology, changing drug entrapment efficiency and release rates [70, 71]. 
 Numerous synthetic biodegradable polymers are available and still being developed for 
sustained release and targeted drug delivery applications. An enormous amount of literature is 
available on various means of altering the performance of these polymers and the delilvery 
systems they constitute. Development of such an optimized drug delivery system using 
biodegradable polymers can offer significant improvements in patient comfort and compliance. 
These systems in many cases reduce the required dose intake and limit unwanted toxicities, as 
well as providing better therapeutic efficacy owing to continuous availability of drug in the 
therapeutic ranges over an extended period. 
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2.0  LDI-GLYCEROL POLYURETHANE IMPLANTS EXHIBIT CONTROLLED 
RELEASE OF DB-67 AND ANTI-TUMOR ACTIVITY IN VITRO AGAINST 
MALIGNANT GLIOMAS 
2.1 ABSTRACT 
The purpose of the present study was to develop a biodegradable and biocompatible 
polyurethane drug delivery system based on lysine diisocyanate (LDI) and glycerol for the 
controlled release of 7-tert-butyldimethylsilyl-10-hydroxy-camptothecin (DB-67). DB-67 has yet 
to be implemented into any clinical due to an inability to be delivered in sufficient quantities to 
impact tumor growth and disease progression. To remedy this, DB-67 was covalently 
incorporated into our delivery system by way of an organometallic urethane catalyst, and was 
found dispersed uniformly throughout the LDI-glycerol polyurethane discs. Scanning electron 
micrographs indicate that the LDI-glycerol discs are uniform and possess a pore distribution 
typical of the non-solvent casting technique used to prepare them. The release rates of DB-67 
from the LDI-glycerol discs were found to follow zero-order kinetics, varying with both time and 
temperature, and were shown capable of delivering therapeutic concentrations of DB-67 in vitro. 
Cellular proliferation assays demonstrate that empty LDI-glycerol discs alone do not 
significantly alter the growth of malignant human glioma cell lines (U87, T98G, LN229, 
SG388). DB-67 loaded LDI-glycerol polyurethane discs were found to inhibit cellular 
proliferation by 50% on average in all the malignant glioma cell lines tested. These results 
clearly demonstrate the long-term slow release of DB-67 from LDI-glycerol polyurethane discs 
and their potential for postoperative intra-cranial chemotherapy of cancers. 
Keywords: drug delivery; polyurethane; camptothecin; glioma; lysine diisocyanate 
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2.2 INTRODUCTION 
Camptothecin (CPT) and its numerous synthetic analogs comprise a special class of anticancer 
agents active in lung, ovarian, breast, pancreas, and stomach cancers previously reported 
resistant to chemotherapy [2, 5, 6, 72]. CPT is a naturally occurring alkaloid first isolated from 
the Chinese tree Camptotheca acuminata (Nyssaceae) by Wall and co workers in 1966 [73]. 
Unsuccessful results in three early Phase I studies lessened the interest in the drug for a number 
of years [74-76]. It was later shown that CPT inhibited the enzyme topoisomerase I, a nuclear 
protein essential for DNA repair during replication, and interest in the drug and its analogs was 
reborn [77, 78]. Currently, two CPT analogs, topotecan and irinotecan, have been approved by 
the FDA, and at least 10 additional CPT derivatives are in various stages of clinical trials – 
including 9-amino-CPT in advanced clinical trials [2, 5].  
The pharmaceutical development and clinical utility of the camptothecins are limited by 
the distinctive dynamics of these agents in the blood stream. All of the camptothecins now in 
clinical development contain a ?-hydroxy-?-lactone moiety, and they exist in two distinct forms 
at the physiological pH of 7.0 and above. The biologically active “lactone-closed” form reacts 
with water to form a biologically inactive “lactone-opened” (carboxylate) form [8, 9]. This 
simple chemical hydrolysis dynamically inactivates the parent drug. Furthering the problem, the 
predominant human blood serum protein, albumin (HSA), preferentially binds the carboxylate 
form – shifting the equilibrium towards the inactive moiety [10-12]. Because camptothecins are 
S-phase specific drugs, optimal topo I inhibitory activity is only obtained when the tumors of a 
patient are continuously exposed to the drug. Accordingly, establishing conditions where a 
therapeutically relevant concentration of the lactone-closed form of a camptothecin is present 
over a suitable period for tumor cells to cycle through the S-phase is a major challenge. 
The CPT analog, 7-tert-butyldimethylsilyl-10-hydroxy-camptothecin (DB-67), was 
synthesized in an attempt to further enhance the therapeutic performance of this class of drugs 
[79-81]. DB-67 displays superior stability in plasma relative to other camptothecin agents, likely 
due to its lipophilicity and reduced interactions with the carboxylate-binding site on serum 
albumin. The analog also possesses a high intrinsic potency against the topo I target enzyme with 
a unique DNA cleavage profile. Ultimately, the combination of its potency and stability profiles 
suggests that it may be more efficacious than the currently used FDA-approved CPT-based 
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therapies. However, the compound is largely water-insoluble, making it difficult to deliver into 
the body through the conventional routes such as oral, intravenous or intramuscular injection 
[12]. As such, DB-67 has yet to be implemented into any clinical therapies due to an inability to 
be delivered in adequate quantities to impact tumor growth and disease progression. 
Surgically implantable polymer matrices loaded with chemotherapeutic agents are a 
proven approach to localized drug delivery [48, 82, 83]. The matrix is loaded with the desired 
agent and then implanted within the tumor site, following as complete a surgical resection as 
clinically possible. The matrix releases its drug load over a period pre-determined by the 
characteristics of the encapsulating polymer, delivering drug to neoplastic cells existing in the 
peritumoral region that otherwise would give rise to recurring tumor. Typically, these types of 
drug delivery systems have been created by dissolving drug in a polymer and processing it into 
the desired morphology. The drug remains physically entrapped in the polymer, but it is not 
anchored through chemical bonds – and a burst release of drug subsequently follows. CPTs have 
previously been delivered in this manner [83-86]. Because the degree of survival improvement 
with previous polymer-based local delivery approaches, although statistically significant, has 
been modest at best, there is a rationale to build on this strategy in order to further enhance 
therapeutic efficacy. Our goal was therefore to develop a synthetic, biodegradable matrix 
incorporating DB-67 through labile chemical bonds, resulting in controlled long-term delivery of 
the agent to tumor cells. 
Our laboratory has developed a new generation of biocompatible polyurethanes 
composed of lysine diisocyanate (LDI) and glycerol that degrade into the non-toxic components 
– lysine, glycerol, and CO2 [87, 88]. Only a handful of studies have reported the successful use 
of polyurethanes in drug delivery applications, and their favorable results support further 
examination of this approach [89-94]. Our peptide-based urethane possesses the versatility of 
commercial polyurethane systems, but lacks the toxicity associated with commercial urethane 
degradation products. The goal of this study was to develop a biodegradable polyurethane disc 
incorporating DB-67 through reactive isocyanate groups capable of controlled, long-term drug 
delivery to tumor cells through hydrolysis of urethane linkages. We hypothesized that it is 
possible to incorporate DB-67 into the backbone of such a polymer and impact cellular growth in 
vitro – the ultimate goal being long-term delivery of active compound over a period of months in 
vivo. 
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2.3 MATERIAL AND METHODS 
2.3.1 Materials 
Lysine diisocyanate methyl ester (LDI) was purchased from Chemical Division, Kyowa Hakko 
Kogyo Co. Ltd. (Tokyo, Japan).  7-tert-butyldimethylsilyl-10-hydroxycamptothecin (DB-67) 
was obtained from Dr. Dennis Curran at the University of Pittsburgh, Chemistry Dept.  
(Pittsburgh, PA). The human malignant glioma cell lines U87 and T98G were obtained from the 
American Type Tissue Culture Collection. LN229 was kindly provided by Dr. Nicolas de 
Tribolet (Lausanne, Switzerland). The SG388 cell line was established at Children’s Hospital of 
Pittsburgh from a tumor specimen identified by a neuropathologist. MTS reagents were obtained 
from Promega. Chemicals were obtained from Sigma–Aldrich Chemical Co. and were of reagent 
grade unless otherwise specified (Milwaukee, WI). 
2.3.2 Reaction of DB-67 with LDI 
Lysine methyl-ester diisocyanate (MW 212, 4.43 mg, 0.021 mmol) was added to DB-67 (MW 
479, 10.0 mg, 0.021 mmol) in a 1:1 molar ratio and dissolved in 1 ml of THF in a dry flask. Two 
samples were prepared and 10 μL of tin(II) 2-ethylhexanoate (MW 405, d 1.251, 0.031 mmol) 
was added to one sample. Samples were sealed and stirred in the dark at room temperature for 48 
hours. THF was then removed at 50 °C in a vaccum oven, and the resulting solid was 
incorporated into a potassium bromide (KBr) window. FT-IR spectroscopy was then used to 
confirm the presence or absence of isocyanate signal at 2265 cm
-1
 in the samples. 
2.3.3 Synthesis of the LDI-glycerol Polyurethane containing DB-67 
DB-67 (MW 479, 10 mg, 0.021 mmol), LDI (MW 212, 3.93 g, 18.52 mmol) and tin(II)-2-
ethylhexanoate (MW 405, 5μl, 0.016 mmol) were added to a small, dry reaction vessel. The flask 
was then flushed with nitrogen, sealed, and the mixture was allowed to stir in the dark at room 
temperature for a period of 24 hours. Glycerol (MW 92, 1.13g, 12.28 mmol) and dry, HPLC 
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grade acetone (2.5 ml) were then added to the flask. The flask was again flushed with nitrogen, 
sealed, and allowed to stir vigorously in the dark at room temperature for approximately 72 
hours. During this time the mixture changed from opaque to translucent and its viscosity 
increased.  
Following a 72-hour reaction period, a non-solvent casting technique was used to cast the 
material into a film. The viscous pre-polymer was transferred to a 65mm PTFE dish submerged 
in an ethyl-acetate (EtAc) bath. The pre-polymer was allowed to cure for 5 days in the dark at 
room temperature and then placed into a vacuum oven at 45 °C for 24 hours to remove residual 
EtAc and acetone. At this time the resulting film was removed from the PTFE dish and cut into 
discs using a 4mm tissue biopsy punch (Sklar Instruments). The discs were placed into an 
ethanol bath in order to remove residual acetone from the polymerization reaction; the discs were 
left to soak in the dark for 7 days and the ethanol was changed daily. Following the ethanol 
wash, the samples were rinsed several times with deionized H2O, and allowed to soak in the dark 
for 72 hours to remove any remaining ethanol. The deionized H2O was changed twice daily. The 
discs were then dried overnight in a vacuum oven at 45 °C and placed into storage in the dark at 
4 °C for further analysis. Control discs not containing DB-67 were prepared by adding LDI, 
glycerol, and tin catalyst in the same amounts as above simultaneously to a reaction vessel. The 
contents were then reacted and processed as previously described. 
2.3.4 Distribution of DB-67 
Twenty LDI-glycerol discs containing DB-67 were placed into individual sample vials. One 
milliliter of 1N NaOH was added to each vial, and the vials were sonicated at 45 °C for 1 hour to 
completely hydrolyze the polymer. In basic solution, DB-67 will exist in it ionized hydroxy-acid 
form, but its fluorescent properties are identical to the closed lactone form [81]. Samples were 
stored in the dark at 4 °C overnight and analyzed the following day. 
The DB-67 content of each LDI-glycerol disc was assessed with fluorescence 
spectroscopy utilizing 430 nm and 550 nm for the excitation and emission wavelengths, 
respectively. Samples were diluted 100-fold with de-ionized water prior to being read. Each 
sample was read 10 times in rapid succession, and an average of the signal was used to calculate 
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DB-67 content from a standard curve (R
2
=0.9995). Standards were prepared by serial dilution 
from a 50 μg/ml stock solution in 1N NaOH.  
Lysine content of the polymer discs was assessed using the ninhydrin colorimetric assay. 
Ninhydrin reagent was prepared by dissolving ninhydrin (MW 178, 2.0 g, 11.23 mmol) in 50 ml 
DMSO and stannous chloride (MW 190, 80 mg, 0.42 mmol) in 50 ml of 0.2 M citrate buffer (pH 
5). These two solutions were mixed; the resulting solution was used the same day. Polymer 
samples dissolved in NaOH were diluted 20-fold with PBS (pH 7.4). 20 μL of the diluted sample 
was added to 1 ml of ninhydrin reagent and immersed in boiling water for 20 minutes. 200 μL 
from each sample was then transferred to a 96-well plate and the absorbance at 570 nm was read 
and used to calculate the lysine content from a standard curve (R
2
=1.0000). Standards were 
prepared by serial dilution from a 10 mg/ml stock solution of lysine methyl-ester in PBS (pH 
7.4) Each sample was assayed in triplicate and the average was used to determine the final lysine 
content. 
2.3.5 Stability of DB-67 in Aqueous Solution 
Previous studies have reported the fluorescence quenching of CPT in aqueous solution [95]. In 
order to assess the stability of DB-67’s fluorescence signal in aqueous solution, 200 nM DB-67 
solutions were prepared in PBS (pH 7.4) from a 10 mM stock solution prepared in DMSO. 
Samples were placed on rocking plates and incubated in a temperature-controlled room at 4, 22, 
and 37° C for 60 days. Every 7 days, 3ml of PBS was retrieved and DB-67 content was assessed 
using fluorescence spectroscopy. 
2.3.6 In vitro Release of DB-67 
LDI-glycerol polyurethane samples containing DB-67 were incubated at 10 mg/ml in PBS (pH 
7.4) on rocking plates in temperature-controlled rooms at 4, 22, and 37° C for 60 days. Sample 
chambers were protected from light during this time. Every few days, 3 ml of PBS was retrieved 
from each sample. The amount of DB-67 released from the polymer was detected using 
fluorescence spectroscopy and a standard curve (R
2
=0.9973), with 430 and 550 nm as the 
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excitation and emission wavelengths, respectively. Lysine and glycerol release from the polymer 
were not assessed at this time due to the extremely low concentration of these species present in 
the degradation media. 
2.3.7 Effect of Polyurethane Tablets on Cellular Proliferation 
A panel of human malignant glioma cell lines consisting of U87, T98G, SG388, and LN229 was 
used for the anti-proliferative analysis of our drug releasing polymer discs. For these studies, 1 x 
10
2
 cells were plated and grown for 24 hr in 100 μl of growth medium in 96-well plates. Polymer 
discs were then added to the cells and they were incubated for 5 days. Positive and negative 
controls received a stock solution of DB-67 (100 nM final concentration) or media alone, 
respectively. In all cases, final concentrations of DMSO were ?0.1%, well below the 
concentrations that interfere with the proliferation in the above cell lines. After the incubation 
period, the number of viable glioma cells were determined by measuring the bio-reduction of the 
tetrazolinium compound MTS by intracellular hydrolases in the presence of the electron coupling 
reagent PMS as previously described [96]. All samples were tested in twelve separate wells and 
averaged. 
Prior to beginning the anti-proliferative analysis described, varying numbers of cells from 
each of the four malignant gliomal cell lines were plated, and the MTS signal was measured at 
24-hour intervals over a 5 day period (data not shown). From these preliminary studies, it was 
found that plating 1 x 10
2
 cells/well retained a linear MTS signal over the proposed 5-day 
incubation period.  
2.4 RESULTS AND DISCUSSION 
2.4.1 Reaction of DB-67 and LDI 
Our laboratory has previously shown that polyurethanes synthesized from LDI and glycerol 
degrade hydrolytically into the non-toxic components lysine, glycerol, and CO2 [87]. DB-67 was 
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incorporated into the LDI-glycerol polymer by way of hydrolysable urethane linkages in an 
attempt to retain its anti-proliferatve activity. Figure 6 illustrates the chemical structure of these 
components and that of the proposed polymer structure. 
 
 
 
 
Figure 6 – Molecular structure of DB-67, LDI, glycerol and the LDI-glycerol polyurethane 
 
FT-IR data demonstrate isocyanate signal at 2265 cm
-1
 that persists in a 1:1 molar reaction 
between DB-67 and LDI after 48 hours (Figure 7). When tin(II) 2-ethylhexanoate, an 
organometallic urethane catalyst, is present there is an absence of any isocyanate band after 48 
hours. Complete disappearance of the isocyanate signal in a 1:1 molar reaction of LDI and DB-
67 (1:1 NCO/OH) suggests that both of the hydroxyl groups present in DB-67 have reacted. 
Identification of the individual carbonyl bands representative of the newly formed urethane is not 
possible here, as DB-67 also contains several carbonyl structures that overlap in that particular 
region of the spectra. Furthermore, the FT-IR spectra of DB-67 and LDI alone demonstrates 
hydroxyl stretching at 3430 cm
-1
, and a shift of that band to 3380 cm
-1
 occurred when catalyst 
was added – suggesting the formation of a secondary amine, and hence urethane linkages. 
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Figure 7 - IR Data depicting 1:1 molar reactions between DB-67 and LDI after 48 hours: (A) without tin(II) 
2-ethylhexanoate, (B) with 10 μl tin(II) 2-ethylhexanoate 
 
2.4.2 Characterization of LDI-Glycerol Tablets 
Our lab has previously synthesized LDI-based foams that support cellular growth and attachment 
[87, 88]. The polyurethane tablets fashioned in this study differ in morphology from those 
materials previously studied.  Scanning electron micrograph images reveal polymer samples with 
a unique pore distribution through out the volume of the tablet (Figure 8). This morphology is 
artifact and is typical of non-solvent casting techniques used to form the film that was later cut 
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into 4mm discs. However, all surfaces of the material appeared identical under higher 
magnification. 
A B
C D
 
 
 
Figure 8 – Scanning electron microscope images of an LDI-glycerol drug delivery system: (A) Top surface of 
tablet which was exposed to non-solvent during the curing process, (B) View of bottom surface in contact with 
Teflon surface during curing, (C) Cross-sectional image of tablet demonstrates pore distribution, (D) 
Examination at 8000x magnification (only bottom surface is shown) 
 
An FT-IR spectrum of the LDI-glycerol polyurethane disc with DB-67 was obtained 
through freezing a small sample in liquid nitrogen, crushing it, and then incorporating it into a 
KBr window (Figure 9). The spectrum does not display the characteristic isocyanate signal at 
2265 cm
-1
, while it does indicate urethane and secondary amine formation at 1720 cm
-1 
and 3400 
cm
-1
, respectively. The spectrum also displays the requisite CH2 (2945 cm
-1
), CH (2865 cm
-1
), 
and C=O (1260 cm
-1
) stretching frequencies, as well as the NH bending frequency (1540 cm
-1
). 
All of these signals are consistent with the polymer structure shown in Figure 1. Individual 
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frequencies of the DB-67 moiety were not able to be resolved due to the low concentration of the 
species in the sample. 
 
 
 
 
Figure 9 - FT-IR spectrum of an LDI-glycerol polyurethane disc containing DB-67 
 
It is essential that drug delivery systems be able to be reliably reproduced in the amounts 
and under the conditions required for clinical use [4]. Therefore, it was important to ensure that 
the polymer processing techniques used in this study resulted in reproducible samples with 
uniform distribution of drug throughout the samples. LDI-glycerol polymer discs containing DB-
67 (n=20) were produced using the aforementioned methods, and analyzed for average DB-67, 
lysine, and glycerol content (Table 2). The relative percentages listed are calculated from the 
total weight of the synthetic constituents, not the degradation products resulting from polymer 
hydrolysis. 
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Table 2 - DB-67, lysine and glycerol content of LDI-glycerol polymer discs 
 
 
DB-67 Lysine Glycerol
a
 
Polymer 
disc (mg) g wt % mg wt % mg wt % 
g DB-67 
mg polymer  
18.3 14.7 ± 0.1 0.08 12.5 ± 0.4 68.2 1.8 10.1 0.8 
22.7 17.7 ± 0.1 0.08 13.9 ± 0.4 61.3 4.3 19.2 0.8 
20.8 16.3 ± 0.1 0.08 12.9 ± 0.4 62.2 3.8 18.0 0.8 
20.9 16.3 ± 0.1 0.08 13.4 ± 0.5 64.2 3.2 15.4 0.8 
19.9 15.4 ± 0.1 0.08 11.9 ± 0.4 60.0 4.2 20.9 0.8 
16.5 12.6 ± 0.1 0.08 11.2 ± 0.5 68.1 1.7 10.3 0.8 
17.4 13.4 ± 0.1 0.08 11.2 ± 0.4 64.2 2.7 15.4 0.8 
17.3 13.4 ± 0.1 0.08 11.7 ± 0.6 67.8 1.8 10.6 0.8 
19.7 15.8 ± 0.1 0.08 13.0 ± 0.5 65.9 2.6 13.2 0.8 
22.1 17.1 ± 0.1 0.08 13.5 ± 0.6 60.9 4.4 19.7 0.8 
17.2 13.2 ± 0.1 0.08 11.4 ± 0.5 66.3 2.2 12.7 0.8 
17.8 13.5 ± 0.1 0.08 11.8 ± 0.3 66.4 2.2 12.6 0.8 
16.2 12.5 ± 0.1 0.08 10.5 ± 0.7 64.5 2.4 15.0 0.8 
17.3 13.6 ± 0.25 0.08 11.4 ± 0.5 65.7 2.3 13.4 0.8 
18.3 13.1 ± 0.1 0.07 11.0 ± 0.4 56.0 3.8 21.0 0.7 
15.5 12.0 ± 0.1 0.08 10.1 ± 0.6 65.2 2.2 14.1 0.8 
21.0 16.0 ± 0.1 0.08 13.4 ± 0.5 63.9 3.3 15.8 0.8 
17.4 13.7 ± 0.1 0.08 10.9 ± 0.3 62.7 3.0 17.4 0.8 
15.9 12.1 ± 0.1 0.08 10.1 ± 0.6 63.6 2.6 16.2 0.8 
18.2 13.8 ± 0.1 0.08 11.2 ± 0.5 61.3 3.5 19.2 0.8 
18.5 ± 2.1 14.32 ± 0.1 0.08 11.9 ± 0.5 64.12 2.9 ± 0.9 15.5 0.8 
 
a
glycerol content = (total mass) – (mass of  LDI and DB-67)  
 
Samples were found to have a consistent drug load of 14.3 μg DB-67 per disc, or 0.08% (w/w). 
The relative percentages of lysine and glycerol were found to be 64.1% (w/w) and 15.5% (w/w), 
respectively. These values agree reasonably well with the nominal percentages predicted from 
the reaction stoichiometry of 58.7% and 22.2% lysine and glycerol, respectively. Although the 
weights of the discs were found to vary, the drug is evenly distributed throughout the polymer 
film (0.772 μg drug/mg polymer). It is clear upon inspection of these results that the processing 
techniques used in this study are reproducible and result in uniform distribution of DB-67 
throughout the material. 
Given 10 mg of DB-67 was used in our synthetic reaction and the weight of LDI and 
glycerol used was approximately 5 grams, we would anticipate the LDI-glycerol polyurethane 
discs to contain 0.2% (w/w) drug. However, the discs were found to contain 0.08 % (w/w) DB-
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67, indicating that only 38.5% of the DB-67 used was successfully loaded into the polymer. We 
believe the decreased loading of drug results from a few key factors. First, the DB-67 
fluorescence signal was found to be light sensitive and to decay significantly at 37 °C when left 
exposed to light in aqueous media (Figure 10).  
 
 
 
 
Figure 10 - Fluorescence decay profiles of 200 nM DB-67 solutions in PBS (pH 7.4) left unprotected from light 
at 4, 22 and 37 °C. Error bars represent one standard deviation from the mean 
 
It is likely that the decaying fluorescence signal results in an underestimation of the total drug 
content in our samples as well as what was being released in vitro. Second, our synthetic reaction 
relies on the use of acetone as a polymerization solvent, and it must be removed from the discs 
prior to tissue culture with a series of ethanol and deionized water washes. The half-life of other 
CPT analogs in aqueous solution has been reported to be on the order of 20 minutes [97]. Our 
discs were subject to an aqueous environment for 72 hours, and this may have contributed to 
some of the loss DB-67 signal. Third, small oligomers if present in the viscous pre-polymer are 
likely to be sparingly soluble in EtAc. As a result they are then lost during the curing process.  
This was confirmed by FTIR of the polymer residue found on the bottom of our curing chambers 
after the EtAc was allowed to evaporate (data not shown). These factors when combined can 
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reasonably account for the “missing” DB-67 in our polyurethane films, and refinement of the 
processing techniques can certainly limit this loss in the future. 
2.4.3 In vitro Drug Release 
DB-67 possesses a characteristic, intense excitation-emission spectra that makes it easily 
detectable in aqueous solution at extremely low concentrations although the drug is sparingly 
soluble [54, 97]. The fluorescence excitation/emission spectrum of a 10 μg/ml DB-67 solution 
prepared in 1N NaOH is shown in Figure 11.  
 
 
 
 
Figure 11 - Excitation-emission fluorescence spectra of a 1.0 mg/ml DB-67 solution in 1N NaOH 
 
There was no appreciable signal present in the DB-67 emission range from the solution used to 
dissolve the samples and to prepare standards. The standard curve used to assess the degradation 
samples was linear over the concentration ranges used for detection (R
2
=0.9998). Since the DB-
67 fluorescence signal was found to be light sensitive and was shown to significantly decay over 
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time when left exposed to ambient light in the temperature controlled rooms, degradation 
samples were kept in the dark in an attempt to limit signal decay. However, it is still possible that 
we are underestimating the true concentration of DB-67 in solution using this method. 
 The small amount of DB-67 incorporated into the discs was assumed to not alter 
the degradative kinetics of the LDI-glycerol material. Figure 12 shows the release profiles of 
LDI-glycerol discs containing 0.08 % (w/w) DB-67 content. 
 
 
 
 
Figure 12 - In vitro release characteristics of DB-67 from LDI-Glycerol tablets incubated at 10 mg/ml in PBS 
at 4, 22, and 37 °C (pH 7.4). Error bars represent one standard deviation from the mean 
 
Drug release was shown to vary in a temperature dependent fashion, with the highest drug loads 
being released at 37 °C. The release at 22 °C was observed to follow zero-order kinetics. These 
results agree well with the degradation profile previously observed for LDI-based polyurethanes 
[87]. By day 65 of the study, DB-67 concentrations of 1.4, 3.1, and 9.2 ng/ml were obtained in 
aqueous solution at 4, 22, and 37 °C, respectively. These values represent 0.02, 0.04, and 0.1 % 
of the total drug load contained in the samples. These results indicate that only a small fraction of 
the total drug load found its way into solution, and that slow release of drug from a polymer by 
way of urethane hydrolysis is indeed a successful long-term release strategy. It was not possible 
to assess whether the DB-67 being released was in its active lactone or inactive hydroxy-acid 
 39 
form, but in vitro cytotoxicity assays should provide insight. It is well-known that in vivo 
degradation rates of polymers are increased relative to those seen in vitro [98, 99], and this effect 
has also been noted to occur in polyurethane materials as well [100]. Therefore, we anticipate 
achieving higher concentrations of DB-67 in vivo than were obtained in vitro. 
2.4.4 Cytotoxicity Assays 
Previous studies indicate that CPT and its many analogs are quite effective at halting the growth 
of malignant tumors [80, 101-104], and one study in particular has examined the in vitro effects 
of DB-67 on malignant gliomal cell lines [96]. In that study, DB-67 was found to inhibit the 
growth of malignant gliomal cell lines at extremely low concentrations. Specifically, the U87, 
SG388 and T98G cell lines were found to have decreased proliferation in the presence of DB-67 
at concentrations of 2, 3, and 6 ng/ml, respectively. Our degradation assays of the LDI-glycerol 
discs containing 0.08 % (w/w) DB-67 have shown that by day 6 a concentration of 3.2 ng/ml was 
attained in PBS at 37 °C.  Therefore, we anticipated that the amounts of drug being released from 
LDI-glycerol discs are great enough to inhibit growth in our panel of malignant glioma cell lines.  
The cytotoxicities of the LDI-glycerol discs containing 0.08 % (w/w) DB-67 in each of 
the malignant gliomal cell line are shown in Figure 13.  
 
 
 
 
Figure 13 - In vitro cytotoxicity results of (A) 3-day and (B) 5-day treatments on malignant gliomal 
cell lines. Error bars represent one standard deviation from the mean 
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Empty polymer discs were found to not significantly differ from cells grown in media alone at 
the ?=0.0001 level of significance. In all malignant gliomal cell lines, a statistically significant 
difference was seen between neat polymer and “drug-loaded” polymer in both 3-day and 5-day 
treatment groups (p<0.0001). In the T98G, SG388, and LN229 malignant gliomal cell lines there 
was no significant difference between the 100 nM DB-67 treated cells and the 0.08% (w/w) DB-
67 discs (p<0.0001). The cytotoxicity data has been summarized in Table 3.  
 
Table 3 - In vitro cytotoxicity of DB-67 loaded LDI-glycerol polyurethanes 
 
 
 3 Day Treatment 
Media alone  100 nM DB-67 Empty disc DB-67 disc 
Cell line 
MTS
a
 MTS % control MTS % control MTS % control 
LN229 0.992 ± 0.045 0.247 ± 0.012 24.9 ± 1.2 1.080 ±0.195 108.9 ± 19.6 0.554 ± 0.179 55.9 ± 18.1 
T98G 1.155 ± 0.103 0.342 ± 0.022 29.6 ± 1.9 0.986 ± 0.179 85.4 ± 15.5 0.452 ± 0.269 39.1 ± 23.3 
SG388 0.938 ± 0.084 0.416 ± 0.024 44.4 ± 2.6 0.755 ± 0.098 80.6 ± 10.5 0.426 ± 0.124 45.4 ± 13.3 
U87 0.625 ± 0.069 0.222 ± 0.013 35.5 ± 2.1 0.568 ± 0.074 90.9 ± 11.9 0.434 ± 0.047 69.4 ± 7.6 
 
 
 5 Day Treatment 
Media alone  100 nM DB-67 Empty disc DB-67 disc 
Cell line 
MTS MTS % control MTS % control MTS % control 
LN229 1.071 ± 0.059 0.247 ± 0.009 23.0 ± 0.8 0.844 ± 0.110 78.8 ± 10.2 0.447 ± 0.226 41.7 ± 21.1 
T98G 2.486 ± 0.202 0.285 ± 0.029 11.5 ± 1.2 2.282 ± 0.278 91.8 ± 11.2 0.482 ± 0.341 19.4 ± 13.7 
SG388 1.720 ± 0.163 0.410 ± 0.010 23.8 ± 0.6 1.545 ± 0.189 89.8 ± 11.0 0.328 ± 0.124 19.1 ± 7.2 
U87 1.202 ± 0.144 0.205 ± 0.011 17.1 ± 0.9 1.201 ± 0.159 99.9 ± 13.3 0.804 ± 0.105 66.9 ± 8.7 
a
MTS = absorbance at 490 nm  
 
These results suggest that DB-67 is being released in its active lactone-closed structure from the 
LDI-glycerol discs and it is present in concentrations high enough to impact malignant glioma 
proliferation in vitro. 
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2.5 CONCLUSIONS 
In this study, we present a novel approach to the controlled delivery of the CPT analog DB-67 
employing biocompatible, biodegradable polyurethanes constructed from LDI and glycerol. Our 
delivery system differs from other conventional approaches in that the drug has been covalently 
bound into the polymer framework. We have shown that DB-67 incorporates by reacting with 
LDI in the presence of an organometallic urethane catalyst. The drug is then released through 
slow, passive hydrolysis of urethane bonds. We were able to demonstrate the ability of an LDI-
glycerol polyurethane disc to steadily deliver drug over a prolonged period. Therapeutic 
concentrations of the potent anticancer compound on the order of nanograms/ml were attained 
through steady, zero-order release from the polyurethane discs over a 65-day period with the 
potential to continue for much longer periods of time. It has also previously been demonstrated 
that the lactone moiety must remain intact in order to observe any cytotoxic effect[80]. Cellular 
proliferation assays conclude that only LDI-glycerol discs loaded with DB-67 exhibited any 
cytotoxic effect. It is unclear at this time how the polymer is able to stabilize the active lactone 
structure during the degradative process. These results from this study clearly demonstrate the 
potential for long-term drug release from a surgically implantable LDI-glycerol polyurethane 
device. 
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3.0  LDI-GLYCEROL POLYURETHANE FOAMS DEMONSTRATE CATALYST-
DEPENDENT CONTROLLED RELEASE PROFILES AND EXHIBIT ANTI-TUMOR 
ACTIVITY AGAINST MALIGNANT GLIOMA CELLS 
3.1 ABSTRACT 
The purpose of the present study was to develop a biodegradable and biocompatible 
polyurethane drug delivery system based on lysine diisocyanate (LDI) and glycerol for the 
controlled release of 7-tert-butyldimethylsilyl-10-hydroxy-camptothecin (DB-67). The impact of 
urethane catalysts on cellular proliferation was assessed in an attempt to enhance the 
biocompatibility of our polyurethane materials. DB-67, a potent camptothecin analogue, was 
then incorporated into LDI-glycerol polyurethane foams with two different amine urethane 
catalysts: 1,4-diazobicyclo[2.2.2]-octane (DABCO) and 4,4’-(oxydi-2,1-ethane-
diyl)bismorpholine (DMDEE). The material morphologies of the polyurethane foams were 
analyzed via SEM. DB-67 distribution throughout the foams was assessed through fluorescence 
microscopy. Release rates of DB-67 from the DABCO and DMDEE foams were found to be 
catalyst dependent and vary with temperature. The foams were capable of delivering therapeutic 
concentrations of DB-67 in vitro over an 11-week period. Cellular proliferation assays 
demonstrate that empty LDI-glycerol foams do not significantly alter the growth of malignant 
human glioma cell lines (p < 0.05). DB-67 loaded LDI-glycerol polyurethane foams were found 
to inhibit cellular proliferation by at least 75% in all the malignant glioma cell lines tested (p < 
1.0 x 10
-8
). These results clearly demonstrate the long-term, catalyst-dependent release of DB-67 
from LDI-glycerol polyurethane foams and their potential for use as implantable drug-delivery 
devices.  
Keywords: lysine diisocyanate, polyurethane, drug delivery, camptothecin; glioma 
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3.2 INTRODUCTION 
Camptothecin (CPT) and its numerous synthetic analogs comprise a special class of anticancer 
agents that appear to be quite active in human lung, ovarian, breast, pancreas, and gastric cancers 
previously reported resistant to chemotherapy [2, 5, 6, 72]. CPT is a naturally occurring alkaloid 
that was first isolated from the Chinese tree Camptotheca acuminata (Nyssaceae) by Wall and co 
workers in 1966 [73]. It inhibits the enzyme topoisomerase I, a nuclear protein essential for DNA 
repair during replication [77, 78]. Currently, two CPT analogs, topotecan and irinotecan have 
been approved by the FDA, and at least 10 additional CPT derivatives are in various stages of 
clinical trials – including 9-amino-CPT in advanced clinical trials [2, 5]. The CPT analog 7-tert-
butyldimethylsilyl-10-hydroxy-camptothecin (DB-67) was synthesized in an attempt to enhance 
the stability and performance of CPTs [79-81]. DB-67 displays superior human blood stability 
relative to other camptothecin agents and possess a very high intrinsic potency against the topo I 
target enzyme. However, the compound is largely water-insoluble which has made clinical use 
quite difficult [12]. DB-67 has yet to be implemented into any clinical therapies due to an 
inability to be delivered in adequate quantities to impact tumor growth and disease progression.  
Polyurethanes are a special class of synthetic materials that are widely used in many 
modern industrial applications as insulations, sealants, coatings, and foams [105]. Many have 
gained FDA approval and currently find a place in numerous medical technologies due to their 
unique chemical and physical properties [106-110]. Polyurethanes are easily synthesized from 
diisocyanate and polyalcohol precursors via a condensation reaction that can be controlled by 
various urethane formation catalysts. The catalytic mechanisms and their effects on the resultant 
polymer architecture are well understood and can be tailored to specific material applications. 
Polyurethane catalysts for the most part are classified into two simple, distinct categories: 
organometallic and amine [18, 20]. The reactions they catalyze can be broken down into three 
categories: blowing, gelling, and cross-linking. The blowing reaction involves the reaction of 
isocyanate and water and generates a carbamic acid intermediate. As carbamic acid readily 
decomposes into an amine and CO2, the polyurethane expands into foam.  The gelling reactions 
simply refer to urethane or urea formation. The crosslinking reactions are generally quite limited 
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and refer to the reaction of isocyanate with itself, urethanes or ureas. Organometallic catalysts 
are often tin-based and tend to be more selective for gelling reactions, catalyzing urethane and 
urea formation. Amine catalysts are chiefly tertiary amines and they catalyze both gelling and 
blowing reactions. In this study, we focus primarily on the tertiary amine catalysts 1,4-
diazobicyclo[2.2.2]-octane (DABCO) and 4,4’-(oxydi-2,1-ethane-diyl)bismorpholine, also 
known as dimorpholino-diethyl ether (DMDEE). DABCO is rather non-selective in nature and 
known to catalyze both gelling and blowing reactions, while DMDEE is specific for the blowing 
reaction. 
The stability and degradative characteristics of polyurethane materials are ideal for the 
construction of controlled-release systems. However, the use of polyurethanes in the arena of 
drug delivery remains largely unexplored, although studies do exist that support their use [111-
114]. Our laboratory has developed a new generation of biocompatible, biodegradable 
polyurethane constructed from lysine diisocyanate (LDI) and glycerol that degrade predictably 
via a hydrolytic mechanism into non-toxic components – lysine, glycerol and CO2 [87, 88]. 
These materials possess the same versatility as widely used commercial polyurethanes, easily 
being processed into forms with unique physical properties. We have previously synthesized 
LDI-glycerol films and demonstrated their use as long-term drug delivery reservoirs. However, 
we can also fashion these materials into foams possessing different drug-delivery characteristics. 
We can also attempt to use the catalytic mechanisms to regulate the incorporation of drug and 
impact the release characteristics of our drug delivery systems. The purpose of this study is to 
formulate and characterize a drug delivery systems based on hydrolysable polyurethane foams 
prepared from LDI and glycerol. 
3.3 MATERIAL AND METHODS 
3.3.1 Materials 
Lysine diisocyanate methyl ester (LDI) was purchased from Chemical Division, Kyowa Hakko 
Kogyo Co. Ltd. (Tokyo, Japan).  7-tert-butyldimethylsilyl-10-hydroxycamptothecin (DB-67) was 
obtained from Dr. Dennis Curran at the University of Pittsburgh, Chemistry Dept.  (Pittsburgh, 
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PA). The human malignant glioma cell lines U87 and T98G were obtained from the American 
Type Tissue Culture Collection. LN229 was kindly provided by Dr. Nicolas de Tribolet 
(Lausanne, Switzerland). The SG388 cell line was established at Children’s Hospital of 
Pittsburgh from a tumor specimen identified by a neuropathologist. MTS reagents were obtained 
from Promega. Bismuth 2-ethylhexanoate was obtained from Alfa Aesar (Ward Hill, MA). All 
other chemicals were obtained from Sigma–Aldrich (Milwaukee, WI) and were of reagent grade 
unless otherwise specified. 
3.3.2 Urethane Catalyst Toxicity 
T98G cells were plated in MEM media at a density of 100 cells/well in 96-well plates. The plates 
were incubated for 24 hours to allow for cell adhesion, and the media was changed prior to any 
treatment. Solutions of bismuth 2-ethylhexanoate (MW 639), tin(II) 2-ethylhexanoate (MW 
405), dibutyltin dilaurate (MW 632), DABCO (MW 112) and DMDEE (MW 244) were prepared 
in DMSO; the final concentration of each solution was 10 mM. The catalyst solutions were 
mixed thoroughly, and 1.0 ml of each was diluted with 4.0 ml of growth media to arrive at 2 mM 
solutions. Serial dilutions of the catalyst/media solutions were performed across two 96-well 
plates, halving the concentration with each dilution. After a 5 day incubation period, the number 
of viable T98G cells were determined by measuring the bio-reduction of the tetrazolinium 
compound MTS by intracellular hydrolases in the presence of the electron coupling reagent PMS 
as previously described [96]. 
The study was then repeated with DABCO (MW 112, 1.122g, 10 mmol) and DMDEE 
(MW 244, 2.443g, 10 mmol), adding each to 5.0 ml of MEM media. The resulting 2.0 M 
catalyst/media solutions were mixed until all of the catalyst had dissolved. The solutions were 
then diluted as before across three 96-well plates, and T98G proliferation was quantified after 5 
days via MTS. LD50 values were taken as the lowest catalyst concentration at which the MTS 
signal registered < 50% of the control value.  
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3.3.3 Reaction of LDI with DB-67: DMDEE vs. DABCO 
DB-67 (MW 479, 32.0 mg, 0.07 mmol) was dissolved in 1.07 ml dry DMSO to yield a 30 mg/ml 
solution. Two small reaction flasks were each loaded with LDI (MW 212, 5.3 mg, 0.3 mmol) and 
400 uL of the DB-67 solution. DABCO (MW 112, 1.3 mg, 0.01 mmol) was added to one flask, 
and DMDEE (MW 244, 3.4 mg, 0.01 mmol) was added to the other. Both flasks were briefly 
mixed and IR spectra immediately taken. The flasks were flushed with nitrogen, sealed, and left 
to mix in the dark at room temperature; IR spectra were taken again in 4 hours. IR scans were 
taken at 0 and 4 hours to minimize the occurrence of urethane side-reactions. 
3.3.4 Synthesis of LDI-glycerol polyurethane foams 
Two small, dry reactions flasks were prepared, each containing glycerol (MW 92, 1.13 g, 12.3 
mmol), LDI (MW 212, 3.93 g, 18.52 mmol), DB-67 (MW 479, 10 mg) and dry acetone (2.5 ml). 
DMDEE (MW 244, 20 mg, 0.08 mmol) was added to one flask, and DABCO (112 MW, 5 mg, 
0.04 mmol) was added to the other. Each flask was then flushed with nitrogen, sealed and stirred 
in the dark at room temperature. During this time, the mixture changed from opaque to 
translucent and its viscosity increased. 
The viscous pre-polymer was transferred to an 80 mm PTFE dish when the viscosity of 
the mixture measured >3.0 x 10
4
 cP (TA Instruments AR2000). Then 200 μL of distilled, 
deionized H2O was added to the pre-polymer and vigorously mixed in – initiating the foaming 
reaction. The samples were thoroughly mixed 3 times at 2-minute intervals to ensure the H2O 
was fully incorporated. The samples were left open to the atmosphere yet covered to protect from 
light while the curing. The resulting polymer foams were then dried overnight in a vacuum oven 
at room temperature and placed into storage in the dark at 4 °C for further analysis. Control 
foams were prepared similarly, except DB-67 was not added to the initial reaction mixture. The 
foams were then assessed for sol content as previously described by Huang [115]. 
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3.3.5 Distribution of DB-67 within the polyurethane foams 
Foam samples were sliced to a thickness of roughly 500 ?m and mounted on a glass slide. 
Fluorescent and non-fluorescent images were taken at 100X filter in order to assess the 
distribution of DB-67 throughout the DABCO and DMDEE polyurethane foams (Zeiss AX10 
Imager.A1). A FITC filter was used to visualize the DB-67 compound within the sample 
(Chroma). 
3.3.6 Release of DB-67 from LDI-glycerol Foams 
LDI-glycerol polyurethane foam samples containing DB-67 were incubated at 10 mg/ml in PBS 
(pH 7.4) on rocking plates in temperature-controlled rooms at 4, 22, 37 and 70 °C for 7-weeks. 
Sample chambers were protected from light during this time. Every 7 days, 3.0 ml of PBS was 
retrieved from each sample; during the first week, PBS was also collected on day 3. The amount 
of DB-67 released from the polymer was detected using fluorescence spectroscopy with 430 nm 
and 550 nm for the excitation and emission wavelengths, respectively. The total amount of DB-
67 collected was calculated as follows: 
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where (m/V)i represents the concentration of each collected sample and VT the total volume 
(where each time point is designated “i” and  “j” represents the last). Lysine and glycerol 
released from the polymer were not assessed at this time. At the end of the 11-week release 
study, the samples were dialyzed, dried and the mass recorded. 
3.3.7 Effect of Polyurethane Foams on Cellular Proliferation 
A panel of human malignant glioma cell lines (U87, T98G, and SG388, LN229) was used for the 
cytotoxicity analysis of our drug releasing polymer foams. For these studies, 1.0 x 10
2
 cells were 
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plated and incubated for 24 hr in 100 μl growth media. Media was replaced and then LDI-
glycerol foam samples approximately 5 mg in size were then added to the cells, and they were 
incubated for treatment periods 3 or 5 days. Positive and negative controls received a stock 
solution of DB-67 (100 nM final concentration) or media alone, respectively. In all cases, final 
concentrations of DMSO were ?0.1%, well below the concentrations that interfere with the 
proliferation in the above cell lines. After the incubation period, the number of viable cells was 
determined by measuring the bio-reduction by intracellular hydrolases of the tetrazolinium 
compound MTS in the presence of the electron coupling reagent PMS as previously described 
[96]. All samples were analyzed in twelve separate wells and an averaged. A two-tailed, two-
sample unequal variance Student’s t-test statistic was used to analyze the results. 
Prior to beginning the anti-proliferative analysis described, varying numbers of cells from 
each of the four malignant gliomal cell lines were plated and the MTS signal was measured at 
24-hour intervals over a 5 day period (data not shown). From these preliminary studies, it was 
found that plating 1.0 x 10
2
 cells/well gave a linear MTS signal over a 5-day incubation period.  
3.4 RESULTS 
3.4.1 Urethane Catalyst Toxicity 
Dose-response profiles were generated for a few common urethane catalysts (Figure 14A). In 
general, the tertiary amine catalysts were tolerated at much higher concentrations by the T98G 
cells than the organometallic catalysts. The concentration of DMSO present in the first few lanes 
of the 96-well plate was calculated to be high enough to interfere with the results for DABCO 
and DMDEE. As a result, the study was repeated with much higher concentrations of those 
catalysts in media alone (Figure 14B).  
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Figure 14 - Dose-response profiles for various organometallic and tertiary amine urethane catalysts: 
(A) baseline studies (B) extended profile for DABCO and DMDEE 
 
Table 4 summarizes the urethane catalysts used for this analysis and the corresponding cytotoxic 
concentrations reported as LD50 values. 
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Table 4 - Polyurethane catalyst structures and toxicities 
 
 
     
  
Catalyst 
 
Structure Class LD50 
Dibutyltin dilaurate Sn
O
O
O
O  
organometallic 0 M 
Tin(II) 2-
ethylhexanoate 
Sn
O
O
O
O
 
organometallic 62.5 M 
Bismuth 2-
ethylhexanoate 
Bi
O
O
O
O
 
organometallic 62.5 M 
Dimorpholino-
diethylether 
(DMDEE) 
O N
O
N
O
 
3° amine 31.3 mM 
1,4-
Diazobicyclo[2.2.2]-
octane (DABCO) 
N
N
 
3° amine 15.6 mM 
 
 
3.4.2 Reactivity of DB-67 and LDI with DMDEE or DABCO 
DB-67 and LDI were reacted together at a 1:1 molar ratio in the presence of either DABCO or 
DMDEE. Infrared (IR) spectroscopy was used to monitor the progress of the reaction through 
signals in the isocyanate (2400-2160 cm
-1
) and carbonyl (1850-1580 cm
-1
) regions of the spectra. 
Peak integrations in those regions of the spectra were also calculated at the start of the reactions 
and at 4 hours. The spectra from the reaction of DB-67/LDI with DMDEE indicate that the 
isocyanate signal persists at 2265 cm
-1
 over the 4-hour reaction period (Figure 15A). Concerning 
the signal integrations, the NCO/C=O ratio initially measured 0.66 and remained 0.64 after 4 
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hours. These findings indicate that DB-67 did not form any urethane bonds with LDI when 
DMDEE was used as a catalyst. On the other hand, the spectra from the reaction of DB-67/LDI 
with DABCO reveal a disappearance of the isocyanate signal after the 4-hour reaction period 
(Figure 15B). Once again using the signal integrations, the NCO/C=O ratio initially measures 
0.66 and decreases to 0.20 after 4 hours. These findings indicate that in the presence of DABCO, 
urethane bonds are formed between DB-67 and LDI. 
 
 
 
 
Figure 15 - FT-IR data assessing the reactivity of DB-67 with LDI in the presence of (A) DMDEE and 
(B) DABCO 
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3.4.3 Characterization of LDI-Glycerol Foams 
It is important that the polyurethane pre-polymer be sufficiently viscous prior to initiation of the 
blowing reaction so that the rising foam does not collapse on itself prior curing. The viscosity of 
the pre-polymer was measured when the reaction could no longer be mixed atop a magnetic 
stirrer, first measuring at a shear stress of 5.0 Pa then again at 50.0 Pa with a 5-minute interval 
between measurements (Figure 16). It was determined that a value of at least 3.0 x 10
3
 cP must 
be attained for proper foam formation.  
 
 
 
 
Figure 16 - Viscosity data for LDI-glycerol pre-polymer prior to initiation of the blowing reaction: 
(A) 1
st
 run at 5.0 Pa shear stress and (B) 2
nd
 run at 50.0 Pa shear stress 
 
 Scanning electron micrograph images were obtained of the LDI-glycerol polyurethane 
foams made with DABCO and DMDEE. Low-magnification images (25X) reveal the DABCO 
foam cavitations are elliptical in nature, of similar size, and appear to have a preferred 
orientation of their long axis as indicated by the arrow (Figure 17A). In contrast, the DMDEE 
foam cavitations appear randomly distributed in terms of size and shape and have no apparent 
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directionality (Figure 17B). High magnification images (10,000X) of the LDI-glycerol foams 
demonstrate “micro-channels” which are apparent on the surface of the materials. The DABCO 
foam appears to have numerous, fine channels that are similar in size and oriented as indicated 
by the white arrow (Figure 17C). The DMDEE material exhibits channels that vary in terms of 
size and orientation and are far less numerous (Figure 17D). 
 
 
 
 
Figure 17 - Scanning electron micrographs of the LDI-glycerol polyurethane foams: (A) DABCO foam @ 25X 
(B) DMDEE foam @ 25X (C) DABCO foam @ 10,000X (D) DMDEE foam @ 10,000X 
  
 Fluorescent and non-fluorescent images were taken in order to assess the distribution of 
DB-67 throughout the DABCO and DMDEE polyurethane foams (Figure 18). Bright field 
images show that the DMDEE material possesses a highly ordered foam structure, while that of 
the DABCO material appears more random in nature. Fluorescent images suggest that DB-67 is 
uniformly distributed throughout the DABCO sample. However, in the DABCO sample DB-67 
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appears to reside in much higher concentrations clustered around the cavitations in the foam. 
Overlaid bright field and FITC images were constructed, and they corroborate these findings. 
 
 
 
 
Figure 18 - Fluorescent and non-fluorescent images of the LDI-glycerol polyurethane foams 
 
3.4.4 DB-67 Release from Polyurethane Foams 
DB-67 release profiles were obtained for both DABCO and DMDEE polyurethane foams over a 
49-day period (Figure 19). Drug release was non-linear and varied in a temperature dependent 
fashion; the highest drug concentrations were achieved at 70 °C. Significant material degradation 
was evident in both DMDEE and DABCO samples at 70 ºC. At all temperatures except for 4 °C, 
both foams exhibit an initial burst release of DB-67. Shortly thereafter concentrations slowly 
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decline in a temperature dependent fashion and were shown to recover at higher temperatures. 
Maximum concentrations were observed early on for samples incubated at 22 and 37 ºC, while 
those incubated at 4 and 37 ºC occur at day-49. 
 
 
 
 
Figure 19 - Temperature dependent DB-67 release profiles for the LDI-glycerol foams 
 
 LDI-glycerol foams synthesized using either DABCO or DMDEE exhibit differences in 
their release profiles. A comparison at 37 °C reveals that greater amounts of DB-67 are released 
by the DMDEE foam over the 77-day test period (Figure 20). Concentrations in solution are 
observed to decrease over time for both the DMDEE and DABCO foams. The concentration of 
DB-67 released from the DMDEE foam remained consistently elevated over that of the DABCO 
foam. A comparison at 70 °C shows that although higher amounts of DB-67 are initially released 
from the DMDEE foam, eventually higher concentrations are obtained from the DABCO foam 
by day-77 (Figure 21). 
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Figure 20 - Comparison of DB-67 release by DABCO and DMDEE foams at 37 ºC 
 
 
 
 
Figure 21 - Comparison of DB-67 Release by DABCO and DMDEE foams at 70 ºC 
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At day-77, concentrations of DB-67 in solution are 21.6 μM and 12.7 μM for the DABCO and 
DMDEE foams, respectively. At that time, 63.4 and 41.4% of the total DB-67 had been released 
for from the DABCO and DMDEE foams, respectively.  At day-63, the release of DB-67 from 
the DMDEE foam is noted to decline, while the DABCO foam continues releasing drug into 
solution. Release characteristics of the DABCO and DMDEE foams have been summarized in 
Table 5.  
 
Table 5 - Release characteristics of the LDI-glycerol polyurethane foams 
 
 
 Maximum concentrations 
Catalyst 
sol content 
(%) 
Temperature 
(°C) 
DB-67 
(mol%)
a
 
Mass loss 
(%)
a
 (?M) day 
Initial 
concentrations 
(?M)b 
Max/initial ratio 
4 2.2 7.8 0.7 70 0.1 7.0 
22 4.2 8.1 1.5 14 1.1 1.4 
37 7.5 9.7 2.6 3 2.6 1.0 
DABCO 7.0 
70 63.4 78.1 21.6 77 3.1 7.1 
4 2.9 6.6 0.9 77 0.1 9.0 
22 7.1 7.3 2.6 14 1.3 2.00 
37 10.8 8.8 4.8 3 4.8 1.00 
DMDEE 7.2 
70 41.4 62.8 12.7 77 5.7 2.2 
a = at day-77, b = at day-3  
 
3.4.5 Polyurethane Foam Cytotoxicity 
The cytotoxicity of DABCO and DMDEE LDI-glycerol polyurethane foams was assessed in a 
panel of human malignant glioma cell lines (SG388, T98G, U87, LN229) via the MTS bio-
reduction assay (Figure 22).  
 58 
 
 
 
Figure 22 - In vitro cytotoxicity results of (A) 3-day and (B) 5-day treatments on malignant gliomal cell lines. 
Error bars represent one standard deviation from the mean 
 
In every malignant glioma cell line tested, a statistically significant difference in cellular 
proliferation was seen for both catalysts between empty and DB-67 loaded foams (p < 1.0 x 10
-
8
). There was also no significant difference in cytotoxicity detected between the drug-loaded 
DABCO and DMDEE foams (p < 0.001) except in the SG388 3-day treatment group (p > 0.25). 
The MTS signals from cells grown with empty DABCO and DMDEE polymer foams were 
found to not differ significantly from those of cells grown in media alone (p < 0.05) in 11 out of 
16 treatment groups. Finally, in every malignant glioma cell line tested, a significant difference 
existed between the 100nM DB-67 solution and either the DABCO or DMDEE drug-loaded 
foam (p < 1.0 x 10
-6
). Note that without exception the MTS signal was always greater for the 100 
nM DB-67 solution. The MTS data has been summarized for the reader in Table 6. 
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Table 6 - In vitro cytotoxicity of DB-67 loaded LDI-glycerol polyurethane foams 
 
 
3-Day Treatment MTS
a
 Signals  
+/- Controls Empty Foams DB-67 Foams 
Cell line 
Media (+) 100 nM DB-67 (-) DABCO DMDEE DABCO DMDEE 
T98G 2.355 ± 0.080 0.324 ± 0.024 2.460 ± 0.175 2.342 ± 0.158 0.145 ± 0.007 0.162 ± 0.007 
LN229 1.207 ± 0.088 0.257 ± 0.015 1.400 ± 0.158 1.325 ± 0.194 0.140 ± 0.016 0.173 ± 0.016 
SG388 0.933 ± 0.047 0.250 ± 0.007 0.920 ± 0.120 0.964 ± 0.120 0.194 ± 0.005 0.201 ± 0.005 
U87 0.602 ± 0.051 0.234 ± 0.011  0.673 ± 0.089 0.544 ± 0.087 0.144 ± 0.007 0.159 ± 0.007 
 
 
 
5-Day Treatment MTS
a
 Signals 
+/- Controls Empty Foams DB-67 Foams 
Cell line 
Media (+) 100 nM DB-67 (-) DABCO DMDEE DABCO DMDEE 
T98G 1.967 ± 0.092 0.197 ± 0.013 2.201 ± 0.371 2.179 ± 0.230 0.122 ± 0.008 0.144 ± 0.005 
LN229 1.985 ± 0.222  0.277 ± 0.016 1.861 ± 0.151 1.922 ± 0.213 0.135 ± 0.013 0.154 ± 0.011 
SG388 1.288 ± 0.171 0.240 ± 0.011 1.289 ± 0.139 1.284 ± 0.128 0.164 ± 0.012 0.189 ± 0.020 
U87 1.569 ± 0.193 0.214 ± 0.012 1.323 ± 0.191 1.512 ± 0.220 0.124 ± 0.006 0.149 ± 0.006 
a
 MTS = absorbance at 490 nm  
 
3.5 DISCUSSION 
Many commercial urethane catalysts are known to exhibit moderate to severe toxic side effects 
[116, 117]. Therefore, it is important to attempt to minimize any toxicity associated with our 
polyurethane materials via proper catalyst selection. To this end, dose-response profiles were 
generated for a series of commonly used organometallic and tertiary amine urethane catalysts. 
From the data, it is clear that tertiary amine catalysts are better tolerated than the organometallic 
catalysts. Consequently, one would expect LDI-glycerol foams prepared with either DABCO or 
DMDEE to be less cytotoxic than our LDI-glycerol discs previously fashioned with tin(II) 2-
ethylhexanoate. 
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Central to our newly developed delivery technology is the ability of a therapeutic 
compound to incorporate into a polyurethane network. Drug incorporation provides the 
opportunity for long-term controlled release through passive hydrolysis of urethane bonds. We 
have previously shown that DB-67 will react with LDI in the presence of an organometallic 
catalyst, but it was uncertain if the same would be true of the tertiary amine catalysts. Via 
infrared spectroscopy, it has been concluded that DB-67 reactivity with LDI is indeed catalyst 
dependent. The non-selectivity of DABCO and the specificity of DMDEE can be utilized to 
manipulate the incorporation of DB-67 into LDI-glycerol polyurethane foams. These differences 
likely account for some of the differences observed in the drug release profiles of the foams. 
It is essential that drug delivery systems be able to be reliably reproduced in the amounts 
and under the conditions required for clinical use [4]. When fashioning polyurethane foams, the 
pre-polymer viscosity is quite important. This value must be sufficiently large to prevent foam 
collapse, but not so large as to inhibit the foam expansion [118, 119]. For our LDI-glycerol 
polyurethane foams, this value was found to be 3.0 x 10
3
 cP. An inspection of the viscous curves 
reveals that the viscosity of the pre-polymer slowly increased over each measurement period and 
jumps significantly from one measurement to the next. This is certainly due to initiation of the 
blowing reaction by atmospheric moisture content. 
Scanning electron images reveal differences in the structure of the polyurethane foams, 
while fluorescent images indicate important differences in the distribution of DB-67. SEM shows 
DABCO foams possessing a more ordered structure at both high and low magnification in terms 
of the cavitations (i.e. - size, shape, and orientation) and micro-channels (i.e. – number and 
orientation). Conversely, SEM shows the DMDEE foams appearing more random in terms of the 
cavitations and micro-channel distribution. Bright field images further confirm these structure-
catalyst correlations. Fluorescent images indicate DB-67 is present in higher concentrations 
around the cavitations in the DMDEE foam. In the DABCO foam, DB-67 appears to be much 
more uniformly distributed. Images lack focus in certain regions of the images due to sample 
thickness being greater than the focal plane of the microscope.  
When interpreting the DB-67 release profiles, one must realize that we are merely taking 
snapshots in time of the concentration profiles, and we may indeed be missing the true 
concentration peaks due to the sampling intervals chosen. This arises due to the lack of stability 
of DB-67 fluorescence signal in aqueous solution that has previously been described [97]. 
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However, “structure-catalyst” and “distribution-catalyst” correlations can be used to elucidate 
some of the differences observed in the DB-67 release profiles of the foams. First, the initial 
burst release is always seen to be greater in the DMDEE foams regardless of temperature. The 
concentration of DB-67 around the cavitations and the lack of DB-67 incorporation in the 
DMDEE foam can account for this observation. Secondly, the maximum DB-67 concentrations 
and mol% observed are always higher for the DMDEE foams except at 70 ºC. Significant 
material degradation at 70 ºC and subsequent release of entrapped DB-67 from the DABCO 
foam can explain the observed difference. It is likely at lower temperatures that diffusive rather 
than degradative processes are accounting for the majority of DB-67 release. As such, the 
DMDEE foam will generally have released more DB-67 on any given day. Finally, the max-to-
initial ratio listed in Table 5 is generally equal to one in every case except for the 70 ºC samples. 
Here the DABCO ratio is significantly greater than the DMDEE, again suggesting the fact that 
material degradation accounts for significant DB-67 release. 
DB-67 release from the foams was shown to be sufficient to inhibit the proliferation of 
malignant glioma cells. The empty DABCO and DMDEE LDI-glycerol polyurethane foams 
were found to be well tolerated by all of the malignant glioma cell lines assessed. The MTS 
signals from cells grown with empty DABCO and DMDEE polymer foams were found to not 
differ significantly from those of cells grown in media alone in 11 out of 16 treatment groups. 
Surprisingly when the difference was significant, the cells grown with the empty catalyst foam 
displayed the higher MTS signal more than half the time. In every malignant glioma cell line 
tested, a significant difference existed between the 100nM DB-67 solution and either the 
DABCO or DMDEE drug-loaded foam; without exception the MTS signal was always greater 
for the 100 nM DB-67 solution. 
3.6 CONCLUSIONS 
In this study, we present a novel approach to the controlled, long-term delivery of the CPT 
analog DB-67 employing biocompatible, biodegradable polyurethane foams constructed from 
LDI and glycerol. We have demonstrated the importance of proper catalyst selection in 
maintaining the biocompatibility of medical-grade polyurethanes. It was also shown that DB-67 
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reactivity and incorporation could be controlled through appropriate selection of a tertiary amine 
urethane catalyst. Structure-catalyst and distribution-catalyst correlations were seen to dictate 
drug release via diffusion and slow, passive hydrolysis of urethane bonds. Release of DB-67 
from LDI-glycerol polyurethane foams was shown to steadily occur over a prolonged periods 
suitable for medical implants. Therapeutic concentrations of a potent anticancer compound were 
attained over a 49-day test period with the potential to continue for much longer periods. Cellular 
proliferation assays conclude that only LDI-glycerol foams loaded with DB-67 exhibited a potent 
cytotoxic effect on human malignant glioma cell lines. Catalyst choice did not appear to affect 
the cytotoxicity of the delivery system. These results from clearly demonstrate that catalyst-
dependent controlled drug release can be achieved from degradation of LDI-glycerol 
polyurethane foams. 
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4.0  CHEMICAL STRUCTURE AND FUNCTIONALITY OF A DRUG DICTATES 
ITS CONTROLLED-RELEASE PROFILE FROM DEGRADABLE LDI-GLYCEROL 
POLYURETHANE FOAMS: A STUDY ON NAPHTHALENE AND RELATED 
COMPOUNDS 
4.1 ABSTRACT 
The purpose of the present study was to determine how the chemical structure of a drug could be 
used in the development of controlled release systems. To this end, a series of naphthalene 
analogs with differing hydroxyl and amine functionality were incorporated into degradable 
polyurethane foams based on lysine and glycerol. The excitation and emission spectra of the 
various naphthalene analogs in aqueous solution were examined to ensure they were capable of 
being quantitatively detected at low concentrations. Then the fluorescence stability of the 
compounds was assessed over a 2-week period at 70 °C, and the analogs were found to exhibit 
significant fluorescent signal decay. The polyurethane materials containing the various analogs 
were then examined via scanning electron microscopy, and the incorporation of small 
naphthalene ligands did not alter the gross morphology of the foams. The distribution of the 
analogs was then assessed with fluorescence microscopy using a DAP filter, and they appeared 
to be evenly distributed throughout the material. Polyurethane foam samples containing various 
analogs were then incubated at 10.0 mg/ml in PBS buffer solution (pH 7.4) at 4, 22, 37, and 70 
°C. Release rates of the naphthalene analogs and mass loss from the polyurethane foam were 
found to be temperature dependent.  The release rates were also found to be highly dependent 
upon the functional groups present on the naphthalene analog. These results clearly demonstrate 
that the chemical structure of a drug can be used to control its release form degradable drug 
delivery systems. 
Keywords: drug delivery, controlled release, naphthalene, polyurethane 
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4.2 INTRODUCTION 
Naphthalene is a volatile, white, crystalline, polycyclic aromatic hydrocarbon that exhibits 
fluorescence near the ultraviolet region of the spectrum [120]. Naphthalene is a natural product, 
being produced in trace amounts by magnolias and specific types of deer [121-123]. It has also 
been found in the termite Coptotermes formosanus, possibly used as a repellant against ants, 
poisonous fungi and nematodes [124]. It is commonly used as both an antiseptic and insecticide, 
being best known as the primary ingredient in mothballs. Naphthalene is manufactured from coal 
tar, a by-product of the coking process, and is routinely converted to phthalic anhydride, a 
compound vital to the manufacture of many commercial solvents and plastics [125-128]. 
Naphthalene is easily modified via electrophilic aromatic substitution reactions; analogs that are 
substituted with combinations of strongly electron-donating functional groups, such as alcohols 
and amines, are intermediates in the preparation of many synthetic dyes [129].  
The term “polyurethane” refers to any polymer consisting of a chain of organic units 
joined by urethane bonds. However, the term is often used to broadly classify materials 
possessing both urethane and urea linkages. A urethane bond is produced via the exothermic 
condensation of an alcohol and an isocyanate, while an analogous reaction between an amine and 
an isocyanate generates a urea bond [19]. These reactions are generally referred to as “gelling” 
reactions, contributing to the overall molecular weight increases observed during polymerization. 
Polyurethane materials also undergo “blowing” reactions in which an isocyanate reacts with H2O 
to form a carbamate intermediate [18]. The carbamate readily decomposes into an amine and 
CO2, expanding the polyurethane into foam. The generated amine then reacts with any free 
isocyanate remaining in the reaction volume, curing the expanded foam. 
Hydrolysis is one of the dominant mechanisms for polyurethane degradation in aqueous 
environments [100]. Thermoplastic polyurethanes exhibit the highest degree of hydrolytic 
instability due to the presence of ester linkages found within their soft-segments [130]. The 
urethane and urea linkages found in the hard-segments tend to be less susceptible to hydrolysis 
[131]. Polyurethane films, thermosets, and highly cross-linked networks lacking a true soft-
segment are generally viewed as stable entities in aqueous environments; yet, they remain 
susceptible to hydrolysis. Urethane and/or urea degradation in these materials proceeds at an 
incredibly slow rate due to the hydrophobic shielding of the urethane bond. However, their 
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degradation rates can be altered by concomitant increases and decreases in the aliphatic and 
aromatic character of the polyols, polyamines and isocyanates used to fashion them [132]. 
Urethanes and ureas are also known to be sensitive to ion concentrations, redox environments, 
enzymes, and cellular degradation – exhibiting elevated decomposition in vivo [133, 134].  
Our laboratory has developed a new generation of biocompatible, biodegradable 
polyurethanes constructed from lysine diisocyanate (LDI) and glycerol that degrade 
hydrolytically into non-toxic components – lysine, glycerol and CO2 [87, 88]. These materials 
possess the same versatility as widely used commercial polyurethanes, easily being processed 
into forms with unique morphology and physical properties. We have previously synthesized 
LDI-glycerol films and foams, demonstrating long-term delivery of DB-67 via hydrolytic release 
and shown in vitro cytotoxicity against malignant glioma cell lines. We propose that urethane 
hydrolysis can be further utilized in the design of controlled-release drug delivery systems. In 
this study, naphthalene and some of its functionalized derivatives were chosen as model drug 
compounds, and they were used to elucidate the connection between urethane hydrolysis and the 
functionality of the incorporated drug. The various functional groups present on the model drugs 
will provide urethane and urea bonds with subtle differences in chemical character. The various 
functional groups present on the naphthalene compounds will in turn determine the nature of the 
resulting urethane bonds, which ultimately impacts their stability, rate of hydrolysis, and 
subsequent release of the compounds from the polyurethane foam. 
4.3 MATERIALS AND METHODS 
4.3.1 Materials 
Lysine diisocyanate methyl ester (LDI) was purchased from Chemical Division, Kyowa Hakko 
Kogyo Co. Ltd. (Tokyo, Japan). All other chemicals were obtained from Sigma–Aldrich 
Chemical Co. and were of reagent grade unless otherwise specified (Milwaukee, WI). 
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4.3.2 Excitation-emission spectra of naphthalene compounds 
A 1.0 mg/ml stock solution of each naphthalene compound was prepared in DMSO, and each 
sample was sonicated for 5 min at 25 ºC to ensure complete dissolution. Then 3.0 ?L of each 
solution was diluted into 3 ml of PBS (pH 7.4) to arrive at 1.0 ?g/ml standard solutions. Each 
10.0 ?g/ml solution was then iteratively scanned over ranges of excitation and emission 
wavelengths, finding the maximal fluorescent spectra for each naphthalene compound. 
4.3.3 Naphthalene fluorescence stability 
Stock solutions of naphthalene and all derivative compounds were prepared in DMSO at a 
concentration of 1.0 mg/ml. Samples were sonicated until all of the material had dissolved and 
mixed thoroughly. They were then diluted to a concentration of 1.0 ?g/ml by taking 50 uL of 
DMSO stock and adding it to 50 ml PBS (pH 7.4). The resulting solutions were mixed 
thoroughly, and a 3 ml sample was immediately collected and a baseline fluorescence signal was 
determined for each compound. All samples were then incubated at 70 ºC and protected from 
ambient light. Three-milliliter samples were withdrawn every 24 hours for 2-weeks, and the 
fluorescent signal was measured within 1-hour of the sample being collected. Fluorescent decay 
curves were then constructed from the data. 
4.3.4 Synthesis of Naphthalene Foams 
Glycerol (MW 92.01, 1.15 g, 12.5 mmol), DABCO (MW 112.18, 6.0 mg, 0.053 mmol), and dry 
DMSO (2.5 ml) were added to a small, dry 20 ml reaction flask. Eight such samples were 
prepared and 0.04 mmol of each naphthalene compound was added to a different flask. The 
flasks were sonicated until the all the reactants had dissolved in the DMSO. Then LDI (MW 
212.20, 4.00 g, 18.9 mmol) was added, and the flasks were flushed with nitrogen prior to being 
sealed. The reaction was allowed to stir atop a magnetic stir plate in the dark at room temperature 
until the viscosity had attained a value of at least 3.0 x 10
4
 cP. At that time the viscous pre-
polymer was transferred to a 100 mm PTFE dish and 100 uL distilled, deionized H2O was 
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added. The pre-polymers were thoroughly mixed 3 times at 2-minute intervals to ensure the H2O 
was fully incorporated. The rising foams were left open to the atmosphere yet covered to protect 
from light while the curing. The resulting polymer foams were then placed into a vacuum oven 
overnight at 25 ºC. The foams were then placed into storage in the dark at 4 °C for further 
analysis. Sol content was also obtained for each foam sample and was calculated as previously 
described by Huang [115]. 
4.3.5 Evaluation of foam architecture by SEM 
Polyurethane foams containing the various naphthalene compounds were cut into small 5 mm x 
5mm x 1mm sections, dried thoroughly, and mounted on sample holders. Samples were observed 
at 25X magnification to ensure there were no gross irregularities. Then 10 images were collected 
at 75X from various regions of each foam sample. Metamorph image analysis software 
(Molecular Devices) was then used to differentiate pores from polymer through a threshold 
algorithm. The threshold images were then used to estimate the % porosity of each polyurethane 
foam.  
4.3.6 Distribution of naphthalene compounds within polyurethane 
Foam samples were sliced to a thickness of roughly 500 ?m and mounted on a glass slide. 
Fluorescent and non-fluorescent images were taken at 100X filter in order to assess the 
distribution of DB-67 throughout the DABCO and DMDEE polyurethane foams (Zeiss AX10 
Imager.A1). A 4',6-diamidino-2-phenylindole (DAPI) filter was used to visualize the 
distributions of 1-naphthalene methylamine, 1-naphthol, 1,5-diaminonaphthalene, 5-amino-1-
naphthol within the sample (Chroma). Naphthalene and the remaining analogs were unable to be 
visualized due to the location of their emission bands. Empty polymer foam not containing any 
analog was used as a control. 
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4.3.7 Naphthalene Release 
LDI-glycerol polyurethane foam samples containing the naphthalene compounds were incubated 
at 10 mg/ml in PBS (pH 7.4) on rocking plates in temperature-controlled rooms at 4, 22, 37 and 
70 °C for 11-weeks. Sample chambers were protected from light during this time. Every 7 days, 
3.0 ml of PBS was retrieved from each sample; during the first week, PBS was also collected on 
day 3. The amount of naphthalene compound released from the polymer was detected via 
fluorescence spectroscopy using the excitation and emission wavelengths particular for each 
compound. Standard curves were constructed and used to determine the concentration of the 
various naphthalene species in solution. The total amount collected throughout the study was 
calculated as follows: 
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where (m/V)i represents the concentration of each collected sample and VT the total volume 
(where each time point is designated “i” and  “j” represents the last). Lysine and glycerol 
released from the polymer were not assessed at this time. 
4.4 RESULTS 
4.4.1 Excitation-emission spectra of naphthalene compounds 
Naphthalene exhibits a characteristic, intense fluorescent spectrum that has been used in the past 
under aqueous conditions to examine partitioning kinetics of micellar systems [135, 136]. An 
investigation of naphthalene and its analogs’ fluorescent behavior was undertaken to ensure each 
was capable of being sufficiently detected in an aqueous environment. The excitation and 
emission spectra of naphthalene, 1-naphthol, 1-naphthylamine, 1-naphthalene methanol, 1-
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naphthalene methylamine, 1,5-dihydroxynaphthalene, 1,5-diaminonaphthalene, and 5-amino-1-
naphthol in PBS (pH 7.4) were obtained in PBS buffer (pH 7.4) (Figure 23).  
 
 
 
 
Figure 23 - Fluorescence excitation and emission spectra for naphthalene compounds in aqueous media 
 
The fluorescence spectrophotometer was adjusted so that the excitation and emission signals 
registered in the maximum range of the detector. All the naphthalene compounds exhibited 
intense excitation bands in the range of 275-325 nm. The emission bands were equally intense 
yet scattered, ranging from 330-470 nm. The excitation and emission peaks were well delineated 
and free from background interference of the PBS buffer (data not shown). Standard 
concentration curves from 1.0 – 1000.0 ng/ml were constructed for each compound, and found to 
be linear (data not shown); 5-amino-1-naphthol exhibited the lowest R
2
 value (0.9791). The 
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excitation and emission wavelengths for each naphthalene compound are listed along with their 
chemical structure and functionality in (Table 7). 
 
Table 7 - Naphthalene compounds – structure, functionality and fluorescent wavelengths 
 
 
Fluorescence (nm) 
Compound Structure Functionality 
Excitation Emission 
Naphthalene 
 
---- 275 330 
1-naphthol 
OH
 
Aromatic 
hydroxyl 
290 470 
1-naphthylamine 
NH2
 
Aromatic 
amine 
315 450 
1-naphthalene-
methanol 
OH
 
Primary 
hydroxyl 
280 335 
1-naphthalene-
methylamine 
NH2
 
Primary amine 280 330 
1,5-dihydroxy-
naphthalene 
OH
OH  
Dual aromatic 
hydroxyl 
300 345 
1,5-diamino-
naphthalene 
NH2
NH2  
Dual aromatic 
amine 
325 405 
5-amino-1-naphthol 
OH
NH2  
Aromatic 
hydroxyl, 
aromatic amine 
320 410 
  
 
4.4.2 Naphthalene fluorescence stability 
Napthalene has been found to be susceptible to photochemical degradation in aqueous and 
oxidative environments [137-140]. Although much harsher conditions than we propose were 
used in these studies, an assessment of the stability of the naphthalene compounds in PBS (pH 
7.4) buffer was needed. The naphthalene analogs were found to lose their fluorescence signal 
over a 2-week test period to varying degrees (Figure 24). 
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Figure 24 - Fluorescence decay profiles for the naphthalene analogs in PBS buffer (pH 7.4) solution 
 
Fluorescent signal decay of naphthalene, 1-naphthol, 1-naphthylamine, 1,5-
dihydroxynaphthalene, 5-amino-1-naphthol and to a much lesser extent 1-naphthalene 
methylamine and 1,5-diaminonaphthalen was observed. The fluorescent signal of 1-naphthalene 
methanol was the only one that remained near its baseline level throughout the 2-week test 
period.  
4.4.3 Polyurethane foams: SEM Analysis and Distribution 
Low-magnification scanning electron micrographs (25X) were taken in order to assess the 
morphology of the polyurethane foam samples (Figure 25).  
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Figure 25 - Low-magnification scanning electron micrographs (25X) of the LDI-glycerol polyurethane foams 
containing the various naphthalene analogs 
 
These images reveal the foams largely similar in terms of pore size, shape and distribution. Some 
variation in the foam morphology is to be expected, resulting from the processing methods used 
to fabricate each sample. Higher magnification images (75X) taken from regions of the foam 
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specimens, and the porosity was estimated using a threshold imaging technique. Metamorph 
imaging software was able to clearly delineate between the polymer and pore regions of the 
images (Figure 26). The average porosity of each foam sample can be found in Table 9, listed 
along with the degradation characteristics. 
 
A
B
 
 
 
Figure 26 - High-magnification SEM image of 1,5-diaminonaphthalene: (A) before and (B) after a threshold 
was applied to determine the porosity of the foam 
 
  DAPI is a fluorescent stain that binds strongly to DNA; it is used extensively in 
fluorescence microscopy. When bound to double-stranded DNA its absorption maximum lies in 
the near-UV at 358 nm and its emission maximum is at 461 nm. The emission band is broad and 
appears blue. The emission wavelength of DAPI closely approximates the fluorescent bands of 
some of the naphthalene analogs. Therefore, a DAPI filter was used to visualize polyurethane 
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foam samples containing either 1-naphthol, naphthalene methylamine, 1,5-diaminonaphthalene, 
or 5-amino-1-naphthol in order to determine the distribution of these analogs throughout the 
material (Figure 27).  
 
 
 
 
Figure 27 - Fluorescent images depicting the distribution of select naphthalene analogs in the LDI-glycerol 
polyurethane foam 
 
The naphthalene analogs were evenly dispersed throughout the polyurethane samples except in 
the case of 1-naphthol, which showed a slight preferential accumulation around the pore surface. 
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Variations in the intensity of the fluorescent signal can largely be attributed to differences in 
sample thickness. There was no appreciable signal arising from the control sample. 
4.4.4 Naphthalene release 
The release of naphthalene analogs from the LDI-glycerol polyurethane foams was assessed at 4, 
22, 37 and 70 ºC over a 77-day period (Figure 28).  
 
 
 
 
Figure 28 - Concentration profiles depicting the release of the naphthalene analogs from the LDI-glycerol 
polyurethane foams 
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The total amount of analog released and previously collected was also calculated as a percent of 
the total amount used in the synthetic reaction and reported as mol% (Figure 29).  
 
 
 
 
Figure 29 - Profiles depicting the mol% of the naphthalene analogs released from the LDI-glycerol 
polyurethane foams 
 
In general, the compounds were found to be eluted in a temperature dependent fashion, with the 
highest concentrations and mol% being found at 70 ºC. Significant material erosion was 
observed by day-49 in all of the 70 ºC samples. As a result, the samples tend to display 
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significant changes in release kinetics around this time. Mass loss for the samples was also seen 
to vary with temperature, with the highest percentages being lost at 70 °C for each sample. Sol 
content of each foam sample was determined and noted to be similar for each of the polyurethane 
samples. Day-3 to day-77 concentration ratios provide insight into the release mechanisms – less 
than one indicates bursting, while greater than one indicates delayed release. The release data for 
each of the compounds has been summarized in Table 8. 
 
Table 8 – Release characteristics naphthalene compounds from LDI-glycerol polyurethane foams 
 
 
Compound 
porosity 
(%) 
sol 
content 
(%) 
Temperature 
(°C) 
mol%
a
 
mass 
loss
b
 
(%) 
day-77 
concentration 
(?M) 
day-3 
concentration 
(?M) 
day-
77/day-
3 ratio 
4 24.0 34.3 4.6 80.4 0.06 
22 16.0 35.5 2.3 55.3 0.04 
37 15.3 36.3 0.5 50.3 0.01 
Naphthalene 
42.2 ± 
7.2 
32.2 
70 14.8 85.4 4.0 24.7 0.2 
4 6.6 35.1 3.5 1.8 1.9 
22 11.6 36.1 6.1 2.6 2.3 
37 25.7 37.7 14.0 5.8 2.4 
1-naphthol 
47.7 ± 
7.0 
27.1 
70 56.1 83.7 39.4 5.1 7.7 
4 0.3 34.5 0.1 0.4 0.3 
22 0.5 35.9 0.3 0.5 0.6 
37 1.4 36.6 0.7 0.8 0.9 
1-
naphthylamine 
32.9 ± 
9.3 
29.6 
70 18.6 82.7 12.8 1.0 12.8 
4 7.9 36.1 0.4 28.0 0.01 
22 6.2 37.5 0.5 28.7 0.02 
37 7.3 38.2 1.2 23.7 0.05 
1-
naphthalene- 
methanol 
46.3 ± 
9.4 
30.2 
70 18.5 95.2 8.7 15.9 0.5 
4 2.3 36.1 1.0 2.7 0.4 
22 4.4 37.5 2.3 1.5 1.5 
37 8.1 38.2 4.2 2.9 1.4 
1-
naphthalene- 
methylamine 
45.2 ± 
11.0 
30.7 
70 62.3 89.9 36.0 4.7 7.7 
4 0.8 32.3 0.05 0.03 1.7 
22 2.0 33.5 0.1 0.03 3.3 
37 6.4 34.3 3.6 0.1 36.0 
1,5-
dihydroxy- 
naphthalene 
33.0 ± 
9.4 
32.9 
70 0.3 68.3 0.2 0.1 2.0 
4 0.1 34.7 0.03 0.1 0.3 
22 0.2 36.8 0.1 0.1 1.0 
37 0.5 39.7 0.2 0.4 0.5 
1,5-diamino- 
naphthalene 
43.4 ± 
8.7 
31.3 
70 3.3 65.9 2.2 0.3 7.3 
4 0.1 34.9 0.05 0.1 0.5 
22 0.3 35.6 0.1 0.4 0.3 
37 1.0 36.6 0.5 0.5 1.0 
5-amino-1-
naphthol 
32.8 ± 
9.7 
27.5 
70 2.1 67.5 1.3 0.6 2.2 
a: at day-77, b: mass loss = (initial mass - final mass)/(initial mass) x 100%  
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Naphthalene was released from the polyurethane foam in a burst fashion. Its 
concentration profiles peaked for each of the temperatures at day 3, and slowly decayed 
thereafter. The aromatic analogs 1-naphthol and 1-naphtylamine were found to differ 
significantly from naphthalene in their release kinetics. Naphthol exhibited an early release 
profile with elevated concentrations detectable in solution by day 3. The concentrations in 
solution were sustained at 4 and 22 ºC and observed to rise at 37 ºC. Subtle burst release was 
seen early on in the 70 ºC profile followed by rapid decay, with release once again becoming 
apparent at day 49. Naphthylamine exhibited a delayed release profile, with the only apparent 
concentration change occurring at day 42 in the 70 ºC sample. Furthermore, the primary 
functional groups demonstrated extreme differences in their release profiles. Naphthalene 
methanol was found to exhibit early burst release followed by steady concentration decay. Only 
after day 28 in the 70 ºC sample was significant release once again observed. Naphthalene 
methylamine did not exhibit any early burst release regardless of temperature. Interestingly, at 70 
ºC linear release kinetics were observed for the mono-functional primary amine.  
The dual aromatic analogs demonstrated release behavior distinct from those already 
observed in the aromatic and primary functional groups. Small concentrations of 1,5-dihydroxy-
naphthalene, 1,5-diamino-naphthalene, and 5-amino-1-naphthol were detected in solution, 
suggesting that the materials are tightly bound within the polyurethane network. Elevation in the 
concentration of 1,5-dihydroxy-naphthalene was observed to occur at day 14 for the 37 º C 
sample. Elevated concentrations of 1,5-diaminonaphthalene were only observed after day 42 in 
the 70 ºC sample. Finally, 5-amino-1-naphthol displayed small changes in concentration, further 
demonstrating that compounds with two functional groups elute from the polymer at slow rates. 
The observed changes in concentration are small for the dual functional aromatics relative to the 
total amount of analog used, but still were well within the detectable range of our assay.  
4.5 DISCUSSION 
We have chosen to pursue a strategy for the long-term controlled release of drugs from 
polyurethane materials constructed from lysine and glycerol. The unique feature of our drug 
delivery technology relies on the drug’s incorporation into the polymer through pendent 
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functional groups. We have previously described this strategy for the controlled release of DB-
67, a potent anti-cancer compound, from polyurethane foams and films. Through those studies, 
we demonstrated that material morphology and even the urethane catalyst used play a significant 
role in release behavior. This study provides some insight into the relationship that exists 
between the release of compounds and the functional groups present on them. 
 Naphthalene was chosen as our model drug for its fluorescent properties, simple chemical 
structure, and availability of a wide variety of functionalized derivatives. The characteristic, 
intense fluorescent spectra of naphthalene and its analogs provide an easy method for 
quantitative detection in solution following release from our polyurethane materials. It was 
unfortunate that many of the naphthalene compounds were subject to significant photo bleaching 
when exposed to aqueous media at 70 °C. Over the 2-week period, all of the naphthalene analogs 
except for 1-naphthalene methanol were shown to lose their fluorescence signals to varying 
degrees. While this fact prohibited us from closing the mass balance of our systems, it did have 
some benefit. Once administered, drugs find themselves subject to a myriad of physiologic 
mechanisms that act to deplete their concentration and limit their performance. We can think of 
the fluorescence decay as clearance or inactivation rate. The results we obtained in light of the 
fluorescence decay suggest that the LDI-glycerol polyurethane is able to provide a protective, 
stabilizing environment for the analogs. This may prove useful in the future, as many promising 
drug candidates are unable to be used due to inactivation via oxidative, acid-base, or 
conformational changes. The signal decay allowed us to note the precise moment at which 
release rates became significant to overcome the decay process. Lastly, an examination of the 
release profiles suggests that the decay is highly temperature dependent allowing for detection of 
some species at temperatures below 70 °C. 
 The LDI-glycerol polyurethane foams were found to be quite similar to one another in 
terms of their morphology. The incorporation of small amounts of naphthalene analog did not 
appear to grossly affect the bulk material. All of the foams were supple and pliable, and could 
easily be cut to specification. While there was some variability in the porosity of the foams, it 
was not statistically significant. Variability in the foam porosity can be expected due to the 
processing methods we used to fabricate the foam systems, and it does not appear to impact the 
various release profiles. The foams were also remarkable similar in terms of their sol content. 
The distribution of the naphthalene analogs in the foam samples could not be assessed in full due 
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to the location of many of the fluorescent excitation and emission bands. However, a DAPI filter 
did provide an opportunity to visualize four of the eight analogs. The distribution was largely 
similar, and the number or type of functional group did not appear to impact the distribution. 
The degradation and release studies did define a number of structure-release relationships 
existing among the analogs. First, the results suggest the aromatic urea to be much more resistant 
to hydrolysis that the aromatic urethane. This is evident from a comparison of the release profiles 
of 1-naphthol and 1-naphthylamine. Steady release of naphthol was observed to occur at 4, 22, 
and 37 °C, while significant release of naphthylamine was observed to occur only at 70 °C 
following that of naphthol. The greater stability of the urea over the urethane is again confirmed 
by examining the bi-functional aromatic analogs, 1,5-dihydroxynaphthalene and 1,5-diamino-
naphthalene. The release of 5-amino-1-naphthol more closely resembles that of 1,5-diamino-
naphthalene than 1,5-dihydroxynaphthalene, suggesting that the aromatic urea dictates its 
release. 
A similar rationale can be used to suggest the primary urethane is more stable that the 
primary urea. An examination of the release profile of 1-naphthalene methanol shows an initial 
burst release, later followed by steady release. Incomplete reaction of the primary hydroxyl in 
naphthalene methanol, can account for the initial rise in concentration. This can be attributed to 
the differences in the relative reactivity of primary amines and hydroxyls with isocyanate [141-
145]. However, the release profile of 1-naphthalene methylamine demonstrates slow, steady 
release throughout the duration of the experiment. Since there is no initial burst release, this can 
be attributed to primary urea degradation. 
The aforementioned structure-release trends can be seen in plots of the mol% release and 
the release normalized to the maximum mol% of each species (Figure 30).  
 
 81 
 
 
 
Figure 30 - Functional group comparison of the mol% and normalized release of naphthalene analogs from 
the LDI-glycerol foams 
 
Examination of the mol% release amongst the amine species shows that primary amines are 
released first, then single aromatic amines, and then the bi-functional aromatic amines. 
Surprisingly, when the mol% is normalized, the aromatic amines display strikingly similar 
release profiles. The hydroxyl release is complicated by variations in the relative reactivity of the 
hydroxyl species. Primary hydroxyl groups are still seen to release from the polyurethane before 
the aromatics. However, the aromatic trend is reversed in the normalized plot. This is likely due 
to the extremely low concentration of 1,5-dihydroxynaphthalene detected in solution due to the 
rapid fluorescence decay of this species, and the trend is greatly influenced by signal noise. 
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4.6 CONCLUSIONS 
In this study, we have demonstrated that the pendant functional groups present in the chemical 
structure of a drug dictate how it is released from degradable polyurethane foam. We used a 
series of naphthalene analogs possessing different chemical functionality in terms of the type and 
number of amine or hydroxyl groups. The urethane and urea bond formed from the reaction of 
the functional groups with isocyanate exist in differing chemical environments and result in 
different hydrolytic rates. The hydrolytic rates then determine how and when the structure is 
eluted from the polyurethane foam into the surrounding media. The polyurethane also served to 
protect the naphthalene analogs from fluorescent signal decay until they were released. The 
results of this study clearly demonstrate that release from degradable LDI-glycerol polyurethane 
foams is highly dependent upon the chemical structure of a drug.  
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5.0  RELEASE OF DB-67, DOXORUBICIN AND PACLITAXOL OCCURS 
SIMULTANEOUSLY AT DIFFERING RATES FROM SINGLE-PHASE LDI-
GLYCEROL POLYURETHANE FOAMS 
5.1 ABSTRACT 
In the present study, we present a novel approach to the controlled release of multiple 
chemotherapeutic agents from single-phase polyurethane foams constructed from lysine 
diisocyanate (LDI) and glycerol. DB-67, doxorubicin, and taxol were incorporated into the 
polyurethane foam network via labile urethane and urea linkages. The reactions of DB-67 and 
doxorubicin with LDI were monitored over a 4-hour period via infrared spectroscopy; each 
compound was found to react to differing degrees with LDI. Doxorubicin, DB-67 and taxol were 
then incorporated alone and in combination into a series of polyurethane foams. The sol content, 
porosity, and drug distribution of each foam sample was measured and found to be similar 
amongst the samples. The fluorescent spectra of DB-67 and doxorubicin were then measured in 
PBS buffer solution (pH 7.4), and the stability of each compound’s fluorescent signal was 
assessed over a 2-week period at 70 ºC. Release rates of DB-67 and doxorubicin from the foams 
were assessed over a 10-week period at 4, 22, 37, and 70 ºC via fluorescence spectroscopy. The 
rates were found to vary with temperature and were dependent upon the chemical structure of the 
incorporated drug. This study demonstrates the controlled release of multiple agents from single-
phase LDI-glycerol polyurethane foams occurs at differing rates dependent upon the chemical 
structure of the incorporated drug. 
Keywords: polyurethane, drug delivery, doxorubicin, DB-67, lysine diisocyanate 
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5.2 INTRODUCTION 
DB-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin), doxorubicin (Adriamycin), and Taxol 
(paclitaxol) are all potent anti-cancer compounds, each exerting their cytotoxic effects by 
interrupting processes essential to cellular growth and proliferation. DB-67 functions by 
inhibiting the enzyme topoisomerase I, a member of a nuclear enzyme family responsible for 
repairing DNA during replication [80, 81, 146, 147]. Doxorubicin functions via two 
mechanisms: first, intercalating DNA and inhibiting transcription, and then by inhibiting the 
enzyme topoisomerase II [148-151]. Finally, taxol exerts its effects via stabilizing polymerized 
microtubules; it is able to halt cell division as well as other vital processes relying on the 
rearrangement of the cytoskeleton [152, 153]. However, when using any of these compounds to 
combat malignancies in the body, it is impossible to avoid exposing normal functioning cells to 
their deleterious effects. The toxic side effects of these compounds ultimately are responsible for 
limiting their efficacy [5, 154-157]. 
Many strategies have evolved in an attempt to selectively deliver chemotherapeutics to 
localized, regions of malignant tissue within the body [4, 41]. One such strategy that has proven 
effective is implantation of degradable polymeric devices at the tumor site loaded with select 
chemotherapeutic agents [158, 159]. Instead of administering a drug to the entire body, these 
strategies serve to limit the exposure of the therapeutic to only a single body compartment or 
even a select region of that compartment. This strategy has proven efficacious and has resulted in 
several patented devices approved by the FDA for the treatment of solid tumors [48, 49, 82, 160, 
161]. Most often, these systems focus on the delivery of a single therapeutic, relying solely on 
diffusion as the primary release strategy. In these systems, the drug load will often be exhausted 
prior to the degradation and absorption of the polymeric material. 
Systems for the simultaneous delivery of multiple therapeutic compounds have also been 
proposed [162-166]. Polymeric systems for the delivery of multiple agents generally consist of 
multiple, distinctly defined phases each capable of delivering a separate compound [167, 168]. 
Typically, each phase possesses different diffusive properties that govern the liberation of the 
impregnated compound. Some of these systems even use multiple synthetic layers to achieve 
staggered rates of delivery [169]. However, the synthesis of such systems is often complex, 
costly, and time-consuming – ultimately preventing their commercialization and application in a 
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clinical setting. A single-phase polymer capable of simultaneous release of multiple therapeutic 
compounds at differing rates would offer an advantage over these systems in terms of cost and 
ease of fabrication.  
Our laboratory has developed polyurethane materials based on lysine and glycerol that 
degrade hydrolytically into non-toxic components – lysine, glycerol and CO2 [87, 170]. These 
polymers can easily be fashioned into differing morphologies using standard urethane processing 
techniques. The degradation characteristics of LDI-glycerol polyurethanes have proven useful in 
design of novel drug delivery systems. The present study is an expansion upon previous work, 
seeking to determine if the release of multiple chemotherapeutic agents at differing rates can be 
achieved from a single-phase polymer system. The delivery strategy is centered on the 
incorporation of drugs into the polymer backbone, being released via passive hydrolysis of 
urethane and urea bonds. The chemical structures of taxol, DB-67, and doxorubicin contain 
different functional groups, and we propose that they can be used to form urethane and urea 
linkages with differing degrees of hydrolytic susceptibility. Due to different rates of hydrolysis, 
each drug should elute from the polyurethane material in a different fashion.  
5.3 MATERIALS AND METHODS 
5.3.1 Materials 
Lysine diisocyanate methyl ester (LDI) was purchased from Chemical Division, Kyowa Hakko 
Kogyo Co. Ltd. (Tokyo, Japan). All other chemicals were obtained from Sigma–Aldrich 
Chemical Co. and were of reagent grade unless otherwise specified (Milwaukee, WI). 
5.3.2 Synthesis of drug-loaded polyurethane foams 
Glycerol (MW 92.01, 0.600 g, 6.5 mmol), LDI (MW 212.20, 2.00 g, 9.5 mmol), DABCO (MW 
112.18, 3.0 mg, 0.027 mmol), and dry DMSO (1.25 ml) were added to a small, dry 20 ml 
reaction flask; four such samples were prepared. Taxol (MW 853.9, 5.0 mg, 5.9 x 10
-3
 mmol), 
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doxorubicin (MW 579.9, 5.0 mg, 8.6 x 10
-3
 mmol), and DB-67 (MW 478.7, 5.0 mg, 1.0 x 10
-2 
mmol) were each added to a different flask. To the fourth flask, the same amounts of taxol, 
doxorubicin, and DB-67 were all added. The flasks were flushed with nitrogen prior to being 
sealed. The reactions were allowed to stir atop a magnetic stir plate in the dark at room 
temperature until the viscosity had attained a value of at least 3.0 x 10
4
 cP. At that time the 
viscous pre-polymer was transferred to a 100 mm PTFE dish and 100 ?L distilled, deionized 
H2O was added. The pre-polymers were thoroughly mixed 3 times at 2-minute intervals to 
ensure the H2O was fully incorporated. The rising foams were left open to the atmosphere yet 
covered to protect from light while the curing. The resulting polymer foams were then placed 
into a vacuum oven overnight at 25 ºC. The foams were then placed into storage in the dark at 4 
°C for further analysis.   
5.3.3 Drug Reactivity with LDI 
Solution of doxorubicin and DB-67 were prepared in dry DMSO at concentrations of 30.0 and 
10.0 mg/ml, respectively. Two small 5 ml reaction flasks were dried thoroughly and flushed with 
nitrogen, and DABCO (1.5 mg) was added to each flask. To one flask, 400 ?L of the DB-67 
(0.025 mmol) solution and LDI (MW 212, 5.3 mg, 0.025 mmol) were added to give a 1:1 molar 
ratio of DB-67 to LDI. To the other flask, 200 ?L of the doxorubicin (0.003 mmol) solution and 
LDI (MW 212, 2.2 mg, 0.009 mmol) were added to give a 1:3 molar ratio of doxorubicin to LDI. 
In each case, a 1:1 isocyanate to total-amine/hydroxyl ratio was obtained. Infrared spectra were 
recorded immediately upon addition of the LDI and 4 hours later in order to determine the 
reactivity of each drug. Taxol reactivity was not assessed at this time due to limited quantities of 
the drug. 
5.3.4 Excitation-emission spectra and fluorescence stability 
Stock solutions of DB-67, doxorubicin, and paclitaxol were prepared in DMSO at a 
concentration of 1.0 mg/ml. Each sample was sonicated for 5 min at 25 ºC to ensure complete 
dissolution. Then 3.0 ?L of each solution was diluted into 3 ml of PBS (pH 7.4) to arrive at 1.0 
?g/ml standard solutions. Each 1.0 ?g/ml solution was then scanned over a range of excitation 
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and emission wavelengths to elucidate the maximum fluorescent spectra for each compound 
(Cary Eclipse). 
Stock solutions of DB-67 and doxorubicin in DMSO at a concentration of 1.0 mg/ml 
were diluted to a concentration of 1000 ng/ml by taking 50 uL of DMSO stock and adding it to 
50 ml PBS (pH 7.4). The resulting solutions were mixed thoroughly, and a 3 ml sample was 
immediately collected and analyzed for content via fluorescence spectroscopy. The samples were 
then incubated at 70 ºC and protected from ambient light. Three-milliliter samples were 
withdrawn every 24 hours, and the fluorescent signal was measured within 1-hour of the sample 
being collected. Fluorescent decay curves were then constructed from the data collected. 
5.3.5 Evaluation of foam architecture by SEM 
Polyurethane foams containing either DB-67, doxorubicin, taxol, or all three were cut into small 
5 mm x 5mm x 1mm sections, dried thoroughly, and mounted on sample holders. Samples were 
observed at 25X magnification to ensure there were no gross irregularities. Then 10 images were 
collected at 75X from various regions of each sample. Metamorph image analysis software 
(Molecular Devices) was then used to differentiate pores from polymer via a threshold algorithm. 
Threshold images were then used to estimate the % porosity of each polyurethane foam. 
5.3.6 Distribution of DB-67 and doxorubicin within polyurethane 
Foam samples were sliced by hand to a thickness of roughly 500 ?m and mounted on a glass 
slide. Fluorescent and non-fluorescent images were taken at 100X in order to assess the 
distribution of drug throughout the polyurethane foams (Zeiss AX10 Imager.A1). Alexafluor 647 
and FITC filters were used to visualize the doxorubicin and DB-67, respectively (Chroma). 
5.3.7 DB-67 and doxorubicin release 
LDI-glycerol polyurethane foam samples each containing either DB-67, doxorubicin, or taxol 
and one containing all three were incubated at 10 mg/ml in PBS (pH 7.4) on rocking plates in 
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temperature-controlled rooms at 4, 22, 37 and 70 °C for 10-weeks. Sample chambers were 
protected from light during this time. Every 7 days, 3.0 ml of PBS was retrieved from each 
sample; during the first week, PBS was also collected on day 3. The amount of drug released 
from the polymer was detected via fluorescence spectroscopy using the excitation and emission 
wavelengths particular for each compound. The amount of drug collected was expressed as a 
percent of the total used in the synthetic reaction, being calculated as follows: 
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where (m/V)i represents the concentration of each collected sample and VT the total volume 
(where each time point is designated “i” and  “j” represents the last). Lysine and glycerol 
released from the polymer were not assessed at this time. 
5.4 RESULTS 
5.4.1 DB-67 and Doxorubicin Reactivity with LDI 
The reactivity of DB-67 and doxorubicin with LDI in the presence of DABCO was determined 
via infrared spectroscopy (Figure 31). Infrared scans of a 1:1 molar reaction between DB-67 and 
LDI show disappearance of the isocyanate (NCO) signal at 2265 cm
-1
 over the 4-hour reaction 
period. The ratio between the peak integrations of the NCO and carbonyl (C=O) was used to 
monitor the extent of the reaction; the ratio decreased from 1.0 to 0.2 over the 4-hour reaction 
period, representing an 80% decrease. Analogous scans of a 1:3 molar reaction between 
doxorubicin and LDI also reveal decay of the isocyanate signal. Initially, the NCO:C=O ratio 
measured 2.8 and decreased to 0.74, representing a 74% decrease of the initial signal. 
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Figure 31 – FT-IR spectra depicting the reactivity of DB-67 and doxorubicin with LID in the presence of a 
tertiary amine urethane catalyst 
 
5.4.2 Excitation-emission spectra and fluorescent stability 
DB-67 and doxorubicin each exhibit characteristic, intense fluorescent spectra that have been 
utilized to study their membrane partitioning kinetics and intracellular mechanisms of action [80, 
81, 171-173]. Taxol also exhibits a fluorescent spectrum, but it is highly dependent upon solvent 
polarity [174]. Each compound also possesses multiple functional groups that can serve as points 
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for chemical attachment into our polyurethane network. An investigation of each compound’s 
fluorescent behavior was undertaken to ensure they were capable of being detected over 
prolonged periods in PBS (pH 7.4) buffer solution. The excitation and emission spectra of DB-67 
and doxorubicin were obtained in PBS buffer (pH 7.4) solution (Figure 32).  
 
 
 
 
Figure 32 – Fluorescent excitation and emission spectra of DB-67 and doxorubicin 
 
The excitation wavelengths for DB-67 and doxorubicin were found to be 395 and 490 nm, 
respectively. The emission wavelengths for DB-67 and doxorubicin were 550 and 590 nm, 
respectively. Unfortunately, the fluorescence of taxol was found to be extremely weak and 
insufficient for accurate detection in PBS buffer solution (data not shown). The chemical 
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structures, number of synthetic attachments, and the excitation and emission wavelengths for 
each compound have been summarized in table 9. 
 
Table 9 – Chemical structure and fluorescent properties of DB-67, doxorubicin, and taxol 
 
 
Fluorescence (nm) 
Compound Structure Attachments 
Excitation Emission 
DB-67 
N
N O
OH
SiCH3 CH3
CH3CH3
O
O
OH
Ch3
CH3
 
2 total: 
aromatic OH,  
tertiary OH 
394 553 
Doxorubicin 
 
6 total: 
primary OH, 
secondary OH,  
tertiary OH, 
 2 aromatic OH, 
primary NH 
490 590 
Taxol 
 
4 total: 
2 secondary OH, 
1 tertiary OH, 
secondary NH 
 
n/a n/a 
  
 
The fluorescence spectrophotometer was then tuned so that the excitation and emission 
signals of DB-67 and doxorubicin registered in the maximum range of the detector. The 
excitation and emission peaks were well delineated from one another and free from background 
interference of the PBS buffer (data not shown). Standard curves ranging from 1.0 – 1000.0 
ng/ml were constructed for each compound, and found to be linear over those concentrations 
(data not shown). Out of the three compounds incorporated into our polyurethane drug delivery 
system, only DB-67 and doxorubicin could be adequately quantified via fluorescence. 
 DB-67 and doxorubicin have been found to be susceptible to chemical degradation in 
aqueous and oxidative environments [175-178]. Although much harsher conditions than we 
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propose were used in these studies, an assessment of the fluorescence stability of the compounds 
in PBS (pH 7.4) buffer was needed (Figure 33). 
  
 
 
 
Figure 33 – Fluorescent decay profiles of DB-67 and doxorubicin at 70 °C over a 2-week period 
 
We chose to only evaluate the fluorescence stability at 70 ºC. Over a 2-week test period, DB-
67’s fluorescent signal was found to increase. On day 14 of the study, DB-67 had achieved a 
32% increase over its original baseline value. On the other hand, doxorubicin’s fluorescent signal 
was found to decay almost immediately upon exposure to aqueous media at 70 ºC. By day-2 of 
the study only 1.4% of the baseline signal remained, and by day-14 only 0.3% registered. 
5.4.3 Polyurethane Foams: SEM analysis and Drug Distribution  
Low-magnification scanning electron micrographs (25X) were taken in order to assess the 
morphology of the polyurethane foam samples (Figure 34). 
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Figure 34 – Scanning electron micrographs demonstrating the morphological features of LDI-glycerol 
polyurethane drug foams 
 
These images reveal the foams largely similar in terms of pore size, shape and distribution. Some 
variation in the foam morphology is to be expected, resulting from the processing methods used 
to fabricate each sample. Higher magnification images (75X) taken from regions of the foam 
specimens, and the porosity was estimated using a threshold imaging technique. Metamorph 
imaging software was able to clearly delineate between the polymer and pore regions of the 
images (data not shown). The average porosity of each foam sample is listed along with the 
release data found in Table 10. 
Fluorescent and non-fluorescent images were obtained in a attempt to qualitatively assess 
the distribution of DB-67 and doxorubicin throughout the LDI-glycerol polyurethane foams 
(Figure 35).  
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Figure 35 – Fluorescent microscope images showing the distribution of DB-67 and doxorubicin through the 
LDI-glycerol polyurethane foam 
 
Bright field images of the foams, each loaded with only a single drug species, appear very 
similar in morphology. Darkened regions of the bright field images are attributable to sample 
thickness. Fluorescent images reveal uniform drug distributions, with the thicker areas of the 
foam samples possessing greater fluorescent signal. Overlaid composite images further prove the 
distribution of both DB-67 and doxorubicin to be uniform throughout the materials. 
 Fluorescent images were then obtained of a sample containing all three drug compounds, 
but only the DB-67 and doxorubicin distributions were assessed (Figure 36).  
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Figure 36 – Fluorescent microscope images showing the distribution of DB-67 and doxorubicin through 
multi-drug LDI-glycerol polyurethane foams 
 
The fluorescence of the multi-drug foam appears more intense than that of the single-drug foams, 
but this can be attributed to sample thickness. The images reveal both DB-67 and doxorubicin to 
be uniformly dispersed throughout the polyurethane, with a composite image further confirming 
this finding.  
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5.4.4 Drug release 
The release of DB-67 and doxorubicin from the polyurethane foams was monitored over a 10-
week period at 4, 22, 37 and 70 °C. The release of each drug species was assessed from multiple 
samples. Polyurethane foams were synthesized containing only DB-67, Taxol or doxorubicin; 
another sample was prepared containing all three. For reasons already mentioned, only DB-67 
and doxorubicin release could be assessed via fluorescence. DB-67 release from the 
polyurethane samples was found to occur in a temperature dependent fashion, with similar 
amounts liberated from both the single and multiple drug foams (Figure 37).  
 
 
 
 
Figure 37 – DB-67 release profiles for single and multi-drug LDI-glycerol polyurethane foams 
 
By day-70 of the degradation studies, 83.9 and 79.4 mol% of the DB-67 had been released from 
the single and multiple agent foams at 70 °C, respectively. The amounts of DB-67 released from 
each foam sample at 4, 22, and 37 °C were substantially less, but occurred in similar amounts for 
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the single and multi-drug foams. Doxorubicin release from the single and multi-drug foams was 
seen to occur in the same temperature dependent fashion (Figure 38).  
 
 
 
 
Figure 38 - Doxorubicin release profiles for single and multi-drug LDI-glycerol polyurethane foams 
 
By day-70, 87.5 and 92.3 mol% were released from the single and multiple drug foams at 70 °C, 
respectively. Again, the amounts released at lower temperatures were substantially less but were 
comparable between the two samples. The release data for the single and multiple drug 
polyurethane foams along with has been summarized in table 10. 
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Table 10 - Release characteristics of DB-67 and Doxorubicin from single and multi-drug LDI-glycerol 
polyurethane foams 
 
 
System Compound 
porosity 
(%) 
sol 
content 
(%) 
Temperature 
(°C) 
mol%
a
 
mass 
loss
b
 
(%) 
day-70 
concentration 
(?M) 
day-3 
concentration 
(?M) 
day-
70/day-3 
ratio 
4 4.58 39.2 1.23 0.57 2.2 
22 4.94 40.1 1.22 1.88 0.6 
37 7.25 39.8 1.84 2.74 0.7 
DB-67 
36.4 ± 
7.8 
25.0 
70 83.30 95.7 29.78 3.20 9.3 
4 0.25 37.4 0.06 0.01 6.0 
22 1.31 37.6 0.33 0.03 11.0 
37 6.00 38.6 1.51 0.13 11.6 
Doxorubicin 
24.7 ± 
7.0 
24.5 
70 87.49 92.1 31.03 0.50 62.1 
4 ----- 38.1 ----- ----- ----- 
22 ----- 38.8 ----- ----- ----- 
37 ----- 38.9 ----- ----- ----- 
Single 
Taxol 
28.6 ± 
9.8 
27.5 
70 ----- 98.8 ----- ----- ----- 
          
4 3.99 37.9 1.08 0.43 2.5 
22 4.50 37.1 1.10 1.48 0.7 
37 6.69 40.7 1.63 2.59 0.6 
DB-67 
28.4 ± 
11.1 
25.1 
70 79.37 92.3 32.91 2.86 11.5 
4 0.79 0.17 0.06 2.8 
22 1.87 0.46 0.15 3.1 
37 2.14 2.14 0.33 6.6 
Doxorubicin 
same as 
above 
same as 
above 
70 92.95 
same as 
above 
30.62 2.27 13.5 
4 ----- ----- ----- ----- 
22 ----- ----- ----- ----- 
37 ----- ----- ----- ----- 
Multiple 
Taxol 
same as 
above 
same as 
above 
70 ----- 
same as 
above 
----- ----- ----- 
a: at day-70, b: mass loss = (initial mass - final mass)/(initial mass) x 100%  
 
 The release profiles of the multi-drug polyurethane foams reveal substantial differences 
to exist between the two drug species at different temperatures (Figure 39). At 37 °C, there is an 
initial rapid rise of DB-67 that stabilizes at a concentration around 1.6 x 10
-6
 M (6.7 mol%). The 
doxorubicin concentration slowly rises in a linear fashion from the onset of the degradation 
experiment, eventually elevating above the concentration of DB-67 on day-49, reaching a 
maximum of 2.1 x 10
-6
 M (8.6 mol%) at day-70. At 70 ºC, the concentrations of DB-67 and 
doxorubicin in solution are seen to rise in parallel with one another. Doxorubicin is slightly 
higher at the onset and then later surpassed by DB-67 by day-63. However, the relative 
percentages of the material eluting from the polymer indicate that doxorubicin is eluting more 
rapidly than is DB-67. 
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Figure 39 – Comparison of DB-67 and doxorubicin release from multi-drug LDI-glycerol polyurethane foams 
at 37 and 70 C° 
 
5.5 DISCUSSION  
The reactions of DB-67 and doxorubicin with LDI reveal differences in their ability to form 
urethane bonds. After a 4-hour period, nearly all the isocyanate signal has disappeared from the 
reaction mixture. The signal registering in the isocyanate region after 4 hours is largely attributed 
to background noise. Notice that there has also been a concomitant decrease in the signal around 
the carbonyl region of the spectra around 1700 cm
-1
. In the reaction of LDI and doxorubicin, we 
would expect a much larger initial NCO : C=O ratio due to the number of functional groups 
present on the drug. However, in the reaction between doxorubicin and LDI there appears to be a 
lower initial isocyanate signal relative to the DB-67 reaction. This apparent discrepancy can be 
largely attributed to the rapid reaction of the primary hydroxyl and amine groups in 
doxorubicin’s structure with the isocyanate before the initial IR scan could be obtained. There is 
also an increase in the carbonyl region of the spectra after 4 hours that was used to calculate the 
NCO:C=O ratio.  
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The fluorescent spectra of DB-67 and doxorubicin exhibit distinct differences and 
provide an opportunity to follow the simultaneous release of both species from a single 
polyurethane foam sample. The doxorubicin excitation band at 490 nm, while somewhat broad, 
is well delineated from the 395 nm excitation band of doxorubicin. The excitation band of DB-67 
at 395 nm does overlap to a small degree with doxorubicin, but if the sample is sufficiently 
dilute, ensuring all of the DB-67 reaches an excited state, minimal interference at the 550 nm 
emission should be present. Furthermore, the aqueous fluorescence of taxol was found to be 
extremely weak, and its inclusion in the polymer sample should not interfere with the detection 
of DB-67 and doxorubicin. Furthermore, the fluorescent excitation and emission bands of taxol 
lie closer to the ultra-violet region of the spectra. These bands being well removed from those of 
DB-67 and doxorubicin should not interfere with their detection. 
 While the fluorescent intensity of free doxorubicin was found to decay rapidly in PBS at 
70 ºC, the same was not found to be true when the drug was released from polyurethane foam. 
The signal of doxorubicin was found to persist throughout the duration of the study allowing us 
to account for more than 85% of the original content, suggesting that the reaction of the drug 
with LDI retarded its fluorescent decay. The ability of the polyurethane foam to stabilize the 
fluorescence of doxorubicin is a striking feature of our delivery system. We have noted similar 
effects related to the release of fluorescent naphthalene analogs from our delivery system in the 
past. Many promising drug candidates have failed to provide any clinical benefit due to 
premature inactivation in the body before interaction with a target site; DB-67 is one such 
candidate. It is our hope that incorporation of a drug into our polyurethane delivery vehicle will 
prove useful in counteracting these limitations imposed by the body’s unique chemical and 
metabolic environment. 
The synthetic conditions and processing methods used in this study resulted in 
remarkable consistent polyurethane foams. The sol% amongst each sample was found to be 
remarkably similar and the porosity was well conserved. The mass losses measured after the 
degradation experiments demonstrated temperature dependence, and the mol% of drug released 
was similar between multi and single drug systems. The distribution of the drugs also appears to 
be uniform when assessed with fluorescent microscopy. It is interesting to consider the ratio of 
drug concentration at day-70 to the initial concentration measured on day-3. A ratio less that one 
can be considered to represent a “burst” release pattern, while a ratio greater than one indicates a 
 101 
“delayed” release pattern. Under this classification, doxorubicin is always released in a delayed 
fashion regardless of temperature. In contrast, DB-67 is released in a burst fashion at 4 and 70 
ºC, while delayed release is observed at 22 and 37 ºC. The contrasting release features at 
different temperatures can account for the initial burst release of DB-67 followed by the delayed 
release of doxorubicin at 37 ºC in the multiple drug system. 
5.6 CONCLUSIONS 
In the present study, we have described the synthesis and performance of novel drug-eluting 
polyurethane foams synthesized from LDI and glycerol capable of releasing multiple drugs at 
different rates. This is achievable due to the incorporation of the drug moieties into the backbone 
of the polyurethane network, utilizing each drug’s pendant functional groups to achieve differing 
rates of hydrolysis. The staggered release of multiple drugs from a single-phase material 
represents an improvement over current controlled-release technology. The improvements are 
manifest in the simplified processing techniques required to achieve staggered-release. This 
research opens new avenues of exploration in dosing strategies limited to select regions of tissue 
accessible to the implanted devices. Also, combining the synergistic actions DB-67 and 
doxorubicin on the topoisomerase enzyme target would certainly prove useful in halting tumor 
progression. It is our hope that this release technology will enable the further development of 
drug candidates previously considered inadequate for clinical use.  
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6.0  INCORPORATION OF INCORPORATION OF CATIONIC AND ANIONIC 
CONSTITUENTS ACCELERATES THE RELEASE OF DB-67 FROM LDI-GLYCEROL 
POLYURETHANE IMPLANTS 
6.1 ABSTRACT 
This study seeks to determine the effect of ionic ligands on the drug delivery characteristics of 
biodegradable polyurethane materials synthesized from lysine diisocyanate (LDI) and glycerol. 
Two naturally occurring ionic ligands, choline chloride (CC) and isethionic acid (ISE), and DB-
67, a potent anti-cancer compound, were covalently incorporated into LDI-glycerol polyurethane 
films and foams using a a tertiary amine catalyst. It was shown that the sulfonate group on ISE 
does not react to a significant degree with LDI. The morphological characteristics of the 
polyurethane films and foams were then assessed via SEM, and significant differences related to 
the ionic ligands were found to exist. Differences in the distribution of DB-67 throughout the 
films and foams were assessed via fluorescence microscopy. The materials were then evaluated 
for their drug delivery characteristics in vitro. The results of this study clearly indicate that the 
incorporation of ionic ligands into LDI-glycerol polyurethanes has significant effects on the 
morphology and drug distribution characteristics, ultimately affecting the drug delivery profiles 
of these materials.   
Keywords: choline chloride, isethionic acid, polyurethane, drug-delivery, camptothecin 
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6.2 INTRODUCTION 
Ionic species are prevalent in biology and are intricately involved in many of the essential 
physiologic processes required to maintain homeostasis. Choline chloride (CC) is a naturally 
occurring amine salt that is found in the lipids that make up cell membranes and in the 
neurotransmitter acetylcholine [179]. It has been classified as an essential nutrient by the Food 
and Nutrition Board of the National Institute of Medicine, usually grouped within the Vitamin B 
complex. Isethionic acid (ISE) is a short chain alkane sulfonate containing hydroxyl group that is 
a water soluble liquid used in the manufacture of mild, biodegradable and high foaming anionic 
surfactants [180]. It is also naturally occurring and studies suggest that cardiac myocytes are 
capable of converting taurine to isethionic acid [181, 182]. The carbon analogue of choline, 3,3-
dimethyl-butanol (DMB), while not naturally occurring, has been used in the past to probe the 
physiology of cholinergic transmission [183, 184]. These three structures, while each serving 
separate and vastly different physiologic roles, do share a unique relationship. 
These three compounds are all similar in terms of their chemical structures, each 
possessing a primary alcohol and an organic functional group separated by an ethyl chain (Figure 
37). The various organic functional groups – quaternary amine for CC, sulfonate for ISE, and t-
butyl for DMB – impart a specific ionic character to the molecule: CC is cationic, ISE is anionic, 
and DMB can be considered a neutral species. These three compounds with similar organic 
structures provide a starting point to begin exploring the effect of ionic additives in erosive drug 
delivery implants. 
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Figure 40 – Structure of CC, ISE and DMB 
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Hydrolysis is one of the dominant mechanisms for polyurethane degradation, and its rate 
is highly dependent upon material composition [185]. Hydrolysis can essentially be considered 
as a “reversal of condensation”. Most degradable polyurethanes are thermoplastic elastomers co-
polymers that are heterogeneous in nature, being composed of both hard and soft segments. The 
hard segment is typically comprised of high glass transition temperature (Tg), semi-crystalline 
aromatic diisocyanate with a low molecular weight chain extender; the soft segment is typically 
low Tg polyester with high molecular weight. Degradation in these materials occurs quite quickly 
via ester hydrolysis, while the urethane bond is more resistant to cleavage [131]. However, 
urethane hydrolysis does occur, albeit at a much slower rate that is largely dependent upon the 
hydrophobic character of the diisocyanate used to fashion the polyurethane [186]. 
Our laboratory has synthesized a new class of polyurethane materials based on lysine and 
glycerol that degrade hydrolytically into non-toxic components – lysine, glycerol and CO2 [87]. 
Lysine diisocyanate (LDI) and glycerol readily react to form dense polyurethane networks 
suitable for a variety of biomaterial applications [88, 170, 187]. These materials hydrolyze on a 
much longer time scale than the typical degradable polyurethane, and we have previously 
fashioned hydrolysable drug delivery systems from these materials intended for the long-term 
controlled release of therapeutic compounds within the body. Our delivery technology relies on 
the chemical incorporation of therapeutic compounds into a polyurethane network via pendant 
hydroxyl and amine functional groups present within a drug’s chemical structure. Drug release 
occurs in a slow, predictable fashion as the polyurethane erodes. 
In an attempt to alter the degradation rates and hence the release characteristics of our 
delivery systems, we propose the incorporation of ionic species into LDI-glycerol polyurethanes. 
Urethane degradation alters in response to local ion concentrations [188], and it is our hope that 
inclusion of biocompatible ionic species into the polymer will provide a similar effect. This 
study should provide yet another means to the alter degradation rates of our LDI-glycerol 
polyurethanes and control the release profiles of drug delivery systems fashioned from them. 
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6.3 MATERIALS AND METHODS 
6.3.1 Materials 
Lysine diisocyanate methyl ester (LDI) was purchased from Chemical Division, Kyowa Hakko 
Kogyo Co. Ltd. (Tokyo, Japan). ).  7-tert-butyldimethylsilyl-10-hydroxycamptothecin (DB-67) 
was obtained from Dr. Dennis Curran at the University of Pittsburgh, Chemistry Dept.  
(Pittsburgh, PA). Bismuth 2-ethylhexanoate was obtained from Alfa Aesar (Ward Hill, MA). All 
other chemicals were obtained from Sigma–Aldrich Chemical Co. and were of reagent grade 
unless otherwise specified (Milwaukee, WI). 
6.3.2 Synthesis of Ionic Films and Foams 
Polyurethane films were fashioned by taking glycerol (MW 92.01, 1.00g, 10.9 mmol), Bismuth 
2-ethylhexanoate (MW 638.61, 5 mg, 7.8 x 10
-3
 mmol), DB-67 (MW 478.70, 10 mg, 2.1 x 10
-3
 
mmol), and dry DMSO (2.5 ml) and adding them to a small, dry 20 ml reaction flask. The 
requisite amount of isethionic acid (ISE) (MW 148.1, 370 mg, 2.5 mmol) choline chloride (CC) 
(MW 139.6, 349 mg, 2.5 mmol) or 3,3-dimethyl-butanol (DMB) (MW 102.2, 255 mg, 2.5 mmol) 
to arrive at 6.0 mol% was added to the flask. Mol% was calculated as the number of mols of 
additive over the total mols of reactant, expressed as a percent. The contents were mixed at room 
temperature until thoroughly dissolved. The reaction flask was then transferred to an ice bath 
atop a magnetic stir plate and allowed to chill for 15 min. LDI (MW 212.20, 6.00 g, 28.3 mmol) 
was then added and the vial was flushed with nitrogen prior to being sealed. The flask was 
placed back in the ice bath and mixed for 1 hr. The reaction flask was removed from the ice bath 
and stirred at room temperature until the viscosity sufficiently increased such that it could no 
longer be mixed atop the magnetic stir plate; its viscosity was approximately 3.0 x 10
4
 cP at this 
time. The viscous pre-polymer was then transferred to a 65 mm PTFE dish submerged in an 
ethyl acetate (EtAc) bath. The polymer was allowed to cure for 48 hours in the EtAc bath. The 
PTFE dish was then removed from the bath and placed into a vacuum oven at 25 ºC for 24 hours. 
The polymer films were then stored in the dark at 4 ºC for further processing and analysis. 
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The same procedure and amounts of reactants were used in fashioning the polyurethane 
foams, except this time 1,4-diazobicyclo[2.2.2]-octane (DABCO) (MW 112.2, 8.0 mg, 7.0 x 10
-2
 
mmol) was used as a urethane catalyst. After sufficient viscosity had been attained, the viscous 
pre-polymer was transferred to a 100 mm PTFE dish and 100 ?L distilled, deionized H2O was 
added. The pre-polymers were thoroughly mixed 3 times at 2-minute intervals to ensure the H2O 
was fully incorporated. The rising foams were left open to the atmosphere yet covered to protect 
from light while the curing. The resulting polymer foams were then placed into a vacuum oven 
overnight at 25 ºC. The foams were then placed into storage in the dark at 4 °C for further 
analysis. The average hydroxyl functionality (Favg) was calculated for each of the materials 
according to the following equation: 
 
Favg =
nixi?
xi?
 
 
where ni is the number of hydroxyl functional groups on a molecule and xi is the number of 
moles of that molecule. 
6.3.3 ISE Reactivity with LDI 
In order to determine if the sulfonate group of ISE reacts with isocyanate (NCO), LDI (89mg), 
ISE (125 mg), and 2.0 ml dry, DMSO were added to a small dry reaction flask to achieve a 1:1 
OH to NCO ratio. Another vial was prepared with the same amount of DMSO and ISE, but LDI 
(178 mg) was used to provide a 1:1 ratio of LDI to ISE. Infrared spectra of each reaction were 
obtained immediately after the addition of LDI. No urethane catalyst was used to facilitate the 
reactions. The flasks were mixed atop a magnetic stir plate for 6 days, and infrared spectra were 
recorded again. Peak integrations for the NCO and carbonyl (C=O) peaks were obtained and 
used to track the progress of the reactions over the 6-day period. 
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6.3.4 Swelling studies 
Polyurethane foams and films containing either 6 mol% CC, ISE or DMB and corresponding 
control materials containing 0 mol% ionic constituent were prepared as previously described. 
Small samples on the order of 50.0 mg was obtained from each of the polyurethane foams, and a 
30.0 mg discs was cut from each film with a 4 mm tissue biopsy punch (Sklar Instruments). The 
samples were weighed and then placed in 40.0 ml distilled, deionized water atop a magnetic stir 
plate and slowly agitated. Their weights were recorded over time in the following manner: every 
minute for the first 10 minutes, every 2 min for the next ten minutes, every five minutes for the 
rest of the first hour, every 10 minutes during the second hour, every 20 minutes during the third 
hour, and then every 30 minutes for the remaining 2 hours. The samples were weighed again 
after 24 hours. The amount of water taken up by the foam and film samples was expressed as a 
percent increase over the original weight. The samples were then dried to constant weight, and 
the sol content of each sample was determined as previously described by Huang [115]. 
6.3.5 SEM Evaluation of Polymer Architecture 
Polyurethane foams and films containing either choline chloride, isethionic acid, taxol, or all 
three were cut into small 5 mm x 5mm x 1mm sections, dried thoroughly, and mounted on 
sample holders. The foam materials were sliced through on horizontal and vertical cross-sections 
in various places about the samples. A 4 mm tissue biopsy probe was used to remove discs from 
several regions of the film, and those discs were sliced through on horizontal and vertical cross-
sections. Samples were observed at 25X magnification to ensure there were no gross 
irregularities. A series of images were taken of each specimen. For foams, images were taken at 
25X, 100X, and 2000X of the sample top, bottom, and cross-section. For films, images were 
taken at 100X, 200X, and 2000X of the sample top, bottom, and cross-section. Images were then 
compared to one another in order to elucidate the morphological changes imparted by the ionic 
constituents. 
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6.3.6 DB-67 Distribution throughout the Polyurethanes 
Film and foam samples were dried thoroughly and then sliced to a thickness of approximately 
500 ?m and mounted on a glass slide. Fluorescent and non-fluorescent images were taken at 
100X filter in order to assess the distribution of DB-67 throughout the ionic and control film and 
foam polyurethane materials (Zeiss AX10 Imager.A1). A FITC filter was used to visualize the 
DB-67 compound within the sample (Chroma). 
6.3.7 Drug Release 
LDI-glycerol polyurethane foam samples containing DB-67 and 6 mol% of CC, ISE, or DMB 
were incubated at 10 mg/ml in PBS (pH 7.4) on rocking plates in temperature-controlled rooms 
at 4, 22, 37 and 70 °C for 10-weeks. A sample containing only DB-67 and no ionic constituent 
was incubated at 10 mg/ml as well. Sample chambers were protected from light during this time. 
Every 7 days, 3.0 ml of PBS was retrieved from each sample; during the first week, PBS was 
also collected on day 3. The amount of DB-67 released from each polymer sample was detected 
via fluorescence spectroscopy using the excitation and emission wavelengths particular for DB-
67. The total amount of drug collected was calculated as follows: 
 
mol% =
1
MWDB?67
3
m
V
? 
? ? 
? 
? ? i
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where (m/V)i represents the concentration of each collected sample and VT the total volume 
(where each time point is designated “i” and  “j” represents the last). Lysine and glycerol 
released from the polymer were not assessed at this time. 
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6.4 RESULTS 
6.4.1 ISE Reactivity with LDI 
It is well know that primary hydroxyl groups readily react with isocyanate to form urethane 
bonds with or without the addition of a urethane catalyst. It is easily concluded that both CC and 
DMB will readily incorporate into LDI-glycerol polyurethane materials in a predictable fashion. 
However, it is difficult to predict how the presence of a sulfonate group in ISE will affect the 
synthetic reaction. Therefore, it was of interest to determine the reactivity of ISE with LDI, and 
this was monitored via infrared spectroscopy (Figure 41).  
 
 
 
 
Figure 41 - FT-IR data depicting the reaction of LDI with ISE at 1 NCO : 1OH and 1LDI : 1 ISE molar ratios 
 
In the 1:1 NCO to OH reaction, complete disappearance of the NCO signal is realized by day-6.  
The ratio of the NCO to carbonyl (C=O) peak integrations progresses from 1.9 at day-0 to 0.3 at 
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day-6, indicating that all of the NCO has reacted with the primary OH. In a 1:1 LDI to ISE 
reaction, significant NCO signal is observed to persist at day-6. The NCO/C=O peak ratio 
changes from 2.1 at day-0 to 1.0 at day-6, indicating that half of the isocyanate has reacted.  
6.4.2 Swelling Studies 
Polyurethane foam and film samples loaded with 6 mol% ISE, CC, or DMB and corresponding 
control materials containing no ionic additives were assessed for their ability to take up water in 
an aqueous environment incrementally over a 5 hour period (Figure 42).  
 
 
 
 
Figure 42 - Swelling studies for the 6 mol% CC, ISE, DMB, and control foam and film LDI-glycerol 
polyurethanes loaded with DB-67 
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Foam samples were observed to take up approximately 3 to 4 times more water than their 
corresponding films. Over a 24-hour period, the control foam and film samples were observed to 
absorb and additional 103% and 23%, respectively. The non-ionic DMB species were observed 
to absorb slightly greater amounts of water, with the foam and film species each absorbing and 
additional 110% and 26%, respectively. The amounts of water absorbed by the ionic foams and 
films were significantly greater than those observed for either of the controls. The ISE foam and 
film samples absorbed 149% and 46%, while the CC foams and films absorbed an additional 
171% and 50%, respectively. The general trend amongst the foam and film samples regarding 
water uptake was as follows: CC > ISE > DMB > control. The samples were left to soak for a 
full 24-hours, and the mass was recorded again. The trend was still observed with each material 
taking up slightly more mass over the 19-hour interval, except for the ISE and CC foams which 
had begun to deteriorate. 
6.4.3 SEM analysis and DB-67 distribution 
Scanning electron micrographs of the LDI-glycerol polyurethane materials demonstrate that 
some significant changes in morphology occur with the addition of ionic constituents. All 
internal surfaces of the sample obtained via horizontal and vertical cross sectioning were similar 
in appearance. The top surfaces of the foams and films both appeared smooth in nature. The tops 
of the film samples free of pores, while the top surface of the foam samples had reduced number 
and size of pores. The bottom surfaces of the film samples appeared similar in nature to the top, 
and the bottom surfaces of the foams appeared similar to the cross sections. Only vertical cross-
sectional images are shown to illustrate the material morphology. Low and high magnification 
images demonstrate the differences that exist between the film samples (Figure 43).  
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Figure 43 - SEM images of the 6 mol% CC, ISE, DMB, and control LDI-glycerol polyurethane films loaded 
with DB-67 
 
The images indicate that the ionic samples, CC and ISE, both possess cavitations throughout the 
materials. The cavitations in the CC sample appear much more ordered and larger at higher 
magnification than those in the ISE material. There are no cavitations present in either the DMB 
or 0 mol% control foams, although there are some distinct surface irregularities. The 
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irregularities are much more prevalent at high magnification on the surface of the 0 mol% 
control film than on the DMB film. Low and high magnification SEM images of the LDI-
glycerol polyurethane foam materials reveal the materials to be much more similar to one 
another than previously observed amongst the film samples (Figure 44).  
 
 
 
 
Figure 44 - SEM images of the 6 mol% CC, ISE, DMB, and 0 control LDI-glycerol polyurethane foams 
loaded with DB-67 
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There are slight variations amongst the foam morphologies in terms of the number and size of 
the pores. However, high magnification images show that the surfaces of the materials are all 
very similar in nature. The surface irregularities are much less drastic in nature than the film 
samples. The surface of the CC foam exhibits small cracks across its surface, while the other 
samples are quite smooth and uniform.  
DB-67 possesses an intense, characteristic fluorescent profile, making an ideal candidate 
for assessing the controlled-release characteristics of our polyurethane materials [81, 177]. The 
emission band of the DB-67 moiety corresponds closely with that of FITC, a fluorescent probe 
commonly used in many biological assays. As such, we were able to visualize the distribution of 
DB-67 throughout thin sections of the various polyurethane materials using fluorescence 
microscopy. The distribution of DB-67 throughout the polyurethane films was observed to vary 
to a considerable degree (Figure 45).  
 
 
 
 
Figure 45 - Fluorescent microscope images demonstrating DB-67 distribution through the CC, ISE, DMB and 
control LDI-glycerol polyurethane film samples 
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Bright field images reveal the ionic film samples to each possess a unique material morphology, 
each differing in appearance quite considerably from either of the control species. Fluorescent 
images of the ionic films demonstrate the DB-67 distribution closely following the material 
morphology, with intense pockets of signal scattered throughout. The DMB sample exhibits a 
relatively disperse distribution of drug, but does possess intense bands coursing throughout the 
film. The control film possesses a uniform distribution of DB-67, similar to what was observed 
in the polyurethane foam materials. The distribution of DB-67 throughout the polyurethane foam 
materials was observed to be uniform relative to the film materials (Figure 46).  
 
 
 
 
Figure 46 - Fluorescent microscope images demonstrating DB-67 distribution through the CC, ISE, DMB and 
control LDI-glycerol polyurethane foam samples 
 
Bright field images demonstrate variations in pore size and shape to exist, and some slight 
variation can be expected after considering the material processing methods used to fashion the 
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foams. The fluorescent images reveal that the DB-67 distribution to be relatively and uniform, 
with signal intensity closely following foam thickness and morphology.  
6.4.4 Drug release 
Incorporation of ionic ligands has already proved to alter the swelling characteristics of the ionic 
foams relative to the DMB and control materials. As a result, we can anticipate distinct 
differences to occur amongst the materials with regard to their release of incorporated DB-67. 
The release of DB-67 and from the polyurethane films and foams was monitored over a 6-week 
period at 4, 22, 37 and 70 °C. The release of each drug species was assessed from multiple 
samples. The concentration profiles of DB-67 obtained in solution for the LDI-glycerol 
polyurethane films and foams were found to be temperature dependent and revealed some 
interesting differences (Figure 47).  
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Figure 47 - Concentration profiles for the release of DB-67 from the CC, ISE, DMB, and control LDI-glycerol 
polyurethane films and foams 
 
Initially, all of the materials exhibit a burst release of drug with subsequent decay. The day-3 
concentrations of DB-67 in solution can be ordered with regard to ionic constituent and follow 
the trend CC > ISE > DMB > control. Concentrations of DB-67 obtained form the ionic CC and 
ISE foams were approximately twice those contained form the corresponding films. Surprisingly, 
more DB-67 was released from the DMB film than from the corresponding foam. Similar 
concentrations of DB-67 were obtained from each of the control materials.  
In addition, the relative amount of DB-67 liberated from each film and foam system was 
recorded, eliciting some key differences between the various materials (Figure 48).  
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Figure 48 - Release profiles showing the mol% of DB-67 retrieved from the CC, ISE, DMB, and control LDI-
glycerol polyurethane films and foams 
 
The burst release observed in the concentration profiles for the films and foams is observed to be 
quite small relative to the total DB-67 content of the materials. At the end of the 6-week period, 
the ionic films had released a greater percentage of their total drug load into solution than the 
corresponding films. The CC and ISE foams released 42.0% and 35.0% of their DB-67 content, 
respectively, while each of the ionic films each released 22.4%. The DMB and control materials 
each released significantly less DB-67 than the materials containing any ionic ligands. The drug 
release characteristics have been summarized in Table 11. 
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Table 11 - Release characteristics of DB-67 from ionic and control LDI-glycerol polyurethane films and foams 
 
 
System Compound Fav g  
sol 
content 
(%) 
Temperature 
(°C) 
mol%
a
 
day-42 
concentration 
(?M) 
day-3 
concentration 
(?M) 
day-42/day-
3 ratio 
4 1.3 0.25 0.05 5.0 
22 3.5 0.71 0.32 2.2 
37 6.9 1.33 0.71 1.9 
choline 
chloride 
2.6 20.3 
70 22.3 4.67 1.64 2.8 
4 0.8 0.16 0.06 2.7 
22 4.0 0.79 0.24 3.3 
37 5.4 0.98 1.00 1.0 
isethionic 
acid 
2.6 28.3 
70 22.4 4.61 1.24 3.7 
4 0.02 0.12 0.01 12.0 
22 1.4 0.26 0.08 3.3 
37 2.5 0.46 0.42 1.1 
3,3-
dimethyl-
butanol 
2.6 23.4 
70 8.3 1.61 0.63 2.6 
4 0.03 0.01 0.00 ----- 
22 0.3 0.06 0.01 6.0 
37 0.7 0.15 0.09 1.7 
Film 
none 3.0 19.9 
70 6.9 1.69 0.22 7.7 
         
4 1.4 0.28 0.10 2.8 
22 3.8 0.73 0.35 2.1 
37 6.2 1.15 0.70 1.6 
choline 
chloride 
2.6 28.1 
70 58.0 12.66 1.42 8.9 
4 1.1 0.21 0.12 1.8 
22 4.4 0.85 0.27 3.1 
37 7.4 1.34 0.77 1.7 
isethionic 
acid 
2.6 26.5 
70 46.3 9.54 1.28 7.5 
4 0.06 0.01 0.00 ----- 
22 0.4 0.09 0.01 9.0 
37 0.9 0.17 0.10 1.7 
3,3-
dimethyl-
butanol 
2.6 25.9 
70 6.9 1.5 0.37 4.1 
4 0.04 0.01 0.00 ----- 
22 0.09 0.02 0.00 ----- 
37 0.6 0.11 0.02 5.5 
Foam 
none 3.0 24.3 
70 14.2 3.07 0.26 11.8 
a: at day-42  
 
6.5 DISCUSSION 
Infrared spectroscopy was used to monitor the reaction of ISE with LDI to determine how the 
presence of the sulfonate group would affect the urethane chemistry. The reactions were carried 
out in the absence of any urethane catalyst in order to avoid many of the common side reactions 
associated with their use [19, 20, 144]. It was determined that all of the available NCO was 
consumed in a 1:1 NCO to OH reaction, and that only half of the NCO was consumed in a 1:1 
LDI to ISE reaction. These findings indicate that the NCO did not react to a significant degree 
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with the sulfonate group present on ISE. Its presence in the reaction should not interfere with the 
synthetic chemistry used to synthesis the polyurethane materials.  
Swelling studies reveal significant differences to exist amongst the polyurethane foam 
and film materials in terms of their water uptake over a 24-hour period. The incorporation of 
ionic ligands can be expected to have two effects on the polymer’s water uptake. First, cations 
and anions are known to hydrate to differing degrees, so the cationic and anionic polymers may 
follow similar trends [189]. Second, the monofunctional additives interrupt the network 
architecture, serving as a site of chain termination since each ionic species is mono-functional. In 
order to control for this, DMB was chosen as a non-ionic control so that the uptake due to 
alterations in the network could be examined separate from the ionic species. As expected, the 
DMB foams and films did absorb more mass that the corresponding control, indicating Favg has 
an effect on swelling. However, the difference between the ionic and non-ionic species was 
substantially larger than the difference between the DMB and control species.  
SEM images indicate that the material morphology is vastly different between the film 
and foam samples. The film samples demonstrate a unique characteristic, morphology for each 
of the CC and ISE ionic samples. Each one demonstrates distinct pores to be present throughout 
the bulk of the material. The film samples also reveal surface irregularities that are strikingly 
different from one another, but it may be that these irregularities are artifacts of the cross-
sectioning process. A razor blade was used to slice the materials so that the internal surfaces 
could be visualized. However, the irregularities are sufficiently different from one another to 
suggest that they are likely related to the material structure. The foam samples for the most part 
appear quite similar under low and high magnifications. 
The vast differences between the film and foam morphology can easily be correlated to 
the processing techniques used to prepare them. A non-solvent casting technique was used to 
prepare the film samples, which provided the materials significant time to cure. The extended 
curing time allowed the pre-polymer to reorient itself prior to the formation of covalent urethane 
bonds. However, the foam process is relatively rapid, and occurs over a much shorter time 
interval. This interval is likely insufficient to allow for material rearrangement. As a result, the 
materials appear quite similar under the electron microscope.  
Fluorescence microscopy was able to clearly demonstrate the distribution of DB-67 
throughout each polyurethane material. Signal intensity is not necessarily representative of the 
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amount of DB-67 from one image to the next due to variations in sample thickness and 
microscope settings, but we do obtain a clear distribution pattern. There was a considerable 
difference observed between the foam and film samples with respect to drug distribution. Each 
of the polyurethane foams exhibited a relatively uniform distribution, while the film materials 
samples each possessed a rather unique distribution characteristic of the material morphology. 
These apparent differences are believed to be by-products of the processing techniques used to 
fashion the foams and films. The foam curing process was rapid, occurring over a period of 
hours. The film curing process was slow, occurring over a period of days. The extended duration 
of film curing process allows the material to segregate, a process that appears to be dictated by 
the ionic species incorporated into the sample. As a result, the DB-67 distribution in the ionic 
materials can be expected to be quite different from that observed in the foam materials. 
Differential release of DB-67 occurred from the ionic film and foam materials in a temperature 
dependent manner. A comparison of the concentration profiles from the materials at 37 °C 
demonstrates reveals some interested in trends that can be correlated to ionic character (Figure 
49).  
 
 
 
 
Figure 49 - Release of DB-67 from the ionic films and foams at 37 °C 
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Release of DB-67 from the ionic foams (CC and ISE) is remarkably similar at 37 °C over the 6-
week test period, in terms of the amounts and timing of drug release. The incorporation of ionic 
ligands was expected to affect the overall network architecture, by decreasing the average 
hydroxyl functionality of the polymer. However, the incorporation of DMB into the polyurethane 
foams and films does not appear to have anywhere near the effect that incorporation of an ionic 
species has. Consistently greater amounts of DB-67 were observed to elute from the ionic 
materials, while there was only a slight increase due to DMB incorporation. 
Similar effects were also observed to occur at 70 °C. Once again, the ionic film and foam 
materials (ISE and CC) are observed to release significantly greater amounts of DB-67 into 
solution than their corresponding non-ionic materials (Figure 50).  
 
 
 
 
Figure 50 - Release of DB-67 by the ionic materials at 70 °C 
 
The chain termination effect of the ligands is apparent when comparing the DMB foam to the 
control material. The release rates of DB-67 observed with the CC, ISE, DMB, and especially 
the control materials are much slower than previously observed for other LDI-glycerol drug 
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delivery systems. This is due to the need to increase the amount of LDI in the synthetic reaction 
in order to completely dissolve the ionic species. The additional LDI that was required resulted 
in an NCO:OH ratio of 1.7 in the synthetic reaction, where previously a value of 1.0 had been 
used. A much more slowly degrading polymer can be expected due to the increased number of 
urea bonds in the material, which hydrolyze much more slowly than urethane bonds. Overall, the 
incorporation of ionic species into LDI-glycerol polyurethane materials was found to increase the 
rates at which DB-67 is eluted into solution through a material degradation and erosion process. 
6.6 CONCLUSIONS 
In this study, we have present a means to alter the controlled, long-tem delivery of the 
camptothecin analogue DB-67 from biocompatible, biodegradable polyurethane films and foams 
constructed from LDI and glycerol via the incorporation of ionic ligands. We have demonstrated 
via FT-IR that LDI does not react to any significant degree with sulfonate functional groups. We 
then incorporated naturally occurring ionic ligands, choline chloride and isethionic acid, and DB-
67 into the polymer network via covalent urethane bonds. The ionic ligands were shown to alter 
the swelling characteristics of the materials to a considerable degree. A non-ionic control ligand, 
3,3-dimethyl-butanol, did not demonstrate a similar effect on swelling characteristics of the 
materials. Scanning electron micrographs revealed substantial differences in morphology 
between the film materials, but not the foams. Fluorescence microscopy was used to demonstrate 
substantial differences in the DB-67 distribution throughout the films, but not the foams. Drug 
release was observed to proceed in a temperature dependent manner via erosive kinetics. The 
incorporation of ionic ligands hastened the release of DB-67 from the polymer films and foams 
in a characteristic and predictable manner. These results clearly demonstrate that the controlled 
release of drugs from LDI-glycerol polyurethanes can be altered with via the incorporation of 
cationic and anionic ligands. 
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7.0  GENERAL DISCUSSION 
7.1 INTRODUCTION 
Humans have always attempted to improve their health by ingesting or administering drugs. 
Examples appear throughout recorded history, from every continent and culture. Biblical 
examples include Noah producing alcohol and Christ being offered a sedative to ease the intense 
pain of crucifixion [190, 191]. The use of opium was described by Theophrastus in the third 
century B.C., the stimulating powers of methyl-xanthines was exploited by ancient Arabian 
shepherds, and the paralyzing properties of curare were recognized by native South Americans 
centuries before the arrival of western civilization [192]. Chemotherapy of cancer, which some 
consider a modern development, existed in some form or another for more than 400 years [193]. 
Vaccination, the intentional exposure to minute doses of pathogen, was used in China and India 
to prevent smallpox and other infections centuries before the birth of Pasteur [194].  
 Even during the 20
th
 century, drug discovery has often resulted from purely empirical 
observations and happenstance. The anticancer effects of nitrogen mustard were realized during 
the development of chemical warfare agents, and penicillin was discovered after the inadvertent 
contamination of a cell culture experiment [195, 196]. As technology has advanced, particularly 
after 1970, methods of drug discovery and mass production of therapeutics have become more 
sophisticated and rational in their approach. The mass production of insulin for the treatment of 
diabetes is merely one example in which advances in scientific technology resulted in 
tremendous gains in therapeutic efficacy [197]. In parallel with the rapid rise of modern 
pharmaceutical technology and biotechnology, the cellular and molecular basis for the action of 
many drugs has been uncovered. Today drug design benefits from an accumulated base of 
scientific knowledge. The interactions between neurotransmitters and their receptors, the 
regulation of hormone secretion, and the sensitivity of tumor cells to specific kinds of chemicals 
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have resulted in advanced treatments for depression, effective means of birth control, and 
curative chemotherapy for some select malignancies (i.e. – Hodgkin’s lymphoma), respectively.  
New technology and clearer biological insight have led to new classes of therapeutic and 
prophylactic agents. Consider some of the new products available to patients in the United States 
over the last few years listed in Table 12 [198]. 
 
Table 12 – Newly approved therapeutics available on the US market 
 
 
AGENT TRADE NAME INDICATION 
Hepatitis B subunit Recombivax HB® (Merck & 
Co., Inc.) 
 
Vaccination against hepatitis B 
Human insulin Humilin® (Eli Lilly) 
 
Treatment of diabetes 
Monoclonal antibody against 
CD3 
Orthoclone OKT® (Ortho 
Biotech) 
 
Prevention of organ rejection 
Human growth hormone Protopin® (Genentech, Inc.) 
 
Growth failure in children 
Human interleukin-2 Proleukin® (Chiron 
Therapeutics) 
 
Metastatic renal cell carcinoma 
Erythropoietin Epogen® (Amgen) 
Procrit® (Ortho Biotech) 
 
Anemia 
Interferon beta-1a Avonex® (Biogen, Inc.) 
 
Multiple sclerosis 
Interferon alpha-n3 Alferon® (Immunex Corp.) 
 
Intralesional treatment of 
refractory external condylomata 
acuminata 
 
Tissue plasminogen activator Activase® (Genentech, Inc.) 
 
Acute myocardial infarction 
ß-cerebrosidase Ceredase® (Genzyme, Corp.) 
 
Enzyme deficiency 
Deoxyribonuclease (DNase) Pulmozyme® (Genentech, Inc.) Cystic fibrosis 
  
 
Even more complex agents such as chimeric antibodies, gene-based drugs, anti-sense 
oligonucleotides, and virus-like particles, are emerging as clinically viable entities. New clinical 
approaches involve cells as well as molecules; the introduction of genetically modified cells into 
humans has blurred the distinction between conventional pharmacology and transplantation. A 
revolution in drug development is clearly upon us. 
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 This wealth of new technology and the resulting new armaments in the war against 
disease will require new strategies for drug and vaccine administration. Most current methods for 
drug administration are direct descendents of ancient practices, changing little over the past few 
decades [199]. Egyptian physicians employed pills, ointments, salves, and other forms of 
treatment over 4,000 years ago. Hippocrates, alluding to modern sterile procedures, warned 
against the introduction of environmental pathogens into open wounds in the 4
th
 century B.C. 
Intravenous injections were first performed in humans in 1665, only a few decades after 
Harvey’s description of the circulatory system. Subcutaneous injections were introduced by 
Wood in 1853 and the modern hypodermic needle was developed by Luer in 1884. 
 While pills and injections have enabled significant medical advances to be attained, these 
methods are inadequate for the delivery of new therapies made possible because of the explosion 
in biotechnology. Recombinant proteins frequently have short half-lives, poor permeability in 
membranes, and serious toxicity when delivered systemically in large doses. General methods 
for the delivery of gene-therapy vectors are still unknown, since the uptake, bio-distribution, 
expression, and toxicity of oligonucleotides have yet to be systematically studied. Similar to new 
rational approaches to drug and vaccine design, new delivery technologies must exploit findings 
from basic science. Some of these hurdles may not be overcome for decades, yet the need for 
advanced therapies persists. 
7.2 OLD COMPOUNDS, NEW APPROACHES 
The approval of new therapies by the US Food and Drug Administration has slowed over the 
past few years, in part due to the new challenges encountered with advanced biotechnologies 
[200, 201]. However, the decline in approvals also stems from a lack of suitable drug candidates. 
Simply put, drug compounds are not being discovered at rates high enough to continue rapid 
expansion of the pharmaceutical industry [202]. Numerous large drug companies are beginning 
to see their blockbuster drug go off patent without any suitable replacement candidates in their 
developmental pipeline. However, substantial room exists for improvement on currently 
available and previously identified drug compounds. New clinical indications for drugs can 
continue to be explored and implemented. In addition, vast numbers of potential drug candidates 
 127 
have previously been identified, but many were unable to be implemented into any efficacious 
therapies. Some reasons for this include stability of the drugs active state within the body, 
susceptibility to physiologic pH changes, rapid clearance via the kidney and liver, and even the 
manifestation of severe, toxic side effects encountered with the most modest of dosing regimens. 
 The design of controlled-release drug delivery systems enables one to reexamine 
previously discarded drug candidates. One of the model drug compounds used in this study, DB-
67, is a perfect example of this phenomenon. DB-67 has been reported successful in numerous 
scientific endeavors, yet its application to any specific disease state has yet to be realized. A 
previously discussed, DB-67 is subject to rapid inactivation within the body in its native state 
[5]. The dynamic equilibrium between the lactone and hydroxy-acid is severely shifted due to the 
drugs ability to bind to serum albumin. As a result, the drug exists almost entirely in its inactive 
state, with little potential to ever realize its therapeutic potential. The work detailed in this 
dissertation focuses on the incorporation of DB-67 into various degradable polyurethane drug 
delivery systems via labile covalent bonds. Yet, this was just a starting point and essentially any 
compound with pendant hydroxyl or amine groups could easily have served as the model 
compound. The incorporation of chemotherapeutic agents into implantable reservoirs is a proven 
strategy in the battle against cancer, and we chose to base our delivery systems on this 
technology [48, 203-205]. DB-67 was chosen primarily for its fluorescent spectrum, which 
enabled the detection of the species at minute concentrations in aqueous media. The true focus of 
this dissertation is to discern how a controlled-release drug delivery system’s properties can be 
modulated via chemical means. 
7.3 CONTROLLED RELEASE VIA COVALENT INCORPORATION 
The vast majority of ddgradable controlled release systems rely on diffusion as the primary 
release strategy [31]. Small molecule drugs are incorporated into a pre-fashioned polymer 
matrix, usually with the aid of a volatile solvent. The drug is dissolved in the solvent, the matrix 
is then soaked in the solvent for an extended period, and the solvent is removed. This leaves the 
drug dispersed throughout the polymer matrix, absorbed onto its surface. These types of systems 
provide only a transient release phase, and the matrix material remains long after the drug load 
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has been exhausted. When delivering large drug molecules such as proteins, the compound can 
be incorporated into porous matrices; the drug becomes entrapped due to small pore size relative 
to the large drug compound or tortuous routes of diffusion. While long-term release over months 
and even years has been reported from such systems, the short half-lives of proteins within these 
matrices often leads to release of inactive drug species [206-208]. 
 It was our goal to design a system capable of releasing small drug molecules over an 
extended period. If this were to be the case, the release rate would need to be dictated by material 
erosion, not by diffusion. It was hypothesized that this could be achieved by covalently 
incorporating a drug moiety via its pendant functional groups into the polymer matrix. The vast 
majority of drug compounds have either free amine or hydroxyl groups, or both, present 
somewhere within their chemical structures. These functional groups can easily converted to 
urethane bonds in the presence of a suitable catalyst. DB-67 possess two hydroxyl groups, one 
aromatic and one tertiary, that were used to incorporate the species into a polyurethane network 
fashioned from LDI and glycerol. We have demonstrated that it is possible to release a small 
molecule drug over an extended period from such systems, with the release dictated by material 
erosion rather than drug diffusion. 
7.4 CONTROLLED RELEASE VIA ALTERATIONS IN MATERIAL 
MORPHOLOGY 
It has been demonstrated repeatedly through numerous scientific studies that a material’s 
morphology significantly impacts its ability to deliver a drug compound [209-211]. For example, 
porous polymer matrices release drug at rates significantly different from hydrogels and thin 
films. Surface to volume considerations become important when designing materials to elute 
drug at pre-determined rates. If one can accurately control the material morphology, then one can 
essentially tailor the release properties to meet specific application criteria.  
The versatility of polyurethane materials results from their unique chemistry. The 
material properties correlate to the poly–alcohols, –amines, and –isocyanates used to synthesize 
them. Once the reactants have been chosen and their relative molar ratios are defined, the 
blowing, gelling, and cross-linking reactions that condense these agents into urethane and urea 
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bonds can be selected to occur to differing degrees This gives rise to numerous structural 
permutations of a solitary reactant mixture. We have utilized these tools to design polyurethane 
materials with differing material morphology. 
The first LDI-glycerol polyurethane drug delivery system described was a small solid 
disc cut from a cast polymer film. A viscous LDI-glycerol pre-polymer was prepared, 
incorporating DB-67 into the material via labile urethane linkages. The film was prepared via a 
non-solvent casting technique, where the polymerization solvent and the polymer non-solvent 
were miscible. The resulting polymer discs were shown to be relatively uniform in terms of their 
drug content and morphology. The first permutation on LDI-glycerol polyurethane drug delivery 
systems was a foam material prepared from the same reactant mixture used in the synthesis of 
the polyurethane discs. By using a different catalyst and processing techniques, we were able to 
construct a second drug delivery system with vastly different material morphology. As 
hypothesized, the drug elution rates from the two systems were vastly different from one another. 
The foam materials degraded at a much faster rate, delivering more of its drug-load into solution 
than the corresponding disc materials. The difference in the release rates of the two-systems can 
be correlated to the material morphology, more specifically, the surface-to-volume ratio. 
Although exact measurements were not taken, it is clear from scanning electron micrographs that 
the LDI-glycerol foam materials possess a much greater surface-to-volume ratio than do the 
polyurethane discs. Considering the crude processing techniques used to fashion these materials 
in the laboratory, there is substantial opportunity to further refine these materials by utilizing 
sophisticated synthetic techniques. Once tighter control on material morphology can be gained, 
materials can begin to be evaluated for their controlled release potential. Further studies will 
elucidate key structure-release correlations that can be used to develop tightly regulated 
controlled release systems.  
7.5 CONTROLLED RELEASE VIA CATALYST MECHANISM 
Polyurethanes are among the most versatile of synthetic materials, and an enormous body of 
literature exists describing their synthesis and differing material properties. As previously 
mentioned, the physical properties of polyurethane materials can easily be tailored to specific 
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material applications. Countless review articles detailing the vast number of processing 
manufacturing techniques exist and aid the engineer in designing a material for a specific 
function [212-218]. The synthetic component that is most important in dictating the material 
properties of the polyurethane is the catalyst. The mechanisms of many urethane catalysts have 
been deduced, and the selectivity and specificity resulting from the individual mechanisms can 
be used to control polyurethane synthesis. 
 In light of these facts, it was hypothesized that the controlled release of DB-67 from LDI-
glycerol polyurethane materials could be altered by a change in catalyst alone. To this end, 
tertiary amine catalysts with different reactivity profiles were selected. The non-selective catalyst 
1,4-diazobicyclo[2.2.2]-octane (DABCO), is known to readily catalyze the gelling, blowing, and 
cross-linking reactions, while 4,4’-(oxydi-2,1-ethane-diyl)bismorpholine (DMDEE) primarily 
catalyzes the blowing reaction [219]. As a result, of the differences in the catalytic activities of 
DABCO and DMDEE, the release of DB-67 from the resulting foams should vary. A significant 
difference in the release of DB-67 from the LDI-glycerol polyurethane foams was detected, 
proving that controlled release can be modulated via only a change of urethane catalyst. 
Considering the crude processing techniques used to fashion the foams, there remains 
considerable room for further investigation.  
Using more sensitive processing techniques should result in the ability to actively control 
material properties and provide finer control of drug release relative to urethane catalyst. In 
addition, other catalyst systems with different selectivity from either DABCO or DMDEE should 
be assessed in order to elucidate key catalyst-release correlations. These correlations can then be 
used in the design and synthesis of highly regulated drug delivery systems. They may even be 
able to be expanded to other polymer systems besides polyurethanes, such as polyesters. 
7.6 CONTROLLED RELEASE VIA DRUG STRUCTURE 
It is no surprising fact that drugs delivered from controlled release systems possess differing 
chemical structures. The chemical structure of the agent ultimately determines the how the 
interaction with the target biological system occurs. Since the modulation of biological processes 
is dependent upon the chemical structure of a drug, it is therefore necessary to incorporate 
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different structures into controlled release systems. Differential release has been observed to 
occur for a variety compounds, based primarily on their hydrophobic or hydrophilic character 
[220-222]. As previously described, drug loading is done in a passive fashion where the drug is 
absorbed onto but not attached into the polymer. Solubility, diffusive properties, and the drug’s 
affinity for the polymer matrix determine its eventual release characteristics. 
However, one can look beyond the hydrophobic and hydrophilic character of a drug, and 
begin to examine its physical structure. DB-67 and doxorubicin possess unique chemical 
structures, characterized by two and six functional groups, respectively (Figure 51). 
 
 
 
 
Figure 51 – Structure and attachments of DB-67 and doxorubicin 
 
We have shown that LDI will react with these functional groups to varying degrees in the 
presence of a urethane catalyst. Since every drug will possess different number and type of 
functional groups, it is possible to form urethane and urea bonds in differing chemical 
environments. It was then hypothesized that these differing urethane and urea bond will exhibit 
different susceptibility to hydrolysis. Since hydrolysis is the primary mechanism governing drug 
release from the LDI-glycerol polyurethanes, each drug should elute at its own characteristic 
rate. In essence, the number and type of functional group present on the drug will dictate it’s 
controlled release when tethered into the polyurethane network via covalent linkages. 
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In order to test this hypothesis, a series of naphthalene related compounds were selected 
to serve as model drug compounds. Mono- and bi-functional hydroxyl and amine derivatives 
comprising the series were incorporated into LDI-glycerol polyurethane foams in order to assess 
their release rates. It was subsequently found that material structure plays a key role in dictating 
the release of these compounds from the polyurethane foams. A “true” drug-delivery LDI-
glycerol polyurethane foam was then made, incorporating DB-67, doxorubicin, and paclitaxol. 
Once again, release rates were shown to correlate to a drug’s chemical structure, presumably due 
to the differential hydrolysis of urea and urethane bonds. 
Typically, when multiple drugs have been released from a single device, it has been 
accomplished via two separate phases or multiple reservoirs[163, 223-230]. The diffusive 
properties of the two-phases govern the release of the encapsulated drug compounds. Our 
approach is different in that multiple drug release has been accomplished from a single-phase 
material. Not only is the material single-phase, but also it was fashioned in a one-step synthetic 
reaction. This area of drug delivery has only just begun to be explored, but one can already see 
the advantages gained in terms of ease of fabrication and versatility with respect to incorporation 
of different drug species. It is our hope to continue exploration of multiple release systems based 
on the differential hydrolysis of urethane and urea bonds. 
7.7 CONTROLLED RELEASE VIA IONIC LIGANDS 
Controlled drug release is a complex process, relying on a precise balance between biology and 
materials science. We can often look to nature for clues on how to exhibit control over material 
performance and behavior. For instance, the amphiphilic nature of phospholipids facilitates the 
ordered structure of cellular membranes, and the precise regulation of ion concentrations 
underlies brain and kidney function. Ionic substances are indeed important to normal physiologic 
regulation, maintaining many of the precise balances required for homeostasis. It was of interest 
to determine if ionic constituents could be used to augment the controlled-release from LDI-
glycerol polyurethanes. 
 The use of ionic species in drug delivery has been limited, mainly augmenting the 
swelling characteristics of various hydrogel delivery systems [231-233]. It was hypothesized that 
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the degradation rates of LDI-glycerol polyurethane materials could be enhanced via the 
incorporation of ionic ligands. The reasons for this are two-fold: (1) the swelling characteristics 
of the material will change leading to enhanced water uptake and (2) the presence of ions is 
noted to affect degradation of polyurethanes, enhancing their breakdown [188]. Choline chloride 
and isethionic acid, two naturally occurring ionic ligands, were chosen to assess ionic effects on 
LDI-glycerol controlled release systems. The biologic function of these materials has already 
been discussed in a previous chapter. However, it should be noted again that both ligands contain 
one primary hydroxyl functional group; choline chloride is cationic and isethionic acid is 
anionic. Incorporation of these ligands into the polymer network essentially results in chain 
termination since they are mono-functional. Chain termination will effectively change the overall 
hydroxyl functionality, changing the network architecture in the process. The non-ionic species, 
3,3-dimethyl-butanol, is structurally similar to CC and ISE and was used as a control for the 
overall change in network architecture 
 We have decidedly shown that the incorporation of ionic ligands drastically alters the 
swelling rates and the overall drug delivery characteristics of the LDI-glycerol polyurethane 
materials. These ligands were mono-functional and represented only two possible ionic groups – 
quaternary amines and sulfonates. Future work should examine the relative effect of other ionic 
groups, such as carboxylic acids and phosphate, both of which are known to react to a slight 
degree with isocyanates. The incorporation of such ligands may result in substantial changes in 
material properties due to the reactivity of the acid and phosphate group. Multi-functional ionic 
species should also be examined. Ligands with multiple hydroxyl groups and amine groups, as 
well as multiple ionizing groups should be evaluated in tandem. The results present here only 
hint at the potential of ionic ligands to modulate drug delivery.  
7.8 CONCLUSION 
The results presented in this dissertation lay the groundwork for future endeavors in controlled 
release drug delivery systems based on LDI-glycerol polyurethane materials. Chemical means of 
controlling drug-delivery have been investigated, including the following: (1) covalent 
incorporation of drug species, (2) manipulation of material morphology, (3) catalytic control of 
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drug elution, (4) differential release based on drug structure, and (5) role of ionic ligands. 
Covalent incorporation of a number of drug structures was possible, and the release rates 
corresponded to material erosion, rather than drug diffusion. The polyurethane film systems 
released materials at a much slower rate then their corresponding foam materials. The film and 
foam drug delivery systems were shown to exert significant anti-proliferative effects in vitro 
against malignant glioma cell lines related to the controlled release of DB-67. A simple change 
in catalyst has been shown to alter release rates from otherwise identical LDI-glycerol 
polyurethane materials. A drug’s chemical structure was able to dictate its release profile 
following covalent incorporation, making release of multiple drugs at different rates from a 
single-phase material possible. Finally, the ionic ligands choline chloride and isethionic acid 
were shown to substantially alter swelling and release characteristics of LDI-glycerol materials. 
As a result, of this work, a number of key design principles have been elucidated that will aid in 
the future development of controlled release systems. Significant progress was made with regard 
to each chemical control method, but in doing so, more questions were posed than could be 
answered. Drug delivery is truly a complex process, lying at the intersection of three worlds: 
chemistry, biology, and engineering. For the rational design of biomaterials, an understanding of 
polymer chemistry and polymer physics is necessary, but not sufficient. Equally important is a 
quantitative understanding of the principle rates that govern drug transport, interaction, and 
clearance in both normal physiologic and abnormal pathologic situations. This is not always an 
easy environment in which to work, but tremendous potential to treat or even cure human disease 
serves as motivation. 
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